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Abstract;
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6-7% of 
the population. It is characterised by chronic anovulation and hyperandrogenism with 
the clinical manifestation of oligomenorrhoea, hirsutism and acne. A ten to twenty fold 
increased risk for type 2 diabetes in PCOS patients compared to weight matched female 
control subjects makes the syndrome of high socioeconomic importance. The use of 
differing diagnostic criteria makes the comparison of studies on PCOS difficult until 
harmonisation through the Rotterdam consensus in 2004. Despite being removed from 
the diagnostic criteria by the the Rotterdam consensus, the LH/FSH ratio is still widely 
used as one of the diagnostic criteria for PCOS. Therefore to determine the usefulness 
of the LH/FSH ratio in the diagnosis of PCOS, I have conducted a study as described in 
chapter two and showed that an elevated LH to FSH ratio was as commonly found in 
normal women as those with PCO, and therefore of no diagnostic value.
In January 2004, the European Society for Human Reproduction and Embryology 
(ESHRE) and the American Society for Reproductive Medicine (ASRM) co-sponsored 
the Rotterdam polycystic ovary syndrome consensus workshop that published 
diagnostic guidelines, building on the consensus statement of the National Institutes of 
Health 1990. The Rotterdam criteria for the diagnosis of PCOS states 2 of the 3 
features needs to be present to make the diagnosis, and with the exclusion of other 
aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Gushing's 
syndrome). These features include (l)Oligo- or anovulation (2)Clinical and/or 
biochemical signs of hyperandrogenism and (S)Polycystic ovaries (either 12 or more 
follicles measuring 2-9 mm in diameter, or an ovarian volume of > 10 cm3). Following
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the introduction of this guideline, the diagnosis of PCOS in patients recruited for 
studies on PCOS have been standardised. However, the current biochemical test for 
hyperandrogenism in women is still not ideal, due to the variation in the assay at low 
values. All three of total testosterone, bioavailable testosterone and free androgen index 
(FAI) are currently used as markers of hyperandrogenism for the diagnosis of PCOS. 
In chapter three, I evaluated the variability of each of the three markers as well as their 
use in the diagnosis and monitoring patients with PCOS and found that FAI is a better 
diagnostic marker for hyperandrogenism in patients with PCOS, but once the diagnosis 
is made, all three methods are equally good in monitoring disease progression.
It has now been recognised that the diagnosis of metabolic syndrome identifies patients 
at increased risk of developing cardiovascular disease, and attempts have been made to 
develop the most convenient and useful criteria for the diagnosis of this condition in 
clinical practice. With the pathogenesis of metabolic syndrome not well understood, 
central obesity and insulin resistance are acknowledged as important causative factors. 
Cardiovascular disease studies in PCOS had so far been inconclusive with some 
suggesting increased cardiac events among women with PCOS whilst other studies 
suggesting no increase compared with normal cycling women. This may be attributed to 
small sample size in studies and variation in characteristics of patients recruited as well 
as surrogate markers used. C-reactive protein (CRP) had been widely used as a marker 
of inflammation, endothelial dysfunction and risk of cardiovascular disease in general 
and in patients with PCOS. However, there had not been any studies on the 
biovailability of this marker as the potential utility of CRP as a marker of 
cardiovascular risk may be limited by the magnitude of this variability in both health 
and disease, since there can be substantial overlap between PCOS and control
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individuals. In chapter four, the biological variation of high sensitivity CRP in women 
with PCOS were compared to normal menstruating women. I found that while the 
mean concentration of CRP was higher in individuals with PCOS compared to healthy 
controls, the intraindividual variation of CRP was similarly large in both groups. 
Therefore, the potential utility of CRP as a marker of cardiovascular risk may be 
limited by the magnitude of this variability in both health and disease, since there can 
be substantial overlap between PCOS and control individuals.
PCOS is associated with a high risk of progression to type 2 diabetes (T2DM) and 
impaired glucose tolerance. A history of T2DM in a first-degree relative appears to 
define a subset of PCOS subjects with a greater prevalence of insulin secretory defects. 
However, factors underlying the progression of PCOS to T2DM are unclear and may be 
due to either an increase in the underlying insulin resistance or the progression of beta 
cell failure. Chapter five described a comparison study between the insulin resistance 
and beta cell functions in patients with PCOS to that of diet controlled T2DM. I found 
that the progression from PCOS to the development of T2DM is unlikely to be due to a 
further increase in insulin resistance (or variability), but rather the progressive failure of 
pancreatic beta cells with a decrease in insulin production.
Having established the effectiveness in the diagnosis of PCOS and its progression, I 
went on to establish the effectiveness of individual treatments of PCOS. The 
treatment of patients with PCOS requires that the specific goal(s) of the therapy be 
first established. Individual goals may include fertility, treatment for hirsutism and/or 
acne, achieving a regular menstrual cycle, weight reduction and the prevention of the 
long term consequences associated with PCOS (type 2 diabetes, dyslipidaemia and
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possibly cardiovascular disease) - or all of the above. Treatments aimed at modifying 
the long-term consequences on cardiometabolic aspect of PCOS include weight 
reduction strategies as well as the use of insulin sensitizers. There is currently 
insufficient data to suggest the superiority of one treatment over another or the use of 
these medications for treatment of cardiometabolic risks in patients with PCOS. 
Endothelial dysfunction had been recognised as an early marker for cardiovascular 
disease and chapter six compared the changes in endothelial function in women 
treated with either metformin or pioglitazone. I found that pioglitazone significantly 
improved endothelial function and hs-CRP whereas metformin did not produce 
significant improvements. Chapter seven evaluates the effects of orlistat, metformin 
and pioglitazone on metabolic profile and biological variability of IR in women with 
PCOS. The results showed that only orlistat reduced both IR and its variability 
significantly, though all three drugs were effective in reducing hyperandrogenism 
within the 12 week period of the study. These effects with orlistat were coupled with a 
significantly reduction in total cholesterol through a reduction in LDL.
After conducting the above studies and searching through literatures, I found that 
studies in cardiometabolic risks in women with PCOS had so far shown conflicting 
results, and this may be due to the heterogeneity within the group. Chapter eight 
evaluates this heterogeneity particularly between anovulatory and ovulatory women 
with PCOS, where all subjects met the Rotterdam criteria. Women with anovulatory 
PCOS were found to have higher mean and biological variability of IR compared to 
those having an ovulatory cycle, and both were higher than women without PCOS. This 
suggests that the subset of patients who ovulate may be better protected against future 
cardiovascular consequences.
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In conclusion, this thesis demonstrated that LH/FSH ratio is of no use in the diagnosis 
of PCOS and that free androgen index appeared to be the best diagnostic marker when 
compared to total testosterone and bioavailable testosterone. Through the biological 
variability concept this thesis demonstrated the limitation of the use of hs-CRP in 
PCOS, and that orlistat, through weight reduction and insulin sensitization, may be a 
better agent in treatment of PCOS due to its multidimensional effect resulting in both 
the reduction in mean IR and its biological variability. Finally, this thesis also showed 
that women with ovulatory PCOS may be better protected against future cardiovascular 
consequences.
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Chapter 1:
Introduction
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1.1 Introduction to Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a common disorder characterised by chronic 
anovulatory infertility and hyperandrogenisrn with the clinical manifestation of 
oligomenorrhoea, hirsutism and acne(l). Most clinical data suggests a prevalence of 
6-7% of the population,(2-5) but this may differ according to ethnic background, for 
example, women of South Asian origin present at a younger age, have more severe 
symptoms and a higher prevalence(6, 7).
Many women with PCOS are obese and exhibit an adverse cardiovascular risk profile, 
characteristic of the cardiometabolic syndrome as suggested by a higher reported 
incidence of hypertension, dyslipidaemia, visceral obesity, insulin resistance and 
hyperinsulinaemia(8). They also have a higher prevalence of type 2 diabetes(9-12), for 
example, in one study, 35% of patients with PCOS had impaired glucose tolerance and 
10% had type 2 diabetes by the age of 40 (11). Obese women with PCOS were also 
found to have a higher prevalence of sleep apnoea(13, 14). Therefore it is important 
that there is a good understanding of the long term implications of the diagnosis in 
order to offer a holistic approach to the treatment of the disorder. The present 
Rotterdam criteria(15) is current best practice for diagnosis of PCOS but it is 
recognised that this condition encompasses a wide spectrum of disorder, blending with 
normality(16). It would appear that many women with PCOS also fulfil the criteria for 
the metabolic syndrome with an observed prevalence between 43 and 47% (8, 17-20). 
The diagnosis of metabolic syndrome in this female population further identifies a 
subgroup with an increased risk of developing cardiovascular disease. With the
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pathogenesis of metabolic syndrome not well understood, central obesity and insulin 
resistance are acknowledged as important causative factors(21-23).
Atherosclerosis in PCOS
The presence of cardiovascular risk factors of obesity, insulin resistance and 
dyslipidaemia may predispose women with PCOS to coronary heart disease, although 
this remains controversial. Cardiovascular disease studies in PCOS so far have been 
inconclusive with some suggesting increased cardiac events among women with PCOS 
whilst other studies suggesting no increase compared with normal cycling women. 
Current studies on cardiovascular disease in PCOS could be divided into three groups 
as below:
• Surrogate markers of cardiovascular risk
• Surrogate markers of cardiovascular disease
• Endpoint studies
Surrogate markers of cardiovascular risk:
1) Dyslipidaemia
Insulin may play a role in lipogenesis via an increased production of Acetyl-Co A, and 
the entry of glucose and triglycerides(24). Data are conflicting on whether women with 
PCOS have a characteristic dyslipidaemia. Studies have reported decreased levels of 
the cardioprotective high-density cholesterol lipoprotein (HDL-C), and elevated levels 
of triglycerides(25-31), although in one study HDL was elevated (32). Of concern, 
dyslipidaemia has been found at puberty in studies on adolescent girls with a history of 
premature pubarche(33) and the metabolic disturbances can often be detected in the
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prepubertal period and throughout puberty(34). This dyslipidaemia is seen in both lean 
and obese PCOS(35).
2) Hypertension
Hypertension may be exacerbated by hyperinsulinaemia which enhances sodium 
retention(36) causing an increased intracellular sodium and calcium(37), and 
stimulation of the sympathetic nervous system(38, 39). However, surprisingly, current 
evidence on prevalence of hypertension in patients with PCOS, including those using 
24 hour ambulatory blood pressure monitoring techniques, have shown conflicting 
results with some studies suggesting a higher prevalence(12, 40-42), but not by 
others(9,43-45).
3) Insulin resistance and Type 2 Diabetes
Obesity, type 2 diabetes and insulin resistance are strongly related to PCOS(31, 46, 47). 
Insulin resistance and compensatory hyperinsulinaemia in PCOS were found to 
correlate to increased cardiovascular risk(48) and linked to later development of 
impaired glucose tolerance and type 2 diabetes, independent of obesity(49). Evidence 
from small long-term cohort studies, case-control studies and case series, points to a 
risk of type 2 diabetes in PCOS in middle age of 10-20%, with a high rate of impaired 
glucose tolerance suggesting that further cases of diabetes will develop later in life(9, 
11, 12, 50, 51). Increased body mass, particularly truncal obesity, and a strong family 
history of diabetes (up to 83% in one study) increase the risk of developing type 2 
diabetes in the presence of polycystic ovary phenotype(l 1). This increased risk of type 
2 diabetes seems to be independent of body mass index as the frequency of type II
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diabetes is also increased in nonobese PCOS patients (body mass index less than 
27kg/m2)(ll,50).
4) Visceral Obesity
The prevalence of obesity in PCOS varies between 10-50% depending on country 
where the study is carried out(52, 53). Obese PCOS have lower levels of luteinising 
hormone (LH), sex hormone binding globulin (SHBG), dehydroepiandrosterone 
(DHEAS), dihydrotestosterone, free insulin-like growth factor (IGF)-I, high-density 
lipoprotein, and higher low-density lipoprotein, compared with the nonobese PCOS 
group(54). However, not all obese people are insulin resistant and not all who are 
insulin resistant are obese. Gluteo-femoral obesity is less associated with insulin 
resistance than is central or android obesity(55). A state of hyperinsulinaemia may 
itself contribute to obesity by the anabolic effect on fat metabolism through 
adipogenesis with increased uptake of glucose into adipocytes, the production of 
triglycerides and inhibition of hormone sensitive lipase(56).
5) Pro-thrombotic state
Hyperinsulinaemia contributes to the prothrombotic state by reducing fibrinolysis and 
raising the level of plasminogen activator inhibitor (PAI-1)(57). In patients with PCOS, the 
level of PAI-1 was found to be elevated(44, 58, 59), and it decreased with improvement in 
insulin sensitivity, either through weight loss(60) or the use of insulin sensitizing agents(61, 
62). The increase in PAI-1 activity in PCOS was thought to be independent of body mass 
index since elevated levels were also observed in lean PCOS women. Moreover, the 
increased level of PAI activity in PCOS was directly correlated with insulin resistance, thus
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implicating it as a contributing cardiovascular risk factor(63). However, other studies 
disagree and suggested that PAI is not an independent risk factor in PCOS (64,65).
6) Non-alcoholic fatty liver disease/Non-alcoholic Steatohepatitis (NAFLD/NASH) 
The clinical associations of hepatic steatosis are increasingly being recognized among 
individuals with metabolic syndrome(66). Hepatic steatosis appears to have a close 
association with vascular disease and might even be an early mediator of 
atherogenesis(67). The liver, once fatty, overproduces most of the known 
cardiovascular risk factors such as very low density lipoprotein (VLDL), glucose, C- 
reactive protein (CRP), PAI-1, fibrinogen and coagulation factors and raises the 
possibility that NAFLD may be not only a marker but also an early mediator of 
atherosclerosis (68). This supports an earlier study suggesting that changes in 
enzyme gamma-glutamyltransferase and alanine-amino-transferase were associated 
with cardiovascular risk factors(69). Abnormal aminotransferase activity and fatty 
liver is common in women with PCOS (15% to 55%), and is significantly associated 
with higher degree of dyslipidemia and hyperinsulinemia compared to women with 
PCOS who do not have non-alcoholic fatty liver disease (70-72). Taken together, 
these data suggested that women with PCOS may have an increased risk of 
developing many of the consequences of metabolic syndrome.
Diagnosis is by abdominal ultrasonography (or CT/MRI), elevated liver enzymes with 
the exclusion of alcohol toxicity, hepatitis B and C. Liver biopsy should be 
considered in cases where there is diagnostic uncertainty or in those at risk of 
advanced hepatic fibrosis(73). One study showed that women with PCOS aged 
between 23-36 years (n=6) already had evidence of NASH with fibrosis on liver
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biopsy(71). Therefore, further studies are needed to evaluate when best to screen 
PCOS women for liver disease.
In a preliminary study from Targher et al, insulin sensitivity, as measured by 
euglycemic clamp, was found to be reduced in young women with both the PCOS and 
NAFLD, whereas it was similar between women with the polycystic ovary syndrome 
alone and healthy controls, who were matched for age and body weight. Moreover, 
NAFLD strongly predicted the response (i.e., ovulation rate) to a 6-month course of 
treatment with metformin in patients with the PCOS. They concluded that NAFLD 
may help to explain why some but not all patients with PCOS have insulin resistance 
and may also help to determine in which of these patients metformin might be 
effectively used(74). Increased physical activity together with dietary restriction 
appear to improve insulin sensitivity and liver disease in NAFLD(75-78). The role of 
pharmacological agents for treatment of NAFLD or NASH remains to be established 
but preliminary studies suggested the beneficial effects of insulin sensitizing agents 
like metformin and thiazolidinediones (pioglitazone and rosiglitazone). In an animal 
model of steatohepatitis, treatment with metformin improved hepatic steatosis and 
inflamniation(79). A more recent study showed an improvement in serum 
aminotransferase activities with metformin, although no histological data was 
provided(SO). Several small open studies have shown encouraging results on 
improvement of ALT levels as well as histology with thiazolidinedione(81, 82). One 
recent double-blind, placebo controlled randomized trial demonstrated that 6 month 
treatment with pioglitazone improved insulin resistance and glycaemic control in 55 
patients with NAFLD and glucose tolerance(83). Bariatric surgery may prove 
beneficial in the severely obese and shown to reduce steatosis, inflammation and even 
fibrosis in established NASH(84-88).
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7) Adipocytokines
Adipocytes are metabolically active cells which secrete adipocytokines like tumour necrosis 
factor alpha, interleukin 6 (IL-6), PAI-1, leptin, resistin, adiponectin, visfatin and 
angiotensinogen(89,90), all of which may have a role in cardiovascular disease.
Leptin is thought to play a role in the control of deposition of fat in tissues such as heart, 
liver and kidneys. It is also involved in the control of vascular tone(91) which may 
contribute to the hypertension. A positive relationship between insulin resistant PCOS 
women (both obese and non-obese) and hyperleptinaemia, regardless of the BMI has 
been suggested in one study(92). Visfatin is also increased in women with PCOS(93). 
IL-6 inhibits liproprotein lipase activity, enhances aromatase activity and increases the 
hepatic production of triglycerides(94). IL-6 is stimulated by TNF alpha and TNF alpha 
further stimulates C-reactive protein that has been found to be correlated with obesity, 
insulin resistance, endothelial dysfunction and therefore cardiovascular risk. Level of IL-6 
had been found to be higher in obese women with PCOS(95). TNF alpha is also increased 
in women with PCOS irrespective of obesity(96). Patients with PCOS have been shown to 
have a higher level of CRP(97-99). Elevation of these inflammatory markers was in accord 
with the hypothesis that atheroma formation is primarily an inflammatory condition. 
Adiponectin is an adipocytokine secreted exclusively by adipocytes and levels are 
reduced in obesity, type 2 diabetes and coronary heart disease. Women with PCOS 
were found to have lower adiponectin level compared to controls(100-102). Recently 
the adiponectin-to-leptin (A/L) ratio has been proposed as a potential atherogenic index 
providing the link between these cardiovascular risk factors in women with 
PCOS(103).
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A significant reciprocal correlation exists between adiponectin and resistin independent 
of insulin resistance in women with PCOS(104). Resistin is implicated in the 
pathogenesis of type 2 diabetes and obesity(lOS) but the role of resistin in patients with 
PCOS is still debatable. Some studies suggested an increase in resistin in women with 
PCOS(106) while others found no difference compared with BMI matched 
controls(100,107, 108).
Surrogate markers of Cardiovascular disease
Coronary Angiography: A 2 year study from New Zealand evaluated 143 women age 
less than 60 years old undergoing cardiac catheterization for the investigation of chest 
pain. Polycystic ovarian morphology was present in 42% of women, and was associated 
with hirsutism, lower levels of HDL cholesterol, and higher concentrations of free 
testosterone, triglyceride and C-peptide. The women with polycystic ovaries had more 
extensive coronary disease on angiography than those with normal ovaries(109). 
However, this study only examined the association between ultrasound evidence of 
polycystic ovaries alone and the extent of coronary disease on cardiac catheterization, 
rather than the full Rotterdam consensus definition of PCOS.
Carotid artery intima-media thickness (IMF): An ultrasonographic study of 16 women 
with PCOS aged over 40 years, showed an increased carotid artery intima-media 
thickness (IMT), suggesting a predisposition towards atherosclerosis compared to that 
in normal controls(HO). However, the mean intima-media thickness in the PCOS 
group was still well below that seen in patients with significant carotid artery disease. 
In a later study by the same researchers involving a larger cohort of subjects of 125
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women with PCOS, they found that among women aged 45 years or above, patients 
with PCOS had significantly greater mean carotid IMT than women in the control 
group(l 11). Two further studies also showed similar results(l 12,113).
Coronary artery calcification (CAC): CAC measured by electron beam computed 
tomography (EBCT) in a cross sectional study of 36 premenopausal women with PCOS 
aged between 30 to 45 yrs showed a higher prevalence in PCOS women (39%) 
compared with matched controls (21%)(114). Another prospective study of 61 women 
with PCOS also showed an increased CAC(111). Young obese women with PCOS has 
a 5-fold higher prevalence on subclinical coronary atherosclerosis as detected by the 
presence of coronary artery calcium compared with weight-matched obese 
controls(115). This increased risk is independent of traditional CV risk factors and 
novel markers of inflammation.
Ventricular function: Two case controlled echocardiographic studies on women with 
PCOS found these women to have lower left ventricular ejection fraction compared to 
controls(31, 116).
Endothelial dysfunction: Endothelial dysfunction is associated with the development of 
atherosclerosis.(117) Despite two studies reported no difference in surrogate markers 
including endothelial function for increased cardiovascular risk in PCOS compared to 
weight matched controls(118, 119), many others showed an abnormal endothelial 
function and arterial stiffness in women with PCOS(112, 120-123). However, the study 
population in the above studies was small. A recent larger case control study of 100 
patients found that overweight women with PCOS have increased arterial stiffness 
measured by pulse wave velocity (PWV) and reduced brachial artery flow mediated 
vasodilatation (FMD), a marker of endothelial function compared with weight-matched
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controls(124). In addition, they also demonstrated that patients with PCOS have 
elevated triglycerides and cholesterol but no differences in CRP or 24 hour blood 
pressure.
End point studies
We currently lack end point studies and the two available at present showed 
conflicting results. In a cross sectional study with a prospective cohort of 80,000 
female nurses who provided information for the Nurses Health Study and subjects 
followed through for cardiovascular events, a history of menstrual cycle irregularity 
was associated with an increased risk of nonfatal and fatal coronary heart disease 
(125). This might be explained by a high rate of PCOS with its associated metabolic 
disturbances in these women, although no other clinical or biochemical androgen data 
was available to confirm that menstrual irregularity was due to PCOS. Another study 
looking at a cohort of 786 women who received a diagnosis of PCOS in the United 
Kingdom before 1979 was traced to investigate the long-term consequences of the 
syndrome. Despite the increase in cardiovascular risk factors including diabetes, 
hypertension, raised plasma cholesterol and body mass index >30, morbidity and 
mortality from of coronary heart disease did not differ significantly between the 
women with PCOS and comparison groups(126).
Although recent surrogate end point studies strongly support an association between 
PCOS and cardiovascular disease, the long term epidemiology studies had been 
inconclusive. There had been discrepancies in the studies that generate this notion 
which may be due to the small sample size of the studies as well as the non-standard 
definition of PCOS prior to the Rotterdam criteria. Furthermore, there are also data
27
that polycystic ovary morphology recedes and disappears with age leading to the 
occurrence of regular menstrual cycle(127, 128). There are unfortunately no 
prospective cohort studies to adequately address the effect of age on PCO, but a cross 
sectional study suggested that the risk factors in later life were not related to 
menstrual cycle pattern but instead influenced mainly by the BMI, with a significant 
increase in glucose, insulin and lipids (except for the triglycerides) in women with a 
BMI >27 kg/m2 compared to those with a BMI <27 kg/m2(129).
Nevertheless, from a clinical perspective, clinicians should continue to identify 
cardiovascular risk factors in women with PCOS and treat these accordingly. In 
clinical practice hypertension should be treated. Persistent blood pressures greater or 
equal to 140 mmHg systolic and or 90 mmHg diastolic, not responding to lifestyle 
measures, need to be considered for drug therapy. In those with diabetes or other high 
risk factors, drug treatment should be started earlier at blood pressure greater than 
ISOmmHg systolic and/or 80 mmHg diastolic(130). Lipid lowering treatment is not 
recommended routinely and its prescription should only be undertaken by a specialist.
Strategies for Reduction of Risk:
1) Execise and weight control
Lifestyle changes through diet and exercise remain the first line for treatment of obesity 
in PCOS. Obesity and abnormal fat distribution, especially of abdominal fat, is 
common in women with PCOS even where the BMI is normal(131). As obesity 
worsens insulin resistance which may exacerbate this dysfunction, loss of significant 
weight has been reported to result in spontaneous resumption of ovulation(132),
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improvement in fertility(133), increased SHBG and reduced basal level of insulin(134, 
135) accompanied by a normalization in glucose metabolism(136), therefore reducing 
the likelihood of developing type 2 diabetes later in life. Whilst there is little long term 
data on the effect of lifestyle intervention in women with PCOS, especially those with 
normal body habitus, the Diabetes Prevention Trial examined subjects with similar 
metabolic profiles and risk factors and found that lifestyle intervention reduced the risk 
of diabetes by 58%(137). In the absence of any robust long term follow-up data for 
lifestyle interventions, it would seem appropriate to advise regular exercise aiming for a 
mean of 30 minutes sweat-inducing exercise daily, and to have a healthy, balanced diet 
of regular, hypocalorific meals through the day.
2) Drug therapy
The demonstration of the potential long-term health consequences of PCOS have been 
accompanied by renewed interest in the use insulin sensitising agents such as 
metformin and the thiazolidinediones (troglitazone, rosiglitazone and pioglitazone) to 
reduce insulin resistance and thereby reduce risk of developing diabetes and other 
metabolic sequelae. Metformin(138-145) and troglitazone(61, 146) have been shown to 
have beneficial short-term effects on insulin resistance in non diabetic women with 
PCOS. There is evidence that metformin may modestly reduce androgen levels by 
around 11% in women with PCOS compared to placebo, and modest reductions in body 
weight have been reported by some, but not all studies. Whilst metformin appears to 
induce cardio-protective effects on serum insulin,(147) serum lipids,(148) PAI-1,(149) 
and endothelial function(150) in patients with PCOS, the actual protection from long 
term mortality and morbidity of cardiovascular disease has yet to be demonstrated.
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Women with a body mass index of more than 37 may not respond well to metformin 
therapy(lSl).
Pioglitazone and rosiglitazone have also shown positive cardiometabolic effects in 
women with PCOS(152-154). Rosiglitazone was found to markedly reduce liver fat, 
increase insulin clearance, double adiponectin concentrations and unlike metformin, it 
also increases peripheral insulin sensitivity (155). However, thiazolidinediones causes 
weight gain that may not be a desireable effect in this population of young women 
whose initial presenting complaint may well be the inability to loose weight.
Despite the possible benefit, there is no current robust evidence to support the use of 
these drugs for the prevention of cardiovascular disease in PCOS and further research 
in this area is required. Inference from the diabetes prevention trial which examined a 
cohort of patients who had similar metabolic profiles to women with PCOS suggested 
that metformin is not superior to lifestyle intervention in improving cardiometabolic 
risk and progression to type 2 diabetes(156). Caution need to be exercised when using 
thiazolidinedione group of drugs in view of the recent reported incidence of increased 
cardiovascular mortality with rosiglitazone(157).
Weight reduction agents like orlistat(158) and sibutramine(159) were shown to be 
effective in reducing body weight and hyperandrogenism in women with PCOS. 
However, sibutramine has to be used with caution in patients with systolic 
hypertension. There is currently no data on the use of rimonabant in women with 
PCOS but evidence suggests its potential benefit in weight reduction and
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improvement in cardiometabolic profile(160). Bariatric surgery may be indicated in 
selected women with morbid obesity(161).
3) Surgery
Surgery has long been used as a treatment for anovulation associated with PCOS, and 
a recent long-term cohort study up to 20 years after laparoscopic ovarian 
electrocautery has shown persistence of ovulation and normalisation of serum 
androgens and SHBG in over 60% of subjects, particularly if they have a normal 
BMI(162). Insulin resistance and serum lipids were not assessed. The long-term 
benefits of ovarian drilling, including alterations in the endocrine profile are 
supported by a second study(163). However, no prospective studies have been 
powered to look at cardiovascular risk profiles and ovarian electrocautery should be 
reserved for selected anovulatory patients with a normal BMI or where a laparoscopy 
is required for other indications.
In summary, cardiovascular disease studies in PCOS have been inconclusive with some 
suggesting increased cardiac events among women with PCOS whilst other studies 
suggesting no increase compared with normal cycling women. Due to lack of long term 
end point studies, the increased cardiovascular risk ascribed to women with PCOS at present 
is almost entirely inferential based on surrogate risk factors. It has been suggested that 
patients with PCOS as defined by hyperandrogenaemia plus either of oligomenorrhoea 
or polycystic ovaries on ultrasound may have a slight increase in cardiovascular risk 
profile as compared with those with only oligomenorrhoea and polycystic ovaries 
without hyperandrogenaemia. Long term cohort studies are particularly needed in young
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women with PCOS and these studies should be of larger sample size with well defined 
diagnostic criteria enabling the identification of subtypes.
32
1.2 Hyperandrogenism in PCOS
The major androgens in the serum of normal cycling women are 
dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), 
androstenedione (A), testosterone (T), and dihydrotestosterone (DHT) in descending 
order of serum concentrations(164). The ovary is the main source of the testosterone in 
a pre-menopausal female with the remainder contributed by the adrenal gland and 
peripheral conversion of other steroids, including androstenedione. Immunoassays for 
total testosterone in the female range are rather unreliable and a recent study had shown 
possible interference with DHEAS(165). Tandem mass spectrometry would have been 
more precise but unavailable to most laboratories in the United Kingdom. Bioavailable 
testosterone (BioT) measurement (which excludes SHBG bound testosterone) and free 
androgen index (FAI), which accounts for the sex hormone bound fraction of 
testosterone, are assumed to be inherently superior estimates of hyperandrogenism than 
the measurement of total testosterone concentration alone. Sex hormone binding 
globulin (SHBG) is a major binding protein for testosterone and its measurement is a 
useful addition to information on androgen activity in the female. Use of a testosterone 
to SHBG ratio is thought to be a useful way of interpreting changes in free hormones.
The primary sites of androgen production in the ovary are in the theca and the stromal 
areas that suround the follicle. Pathways of androgen production in these sites are 
shown in Fig. 1. Under normal circumstances, some of the androgens produced in the 
theca are exported across into the granulosa cell layer of the ovary where 
aromatisation leads to production of oestrogens. Both the excess production of 
androgens as well as failure of aromatisation led to a higher circulating level of 
androgens.
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Fig. 1. Major steroid pathways in the ovary according to the two cell hypothesis of 
ovarian function 3B, 3 beta hydroxysteroiddehyrogenase.
Thecal androgen production is triggered by a rise in LH as well as the physiological 
and pathological increase in androgen secretion seen in women(166, 167). Several 
clinical conditions where subjects are extremely hyperinsulinaemic have been 
associated with excess of androgen production and is thought is to be due to either a 
genetic defect of insulin production or of the insulin receptor. For example, defects in 
quantity or affinity of the insulin receptor for insulin can leads to marked insulin 
resistance and very high concentrations of circulating insulin. A similar clinical 
picture results from the presence of antibodies to insulin receptors. More commonly,
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conditions such as PCOS present with mildly elevated insulin and lesser degrees of 
androgen elevation in the blood(168).
Insulin action on thecal cells augments that of LH and appears to be mediated by the 
insulin receptor rather than by the insulin-like growth factor receptor(169). Other 
stimulators of androgen production in the theca include activin, TNFa, insulin-like 
growth factors and interleukins. There is little evidence of aromatase deficiency in 
PCOS and this is not thought to contribute to a major degree of 
hyperandrogenaemia(170). Concentrations of follicle stimulating hormone (FSH) are 
normal in this condition and the bioactivity of the molecule appears to be unaffected.
Women with congenital adrenal hyperplasia due to the deficiency of either 21 
hydroxylase or 11 beta hydroxylase deficiency were found to have a higher 
prevalence of polycystic ovaries(171). This may indicate that the enzyme deficiency 
has a correlate in the ovary or alternatively, that the high androgen concentration has 
an adverse impact on the functioning of the ovary. This latter hypothesis finds support 
from the work of Abbott et al. who showed that prenatal androgen treatment of rhesus 
monkeys caused morphological changes in the ovary similar to those of PCOS, 
together with significant changes in the glucose and insulin axis characteristic of 
insulin resistance(172). A further clue as to the potential impact of prenatal factors is 
the association between low birth weight and some types of androgen excess 
conditions, including PCOS and premature pubarche(173, 174). These studies suggest 
that genetic contributions to the origins of hyperandrogenism are not the only 
explanation for the aetiology of PCOS.
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1.3 Ovulatory and Anovulatory PCOS
To date, studies on patients with PCOS had produced conflicting results, especially on 
the cardiometabolic risks in women with PCOS. The differences in results may be 
related to the heterogeneity among the patients studied with PCOS, given the expanded 
diagnostic criteria for the diagnosis of PCOS, which includes ovulatory 
hyperandrogenic women and anovulatory normoandrogenic women. Carmina et al 
recently found that central fat distribultion is increased in anovulatory women with 
PCOS compared with ovulatory PCOS and matched controls. Adiponectin was 
significantly decreased in women with anovulatory PCOS and those with ovulatory 
PCOS had a similar fat distribultion to matched controls but altered levels of visfatin 
and RBP4 (175). Further studies will be warranted to better categorise the risks of 
different phenotypes of PCOS.
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1.4 The Biological Variation Concept and its Clinical Relevance
Most bio-analytes changes with time. Therefore the knowledge of temporal changes 
following an acute episode of disease, for example, in serum enzyme activities 
following myocardial infarction will allow appropriate tests like troponin to be taken at 
the right time for the correct interpretation of results.
Changes that occur in health are also important. Reference values for many analytes 
vary depending on the different stages in life and particularly significant periods 
include neonatal life, adolescent, during pregnancy and old age. Many hormones and 
proteins showed cyclical rhythm which can be circadian, monthly or seasonal in nature. 
Being aware of these changes will enable samples to be collected at the appropriate 
times for appropriate interpretation. In certain conditions the absence of the expected 
rhythm may indicate the presence of a disease, for example in Gushing's disease. 
However, the rhythm can be variable from one individual to another and to minimize 
such influence as much as possible, sample collections should be done at the same time 
of the day.
Biological variation is inherent in most medical analysis and is a major source of error 
in clinical test interpretation. It represents the fluctuation of a value around a certain 
homeostatic set point. Biological variation consists of analytical variation, variation 
within subjects (intra individual variation), and variation between subjects (inter 
individual variation). These components of biological variation are used to set 
analytical quality specifications for bias and imprecision, evaluate serial changes in 
individual analytes, and assess the clinical utility of population-based reference range.
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For example, most of the tests requested in hospitals were used either for diagnostic 
purpose or as a way of monitoring the progress disease process in a patient. For a test 
to be useful in diagnosing a disease, it should not have a large variation in value 
between individuals. This is formally expressed as the index of individuality (lol) 
which is represented by the ratio of intra- and interindividual variation (SDi/SDG). 
When the lol for a particular test is 0.6 or less, conventional population based 
reference intervals are of limited value in the detection of unusual results for a 
particular individual. When the lol is 1.4 or more, the variation in an individual will 
fit populations reference limits more closely, thus being suitable as a screening test 
(176). However, a good screening test is not necessarily a good test when it comes to 
serial measurements for the purpose of monitoring. This can occur when the test has 
a large variation within an individual, i.e. the critical difference, or the difference 
between two successive measurements in an individual. A good example is the use of 
serum creatinine and creatinine clearance in measurement of renal function. Serum 
creatinine has marked variation between individuals and therefore conventional 
population based reference values are of limited use. In contrast, urinary creatinine 
and creatinine clearance have less individuality, making reference values more useful 
in detecting unusual results. Therefore creatinine clearance would be a better test for 
initial assessment of patients. On the other hand, creatinine clearance has a large 
critical difference while serum creatinine has a small critical difference, making serial 
serum creatinine assays more useful for monitoring individuals(177).
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1.4 The Aims of Undertaken Research
The overall aim of this thesis and thus research undertaken was to investigate the 
cardiometabolic parameters in women with PCOS. The secondary aim was to address 
parameters involved in the diagnostic criteria of PCOS (hence the LH/FSH ratio and the 
differing testosterone measurements).
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Chapter 2:
Diagnosis of PCOS
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2.1 The LH/FSH ratio has no use in diagnosis of Polycystic Ovary 
Syndrome
Introduction:
An elevated luteinising hormone/follicle stimulating hormone (LH/FSH) ratio has 
been used as a diagnostic test for polycystic ovarian syndrome (PCOS) for many 
years(178, 179). Despite its continued use, concerns about the clinical utility of the 
ratio have led to the recent Rotterdam ESHRE/ASRM consensus statement on PCOS 
recommending against its inclusion(lS). Only one previous study had evaluated the 
variation of the LH/FSH ratio in PCOS(180) and this was only from specimens 
collected at monthly intervals. Therefore, this study aimed to determine the variability 
of the ratio in women with PCOS in comparison with normal controls throughout the 
time period of a full menstrual cycle.
Research Design and Method:
Twelve overweight Caucasian women with PCOS (median age 28 y, range 18-31 y) 
and 11 weight-matched non-affected Caucasian women (median age 30 y, range 19- 
33,) with regular menses (every 28-30 d) and normal free andogen index (FAI) 
participated in the study. PCOS was diagnosed using the Rotterdam criteria. All 
subjects had evidence of clinical or biochemical hyperandrogenism and oligo or 
anovulation (period <8 per year). Trans vaginal ultrasound scan was done on all 
patients. The body mass index (BMI, calculated as weight (kg)/height (m)2) in the 
PCOS group was not significantly different from that in the non-affected group 
(mean±SD, 33.2±6.3 vs. 29.9±3.3, p=0.151 using Mann-Whitney U test). Fasting 
venous blood was collected into serum gel tubes (Becton Dickinson, Cowley,
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Oxfordshire, UK) at the same time each day (0800-0900) on 10 consecutive occasions 
at 4-day intervals to encompass measurement over at least a complete menstrual 
cycle. Samples were separated by centrifugation at 2000 g for 15 minutes at 4°C, and 
stored at -20°C within 1 h of collection. All subjects gave their informed written 
consent that had been approved by the local research ethics committee.
Aliquots were thawed and analyzed in a single continuous batch of reagents. Serum 
FSH, LH and testosterone were measured using a two-step procedure that used 
microparticle immunoassay technology (Abbott Diagnostics, Maidenhead, UK). Sex 
hormone binding globulin (SHBG) and insulin were measured using a 
chemiluminescent immunometric assay on the DPC Immulite 2000, (Euro/DPC, 
Llanberis, UK). Plasma glucose was measured using a hexokinase method on the 
Synchron LX 20 analyzer (Beckman Coulter, Inc., High Wycombe, UK). The FAI 
was calculated from total testosterone xlOO /SHBG. Statistical analysis was 
performed using SPSS, version 11.5.
Results:
Four patients from the PCOS group showed biochemical evidence of ovulation 
(progesterone >16 nmol/L)(181) during the collection period, so a third comparison 
group of anovulatory PCOS patients (n=8) was added (Table 2.1).
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Table 2.1 Biochemical features of clinical PCOS, anovulatory PCOS and non- 
affected group.
Data presented as median (range), n denotes number of samples. LH luteinising 
hormone, FSH follicle stimulating hormone, SHBG sex hormone binding globulin 
and FAI free androgen index.
Parameter 
(reference 
range)
Fasting glucose 
mmol/L (3.5- 
S.Ommol/l)
Fasting insulin 
mU/L
Testosterone 
nmol/L
(0-4.1nmol/L)
FAI (0-8%)
SHBG nmol/L
LHU/L
FSH U/L
LH/FSH ratio
Non-affected 
group 
(n=ll)
4.7 (3.6-5.7)
7.8 (2.0-19.2)
3.0(1.4-7.7)
5.3 (1.7-22.5)
53.8(18.9- 
153.0)
5.9 (0.7-82.6)
5.2(1.3-13.2)
1.2(0.3-11.0)
Clinical 
PCOS
(n=12)
4.9 (4.0-9.0)
19.8(5.6- 
153.0)
3.8 (2.2-6.0)
13.6 (2.6- 
40.1)
24.8 (12.8- 
141.0)
9.3 (1.1-54.8)
5.6(1.7-11.0)
1.6(0.3-6.2)
p value 
(clinical 
PCOS vs. 
non-affected)
<0.001
O.001
<0.001
O.001
O.001
0.003
0.127
0.136
Anovulatory 
PCOS
(n=8)
4.9 (4.0-6.2)
22.0 (4.6- 
153.0)
3.8 (2.3-6.0)
13.0(2.6- 
40.1)
25.8 (12.8- 
141.0)
11.1(1.4- 
22.2)
5.8 (3.3-8.4)
1.8(0.4-4.0)
p value 
(anovulatory 
PCOSvs' non- 
affected)
0.034
O.001
O.001
O.001
<0.001
O.001
0.017
0.013
The number of samples analysed in the non-affected group was 109, in the clinical 
PCOS group was 119 and in the anovulatory group was 80.
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Overall, the median LH/FSH ratio for individual subjects did not differ significantly 
between the clinical PCOS and the non-affected groups (1.6 vs. 1.2, p=0.14 using 
Mann-Whitney U test), although the median ratio was higher in the anovulatory group 
compared to controls (1.8 vs. 1.2, p=0.013). LH concentrations alone were 
significantly higher in both clinical and anovulatory PCOS compared to controls. 
Tukey's test for indices of heterogeneity applied to the clinical PCOS and non- 
affected group showed no significant differences. LH/FSH ratio exceeded 3 in only 
9/119 (7.6%) of samples in the clinical PCOS patients and in 17/109 (15.6%) of the 
controls. (3^=2.047, p=0.153) Two non-affected women had testosterone 
concentrations between 4.0 and 7.0 nmol/L among their 10 samples but have no 
clinical evidence of abnormal menstrual cycle or hyperandrogenism.
44
Figure 2.1 shows the overall median and range values for LH/FSH ratio in women 
with PCOS and normal women. (PCOS subjects 5,6,7,9 had an ovulatory cycle)
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Discussion:
This study has shown that the median and ranges of the LH/FSH ratio for individual 
subjects do not differ significantly between clinical PCOS and normal menstruating 
women. Whilst FSH and LH vary throughout the menstrual cycle, it may have been 
expected that the median of the LH/FSH ratios would have been similar between 
normal individuals. However, it was found that there was a wide variation in the 
overall ratio of any given individual. Traditionally, a LH/FSH ratio of above 3 has 
been used to diagnose PCOS (179). I found that only 7.6% of all data from our PCOS 
subjects showed a ratio of above 3 while in normally cycling women this ratio was 
actually exceeded more frequently (15.6%). In fact, repeated measurement of just LH
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seemed better than the LH/FSH ratio at discriminating clinical PCOS from controls, 
although it would be premature to use this data to advocate such a use.
Confirmation of the unreliability of the LH/FSH ratio is important as whilst the 
Rotterdam consensus(lS) now does not recommend it as a diagnostic test, it is still 
often requested for that purpose. For example, in my institution approximately 20% of 
the 12,000 annual requests for LH and FSH measurement indicated PCOS as a reason 
for the request, on at a cost of over £20,000.
This data is the first to look at the LH/FSH ratio over a complete menstrual cycle and 
is in accord with a previous study by Oei and Kazer(lSO) that looked at the LH/FSH 
ratio variability by repeating LH and FSH concentrations once monthly for four 
consecutive months. Like me they concluded that the LH/FSH ratio was too 
unreliable in distinguishing between PCOS and normal menstruating women in 
clinical practice.
The reasons for the apparently poor performance of the ratio must remain speculative. 
However, it is possible that the test has become less useful than it used to be because 
of changes to the diagnostic criteria for PCOS (leading to the inclusion of more 
ovulatory patients) as well as changes in the specificity of gonadotrophin assays.
In conclusion, this data has shown that variability in the LH/FSH ratio is at least as 
large for normal women as it is for those with clinical PCOS. In support of the recent 
Rotterdam consensus this study therefore confirms that the ratio has little diagnostic 
utility in clinical practice.
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2.2 Is Ultrasound scan to diagnose PCOS necessary?
Whether the presence of polycystic ovaries on ultrasound scanning should be used to 
diagnose polycystic ovary syndrome is still debatable. A recent study involving 
questionnaires to endocrinologists and gynaecologists to compare their clinical 
practices in management of patients with PCOS suggested that ovarian ultrasound 
was requested by almost all gynaecologists (91%) but by less than half of the 
endocrinologists (44%)(182). This difference in opinion is indicative of the 
controversies over the inclusion of the ultrasound findings in the diagnostic criteria 
for PCOS. Polycystic ovary is a common finding even in women without PCOS 
(173, 183-185). In a study where an ultrasound scanning was performed in normal 
women of reproductive age, of the 158 subjects who were not on oral contraceptives, 
23% had polycystic ovary(186). Furthermore, the appearance of polycystic ovaries 
on ultrasound has been shown to have no impact on fertility(187) and neither 
morphology nor volume of the ovaries was associated with distinctive metabolic or 
reproductive phenotypes in women with PCOS(188). On addition, about 10% of 
women with PCOS do not have polycystic ovary on ultrasound scan. A recent study 
in Germany found polycystic ovary in only 78% of women in a cohort of 212 PCOS 
patients previously recruited using the NIH criteria(189). Nevertheless, it should be 
noted that some of the studies above were done using the older criteria for polycystic 
ovaries and relevance of diagnosis made using the new criteria remained to be 
determined.
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The definition of PCOS was first drawn up in 1990 from an expert conference 
sponsored by the National Institutes of Health (NIH). This criteria defines PCOS as a 
disorder of ovarian androgen excess as characterized by hyperandrogenism and 
oligo/amenorrhoea after exclusion of other disorders. However, in 2003, another 
expert conference held in Rotterdam, sponsored in part by the European Society for 
Human Reproduction and Embryology and the American Society for Reproductive 
Medicine where a new criteria was drawn up(15). According to the Rotterdam 
criteria, PCOS can be diagnosed if two out of three of hyperandrogenism, 
oligo/amenorrhoea or polycystic ovary on ultrasound is present after excluding related 
aetiologies. If we look at it closely, the Rotterdam criteria does not replace but in fact 
expands the definition of PCOS to include 2 extra subgroups i.e. those with polycystic 
ovary and hyperandrogenism and those with polycystic ovary and ovarian 
dysfunction. Whether polycystic ovary confers an increase in insulin resistance is still 
debatable(190-192). The classical phenotype of insulin resistance, hyperandrogenism 
and menstrual irregularity may be associated with an increased risk of type 2 diabetes 
and metabolic syndrome but as yet, we do not have data to suggest this in the two new 
phenotypes mentioned above. As we still lack of a clear aetiologic mechanism of 
PCOS, study population may need to be clearly defined in research settings as the 
different groups may pose different risk issues and respond to treatments differently. 
Therefore in the following studies, attempts were made to only recruit patients with 
PCOS with the phenotype of hyperandrogenism and oligomenorrhoea.
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Chapter 3:
Reliability of Total Testosterone, Free Androgen
Index and Bioavailable Testosterone in the
diagnosis of Hyperandrogenism
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Introduction:
The recent Rotterdam consensus 2003 has recommended hyperandrogenism as one of 
the three diagnostic criteria for diagnosis of PCOS(15). Hyperandrogenism presents 
as hirsutism, acne or male pattern alopecia; serum concentrations of total testosterone 
are often at the upper limit of normal or modestly elevated, but free testosterone 
(direct measurement or using the free androgen index) is usually elevated(193). This 
is recognised to be due to the clearance and bioavailability of testosterone which is 
affected by the serum concentration of sex hormone binding globulin (SHBG) hence, 
the diagnostic utility of an isolated serum testosterone measurement is questionable 
and probably adds to the heterogeneity of diagnostic criteria used hi PCOS. 
Bioavailable testosterone (BioT) measurement (which excludes SHBG bound 
testosterone) and free androgen index (FAI), which accounts for the sex hormone 
bound fraction of testosterone, are assumed to be inherently superior estimates of 
hyperandrogenism than the measurement of total testosterone concentration alone. 
While the biological variability of total testosterone had been previously studied(194, 
195) in normal individuals, no comparative data currently exists on the biological 
variation of BioT and FAI. This data is critical to determine the relative suitability 
and/or superiority of these measures in both the initial and subsequent follow-up of 
the biochemical assessment of androgen excess in PCOS. Therefore, this study aimed 
to compare the biological variability of total testosterone with that of the biological 
variability of both the free androgen index and bioavailable testosterone, to determine 
the least variable measurement for clinical practice.
Research Design and Method:
50
Twelve overweight Caucasian women diagnosed to have PCOS (median age 28yrs, 
range 18-31) and eleven weight matched Caucasian women (controls) having regular 
menses (every 28-30 days) and without PCOS (median age 30yrs, range 19-33), 
participated in the study. The diagnosis of PCOS was based on evidence of a history 
of oligomenorrhea and either hirsutism or acne, together with hyperandrogenemia 
(Free androgen index > 8). Free androgen index (FAI) was defined as testosterone x 
100/SHBG, with both units in nmol/L. Nonclassical 21-hydroxylase deficiency, 
hyperprolactinemia, and androgen secreting tumours were excluded by appropriate 
tests before the diagnosis of PCOS was made(196). No subject was taking any 
medication at the start of the study, nor during the preceding six months, and there 
was no concurrent illness. All subjects were on an unrestricted diet and were 
instructed not to modify their usual eating patterns during the period of sampling. 
Fasting plasma glucose, age and BMI were obtained. Patients and controls were 
matched for BMI (Table 3.1). Fasting venous blood was collected into serum gel 
tubes (Becton Dickinson) at the same time each day (0800-0900h) on 10 consecutive 
occasions at 4-day intervals. Samples were separated by centrifugation at 2000g for 
15 minutes at 4 °C, and aliquots of the serum were stored at -20 °C within 1 hour of 
collection. The study was conducted in accordance with the guidelines in the 
Declaration of Helsinki. All subjects gave their informed written consent prior to 
entering the study that had been approved by our local ethics committee. The clinical 
trial registration number for this study was ISRCTN65353256.
Reagents
Before analysis, all the serum samples were thawed and thoroughly mixed. The
duplicate samples (i.e. two per visit) were randomized and then analysed in a single
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continuous batch using a single batch of reagents. Duplicate aliquots of stored serum 
were analysed for SHBG, total testosterone and Bio T and analysed in singleton. The 
FAI was obtained as the quotient 100 T/SHBG. Serum testosterone, was measured on 
an Architect analyser (Abbott Laboratories, Maidenhead, UK) and SHBG was 
measured on the DPC Immulite 2000 (Euro/DPC, Llanberis, UK) analyser using the 
manufacturers recommended protocol. The intra-assay coefficient of variation for 
total testosterone and SHBG as determined from duplicate study samples was 4.9% 
and 5.8% respectively. Bioavailable testosterone was measured using minor 
modification of the method of Tremblay and Dube(197) that was widely reported as a 
measure of non-SHBG-bound testosterone(198-201). Briefly, this technique used 3H- 
labelled testosterone as a tracer, where SHBG was precipitated from charcoal-stripped 
serum using saturated ammonium sulphate and the radiolabelled testosterone 
measured in the supernatant as an estimate of the percentage non-SHBG-bound 
fraction. Concentration of bioavailable testosterone was then calculated as this 
fraction of the total testosterone. Inter-assay precision was 5.25% at a concentration of 
5.0nmol/L.
Statistical Analysis
Statistical analysis was performed using SPSS version 14. Biovariability data was
analysed by calculating analytical, within subject, and between subject variances
f\ ry f*
(SDA , SDi , SDo , respectively) according to the methods of Fraser and Co- 
workers(176, 202). Using this technique, analytical variance (SDA2) was calculated 
from the difference between duplicate results for each specimen (SDA2 = 2d2/2N, 
where d is the difference between duplicates, and N is the number of paired results). 
The variance of the first set of duplicate results for each subject on the ten assessment
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days was used to calculate the average biological intraindividual variance (SDj2) by 
subtraction of SDA2 from the observed dispersion (equal to SDi2 + SDA2). Subtracting
r\ n
SDi + SDA from the overall variance of the set of first results determined the 
interindividual variance (SDG2). The intraindividual (SDj) and interindividual (SDG) 
variations were estimated as square roots of the respective variance component 
estimates. The reference change value or critical difference between two consecutive 
samples in an individual subject (i.e., the smallest percentage change unlikely to be 
due to biological variability) was calculated using the formula 2.77(CVi), where CVi 
is the within subject biological coefficient of variation(176). The index of 
individuality (lol) was derived from the ratio of intra- and interindividual variation 
(SDi/SDo)(176). When the lol for a particular test is 0.6 or less, conventional 
population based reference intervals are of limited value in the detection of unusual 
results for a particular individual. When the lol is 1.4 or more, the variation in an 
individual will fit the population reference limits more closely, thus being suitable as 
a screening test. A power calculation based on our previous biological variability 
studies suggested that a total number of 8 patients per arm were sufficient to achieve 
statistical significance p<0.05.
Results:
The baseline clinical and biochemical details of the subjects are shown in Table 3.1.
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Table 3.1. Baseline clinical and biochemical features of subjects with PCOS and 
controls.
Parameter
*Age (years)
*BMI (kg/m2)
#Testosterone 
(nmol/L)
*SHBG (nmol/L)
#Bio T (nmol/L)
# Free androgen 
index %
#Non SHBG 
bound 
testosterone 
(nmol/L)
PCOS
(11=12)
26.3 ±4.58
33.216.32
3.9 (3.1-4.6)
22.9 ± 5.06
1.3(1.0-1.6)
16.1(11.6-21.1)
0.19(0.13-0.26)
Controls 
(n=ll)
28.4 ± 4.72
29.913.25
3.2 (2.6-4.0)
64.5 ± 7.65
0.9(0.7-1.1)
7.4 (5.9-9.4)
0.07(0.06-0.11)
P value
NS
NS
< 0.001
< 0.001
< 0.001
0.001
0.001
*Data presented as mean ± SD.
#Data presented as median (range) due to non Gaussian distribution
Figure 3.1, 3.2 and 3.3 showed the median and range of Bio T, FAI and total 
testosterone for the individuals in the three groups. The PCOS group had 
significantly higher median BioT, Total T and FAI than the control group (median 
(range), 1.3 (1.0-1.6) vs 0.9 (0.7-1.1) nmol/L, p=0.001, 3.9 (3.1-4.6) vs 3.2 (2.6-4.0) 
nmol/L, p=0.001 and 16.1 (11.6-21.1) vs 7.4 (5.9-9.4), p=0.001, respectively). The 
distribution of both Bio T and FAI in controls and patients with PCOS were non-
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Gaussian using the Kolmogarov-Smirnov test. Data was therefore log-transformed 
before calculations were performed.
Figure 3.1 Median and range of values (unadjusted for analytical variation) for 
Bioavailable Testosterone (Bio T) in control and PCOS
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Figure 3.2 Median and range of values (unadjusted for analytical variation) for FAI in 
control and PCOS
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Figure 3.3 Median and range of values (unadjusted for analytical variation) for Total 
Testosterone in controls and pcas 
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In both the pcas and control groups the intraindividual variance was small and 
similar for BioT and FAI, as shown in Table 3.2. Index of individuality for FAI, Bio 
T and total testosterone were 0.87, 0.91 and 0.69 respectively for pcas and 0.61 , 
0.71 and 0.43 for controls. There was no significant difference between CVi of BioT, 
F AI and total testosterone. 
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Table 3.2 Percentage contribution from intra, inter and analytical variance to total 
variance in PCOS and controls.
PCOS
BioT
FAI
Total
testosterone
Non SHBG
bound T
% analytical
variance from
total variance
2.8
1.8
5.2
1.6
%intraindividual
variance from
total variance
28.8
29.0
30.7
21.8
%interindividual
variance from
total variance
68.4
69.2
64.1
76.6
Control
BioT
FAI
Total
testosterone
Non SHBG
bound T
% analytical
variance from
total variance
3.5
1.1
1.5
1.0
%intraindividual
variance from
total variance
5.6
5.4
15.1
7.4
%interindividual
variance from
total variance
90.8
93.5
83.4
91.6
In the group with PCOS a strong correlation was seen between the Bio T values and 
FAI (r=0.9, p=0.001). However, this correlation was not observed in the control 
group (r=0.2, p=0.079). The minimum and maximum critical difference between two 
consecutive BioT samples in an individual patient with PCOS was -37% or +58% of 
any initial level of BioT. This indicates that a subsequent sample must rise by greater 
than 58% or fall by more than 37% to be considered significantly different from the
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first. In comparison, the critical difference for FAI was -41% and +70%. Total 
testosterone was normally distributed and critical difference was ±33%.
Discussion:
This is the first study to systematically examine and compare the biological variability 
of Bio T and FAI to total testosterone in PCOS, and demonstrates the relative 
suitability of each measure in detecting hyperandrogenism in PCOS. Indeed, one of 
the advantages in specifically assessing the biological variability of these tests is that 
any differences found between them can be attributed more to the test itself rather 
than due to analytical limitations of the assays involved.
There were high between-subject variations for BioT and FAI in both PCOS and 
controls limiting their potential use as a measure to assess the degree of androgen 
excess present from a single estimate. However, if we consider the range of values in 
PCOS women, there was an overlap in values between women with PCOS and 
controls in total testosterone and BioT but no overlaps in FAI making it a potentially 
better marker in identifying patients with PCOS than total testosterone alone.
Testosterone circulates in blood bound to both albumin and to the specific binding 
protein, sex hormone binding globulin, with about 1% in women present in the free, 
non-protein state (203-205). The bioactive component includes the free plus albumin 
bound fraction testosterone but not the SHBG-bound testosterone. Therefore, 
variation in concentration of SHBG will influence the total concentration of 
testosterone and thus present difficulty in interpretation of results. SHBG 
concentration increases during pregnancy, oral contraceptive (oestrogen) usage,
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hyperthyroidism, administration of antiepileptic drugs and weight loss. On the other 
hand, it decreases with hypothyroidism, obesity or androgen excess(206). As 
bioavailable testosterone measures only the bioactive and not the SHBG-bound 
component and the free androgen index is a calculated measure of testosterone 
adjusted for abnormalities in SHBG, they are presumed to be a more reliable index of 
measurement for hyperandrogenism.
The low lol value for all three tests in control subjects suggest that none are ideal 
diagnostic markers for detecting hyperandrogenism in patients with PCOS. This is 
because a low lol means that healthy individuals have androgen values which 
repeatedly remain close to their 'set point' within the population reference range 
rather than moving within the reference range. As a consequence, it means that 
individuals who usually have their set point at the lower end of the reference range 
can develop significant hyperandrogenaemia (in relation to themselves) but be 
regarded as 'normal' because their result still falls within the population reference 
range. In contrast, use of a low lol test to follow up patients already known to have 
the disease can actually be of advantage as it means that a relatively small change in 
their test result will be of likely significance.(207).
In this respect, both the lol and CVi of total testosterone, BioT and FAI in PCOS 
patients were relatively similar suggesting that all three are as useful (or otherwise) in 
monitoring of androgen levels once diagnosis has been made. Both the strong 
correlation seen between Bio T levels and FAI in the group with PCOS and the 
similar intra/interindividual variance suggests that when the diagnosis of PCOS has 
been made, measurement of either Bio T or FAI could be used with equal utility when
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assessing androgen status using a single measure. This correlation was not seen in 
the control group possibly, presumably due to the much smaller range of results 
amongst the healthy participants compared to those with PCOS. The critical 
difference value determined in this study means that for any given individual, when 
serial measures of Bio T are used to assess change in androgen status a subsequent 
value must rise by greater than 58% or fall by greater than 37% to be considered 
significantly different from the first (i.e., the change is greater than that explained by 
biological variation alone). The same argument applies for FAI where the value 
should be greater than 70% or less than 41%. The Rotterdam criteria suggested the 
use of hyperandrogenaemia as a means of diagnosing PCOS. However, once the 
diagnosis is made, monitoring in response to treatment may be useful to assess a 
treatment effect.
The non-SHBG bound T was calculated according to the method of Pearlman and 
Crepy(208) which was found to have a good correlation with that of the direct 
radioimmunoassay of T in ammonium-sulfate-precipated plasma(209). The results 
were also included in Table 3.1 and 3.2. As expected, the calculated non-SHBG 
bound T and its variability was found to be closely correlated to FAI as both represent 
an indirect measure of free testosterone.
There are limitations to this study. Firstly, this study was executed and analysis 
performed before solvent extraction of raised testosterone samples was routinely done 
by the local laboratory. A recent publication suggested that the Abbott testosterone 
assay is prone to interference by DHEAS that can be removed by a solvent extraction 
and re-analyses method.(165) This in turn, could potentially have an influence on the
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study findings. However, DHEAS interferes not only in the Abbott testosterone assay, 
but in most other immunoassay methods as well(210). Therefore these results should 
be comparable to those measured on women in most routine clinical laboratories in 
the UK, albeit unknown the proportion of laboratories which would investigate a 
raised result further by either solvent extraction or referral to another laboratory. It 
should however be noted that these findings may only be relevant for the defined 
methodology and be cautious of general application. Secondly, by selecting patients 
for the study as having PCOS on the basis of a raised FAI, this could itself have 
introduced a bias in establishing which test was superior at identifying the disease. 
Nonetheless, any androgen cut-off used for diagnosis, whether being total T, BioT or 
FAI, is necessarily arbitrary and the routine use of FAI does not detract from the fact 
that the overlap between measurements of total testosterone and BioT in healthy and 
PCOS subjects were far greater than with FAI.
In conclusion, FAI appears a better diagnostic marker for hyperandrogenism in 
patients with PCOS as there is less overlap with normality, but once the diagnosis is 
made then all three methods have equal utility for monitoring changes in the androgen 
status.
62
Chapter 4:
Use of CRP as marker for cardiovascular 
disease in PCOS: The biological variation of hs-
C Reactive Protein
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Introduction:
Chronic subclinical inflammation had been shown to be an integral part of the insulin 
resistance syndrome(211) and had been proven to independently predict future risk of 
coronary events in both apparently healthy subjects and those with acute coronary 
syndromes(212-216). Elevated C-reactive protein (CRP) concentrations with an 
inverse relationship with insulin sensitivity, had been shown to occur in individuals 
with PCOS(97) and was thought to be contributory to an increased risk of coronary 
heart disease(121). The measurement of CRP as an additional screening test for 
cardiovascular risk assessment has been suggested(217) due to its association with 
insulin resistance(218, 219). This may be of particular relevance to a high-risk group 
such as women with PCOS. No data currently exists on the biological variability of 
CRP and insulin resistance within the same individuals with PCOS, information that 
is essential to assess the full relationship between the two measures. Therefore, this 
study aimed to establish whether a PCOS patient's CRP concentration remains within 
narrow biological limits or varies more widely, over a given time period, as well as to 
correlate its variability to that of insulin resistance.
Research Design and Method:
Twelve overweight, (body mass index (BMI) mean±SD, 33.2± 6.3 kg/m2), Caucasian 
women diagnosed to have PCOS (median age 28 yrs, range 18-31) and eleven weight 
matched Caucasian women (controls) (BMI mean±SD, 29.913.3 kg/m2), having 
regular menses (every 28-30 days) and without PCOS (median age 30 yrs, range 19- 
33), participated in the study. The body mass index in the PCOS group was non- 
significantly greater (p=0.151) than that of the control group. Diagnosis of PCOS was 
based on evidence of hyperandrogenemia (Free androgen index > 8, mean±SD PCOS
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21.8517.95, controls 4.6812.05, with a history of oligomenorrhea and hirsutism or 
acne. Mean and SD of testosterone and sex hormone binding globulin (SHBG) in 
PCOS group compared to control group were 4.69±0.76 vs. 2.66±0.87nmol/L 
(p<0.001) and 22.87±5.06 vs 64.51±7.65nmol/L (pO.OOl). Fasting venous blood 
was collected into serum gel tubes (Becton Dickinson) and one fluoride oxalate tube 
at the same time each day (0800-0900) on 10 consecutive occasions at 4-day intervals. 
Samples were separated by centrifugation at 2000g for 15 min at 4 °C, and two 
aliquots of the serum were stored at -20 °C within 1 h of collection. Plasma glucose 
was analysed in singleton within four hours of collection. The serum samples were 
split before assay. All subjects gave their informed written consent prior to entering 
the study that had been approved by the Hull and East Riding Local Research Ethics 
committee.
Serum CRP was measured using the high sensitivity method on a DPC Immulite 
analyzer (Euro/DPC, Llanberis, UK), using the manufacturer's recommended 
protocol. The interassay coefficient of variation was 4.5% using the study samples. 
Serum insulin was assayed using a competitive chemiluminescent immunoassay, 
supplied by Euro/DPC, Llanberis, UK. The assay was performed on a DPC Immulite 
2000 analyser (Euro/DPC, Llanberis, UK), using the manufacturer's recommended 
protocol. The coefficient of variation of this method was 8% calculated as below 
using study samples. The analytical sensitivity was 2 ^lU/ml and there was no stated 
cross- reactivity with proinsulin. Plasma glucose was measured using a Synchron LX 
20 analyzer (Beckman-Coulter, High Wycombe, UK), according to the 
manufacturer's recommended protocol. The coefficient of variation for this assay was 
1% with a mean glucose value of 5.3 mmol/L during the study period. Fasting
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glucose in the PCOS group (mean±SD, 4.98±0.58mmol/L) was not significantly 
different from the control group (4.81±0.32mol/L). Fasting insulin was much high 
in the PCOS group than in the control group (meaniSD, 23.56±8.54 1 
7.70±1.83umol/L, pO.OOl)
Statistical analysis was performed using SPSS for Windows NT, version 9.0 (SPSS 
Inc., Chicago, Illinois). Biovariability data was analysed by calculating both intra- and 
interindividual analytical variances (SDA2, SDj2, SDo2, respectively), according to the 
methods of Fraser and Harris(176). The insulin resistance was calculated using the 
Homeostasis Model Assessment (HOMA) method (Resistance = (Insulin x glucose)/ 
22.5)(220).
Before analysis, all the serum samples were thawed and thoroughly mixed. The 
duplicate samples (i.e. 2 per visit) were randomized and then analysed in a single 
continuous batch using a single batch of reagents. The distribution of CRP was found 
to be Log Gaussian (by Kolmogorov-Smirnov) in both the women with PCOS and the 
control group and consequently was logarithmically transformed before statistical 
analysis.
Results:
The CRP concentration in the PCOS group was greater than in the control group 
(median (range), 3.54 mg/L (0.80-61.35) vs. 1.07 mg/L (0.18-9.24), p=0.0001 using 
the Mann -Whitney test).
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Figure 4.1 Median and range of CRP concentration in the PCOS and control groups
20
1ri<r
Ko
5
0
___ ___ __
1 * 
—— I —— I—
1 2
PCOS
±::::• in
— i — i — i — i — i — i—
346678 
subjects
j
_
-1—
9
-r-
t— 1 — 1 — 1
10 11 12
!- 1U
ccu s-
0-
Controls
" i r, ,~* j i , .—— 1 ——— (-"H ——— III ——— 1 —— 1 1 ' 1 ——— 1 
123456789 10 11
subjects
For the group with PCOS the analytical variance contributed to 0.2% of the total test 
variance; intraindividual variance, 30.2% and interindividual variance, 69.6%. For the 
control group the analytical variance contributed to 1% of the total test variance; 
intraindividual variance, 36.8% and interindividual variance, 62.2%. After accounting 
for analytical variation, the mean intraindividual variation was similar in both the 
group with PCOS and the control group (mean 1.63 vs. 1.76). In contrast, as 
previously reported for the same individuals(221), the HOMA-IR was not only greater 
in the group with PCOS (mean (range), 5.85units (1-42.1) vs. 1.67 units (0.48-3.49), 
p=0.001) but also more variable than the control group (mean 1.19 vs. 0.23). The 
interindividual variation in CRP in its natural log for both groups was similar at 0.5. 
The critical difference between two consecutive CRP samples in an individual patient 
with PCOS, calculated using the formula 2.77(CVi)(176) on the Log derived data, 
was -64% or +179% of any initial level of CRP. This indicated that a subsequent 
sample must rise by greater than 179% or fall by more than 64% to be considered 
significantly different from the first.
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Discussion:
This is the first study to examine the biological variation of CRP in women with 
PCOS and showed that while the mean concentration of CRP was higher in 
individuals with PCOS compared to healthy controls, the intraindividual variation of 
CRP was similarly large in both groups. Indeed, the potential utility of CRP as a 
marker of cardiovascular risk may be limited by the magnitude of this variability in 
both health and disease, since there can be substantial overlap between PCOS and 
control individuals. The control group data was in accord with results demonstrated 
by previous studies suggesting a similarly wide intraindividual variability in CRP of 
approximately 30-40%.(222-225). In contrast, Ockene et al have suggested that hs- 
CRP had a degree of measurement stability that was similar to that of total cholesterol 
therefore providing evidence of potential clinical utility of hs-CRP screening as a tool 
for vascular risk prediction(226). This issue of clinical usefulness, therefore, has yet 
to be resolved.
Low grade chronic subclinical inflammation as evidenced by modest elevation in 
CRP levels has emerged as a powerful predictor of cardiovascular disease(227) and 
has also been shown to predict the risk of developing type 2 diabetes(228, 229). The 
elevated CRP levels in individuals with PCOS compared to healthy controls with 
normal menstrual rhythm and normal androgens in this study was similar to that 
previously reported(97) and would explain, at least in part, the increased risk of 
cardiovascular disease and type 2 diabetes in this group. The benefit of therapy in 
reducing the rate of cardiovascular events in individuals with elevated levels of CRP 
was shown in the Cholesterol and Recurrent Events trial where long-term therapy 
with pravastatin significantly lowered CRP levels(230) and the efficacy of pravastatin
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in lowering the rate of cardiovascular events was greatest in those with increased 
levels of CRP(231). The measurement of CRP by itself or in conjunction with other 
measurements such as serum lipids in the screening and risk stratification for 
cardiovascular disease is therefore an attractive proposition and has been considered 
by some observers(226, 232). The potential utility of CRP as a marker of 
cardiovascular risk is however somewhat limited as in accord with previous data, my 
results show a significantly greater interindividual variation of CRP levels compared 
to the intraindividual variation observed in both groups. This means that CRP, like 
many clinical chemistry analytes, had limited usefulness when used in conjunction 
with a healthy reference interval as many individuals can have early disease 
associated changes that do not exceed the reference interval. The current lack of 
standardization in low level CRP measurements(233) further limits its application as a 
screening tool. The calculated critical difference should be accounted for and in my 
study was calculated to be -64% or +179%, that is the CRP value would have to fall 
by 64% or rise by 179% before a significant critical difference can be assured.
Chronic subclinical inflammation is thought to be a part of the insulin resistance 
syndrome(211) and an inverse relationship exists between CRP and insulin 
sensitivity(97, 234). These observations together with the known association between 
elevated CRP and the risk of developing type 2 diabetes(228, 229) raises the 
possibility of elevated CRP being a surrogate measure for the presence of insulin 
resistance. The lack of concordance however, between the variability of CRP and the 
variability of insulin resistance in PCOS compared to the controls, indicates that 
despite this known inverse relationship, CRP is not an integrated measure of insulin 
resistance in PCOS. Therefore, an elevated CRP level cannot be used as a surrogate
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marker to establish the presence of insulin resistance in this group. There has also 
been the assumption that in patients with PCOS, CRP value may reflect the presence 
of the metabolic syndrome(97, 235) and indeed it still might, but insulin resistance 
alone would not seem to be the sole cause or the main factor.
It is known that smoking, age and body mass index can influence an individuals CRP 
level(236, 237). The two groups in this study were closely matched for age and body 
mass index. The two individuals who smoked were requested to abstain overnight and 
as their results were indistinguishable from the other subjects in both groups their data 
was included in the analysis. Variations in the automated assays used to measure low 
level CRP exist and have previously been reported(233). A particular advantage of the 
type of study used here is that by eliminating the effect of analytical imprecision and 
concentrating on biological variation several aspects of a diagnostic test can be 
assessed without hindrance from assay limitations.
In conclusion, my results poses limitation of the potential for elevated CRP to be used 
as a screening tool to identify those individuals with PCOS at risk of developing 
cardiovascular disease. Also, as there does not appear to be a direct relationship 
between the variability of IR and CRP, this possibly means that the relationship 
between the two measures is maybe not as intimate as first thought. It seems more 
likely that CRP may reflect or be a marker of many factors which contribute to the 
syndrome.
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Chapter 5:
Association of PCOS and type 2 diabetes:
Comparison of beta cell function in women with
PCOS to those with type 2 diabetes
71
Introduction:
Patients with PCOS have an increased risk of developing type 2 diabetes 
(T2DM)(11), and both conditions are characterised by insulin resistance (IR). 
Increased IR is thought to be central to PCOS and may play a pathogenic role (238). 
There is strong epidemiological evidence that insulin resistance (IR) is an independent 
cardiovascular risk factor (25). The factors underlying the progression of PCOS to 
T2DM are unclear and may be due to an increase in the underlying insulin resistance, 
perhaps due to increasing age, that may differ in both its mean and by its increased 
variability within the same individual (221, 239). The aim of this study was to 
compare the mean and biological variation in IR levels in patients with PCOS to that 
of T2DM, together with age and BMI matched control subjects.
Research Design and Method:
The biological variation of IR was assessed by measuring IR at four day intervals on 
10 consecutive occasions in 12 overweight patients ( BMI >25) with PCOS (BMI 
means ± SD; 33.2 ± 6.3), 12 postmenopausal Caucasian subjects with diet controlled 
T2DM (31.1 ± 3.3), 11 healthy women with normal menstrual periods (every 28-30 
days) (29.9 ± 3.25) and 11 healthy postmenopausal women (32.4 ± 5.3). Diagnosis of 
PCOS was based on the Rotterdam criteria 2003(15). All patients with PCOS had 
evidence of hyperandrogenemia (Free androgen index > 8), with a history of 
oligomenorrhea and hirsutism or acne. Diabetes was diagnosed on a fasting venous 
plasma glucose concentration >7.0 mmol/1 (126mg/dl) or a 2-hour concentration 
>11.1 mmol/1 (200mg/dl) after a 75g oral glucose tolerance test. Women were 
considered postmenopausal if they had amenorrhoea for >1 year and follicle 
stimulating hormone levels >20 IU/1. Exclusion criteria included any secondary cause
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of hyperglycaemia, current or previous (in the preceding 6 months) use of oestrogen 
therapy, treatment with insulin or oral hypoglycaemic agents, untreated 
hypothyroidism, history of drug or alcohol abuse or smoking. Subjects on 
medications unrelated to diabetes took their medication as usual with no changes 
reported during the sampling period. Fasting venous blood was collected at the same 
time each day (0800-0900). Samples were separated by centrifugation at 4°C, and two 
aliquots of the serum were stored at -20°C within 1 hour of collection. Plasma 
glucose was analysed in singleton within four hours of collection. The serum samples 
were split before assay. All subjects gave their informed written consent and the study 
had been approved by the local ethics committee.
Serum insulin was assayed using a competitive chemiluminescent immunoassay, and 
plasma glucose measured using a Synchron LX 20 analyser. Before analysis, all the 
serum samples were thawed and thoroughly mixed. Duplicate samples (ie. two per 
visit) were randomized and analysed in a single continuous batch. Insulin resistance 
was derived using the Homeostasis Model Assessment method (HOMA-IR) from 
fasting measures of serum insulin and plasma glucose, calculated using the 
homeostasis model assessment (HOMA) method (HOMA-IR = (insulin x 
glucose)/22.5)(220). Percentage beta cell function were calculated using the computer 
based programme(220, 240).
Statistical analysis was performed using SPSS for Windows, version 11.0. Data on 
insulin and HOMA-IR was non Gaussian and therefore non-parametric calculations 
were used. Group differences were compared by analysis of variance. Where significant 
differences were indicated Scheffe's post-hoc test was applied.
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Bio variability data was analysed by calculating analytical, within subject, and 
between subject variances (SDA2, SDj2, SDG2, respectively) according to the methods 
of Fraser and Co-workers(176, 202). Using this technique, analytical variance (SDA2) 
was calculated from the difference between duplicate results for each specimen (SDA2 
= 2d2/2N, where d is the difference between duplicates, and N is the number of paired 
results). The variance of the first set of duplicate results for each subject on the ten 
assessment days was used to calculate the average biological intraindividual variance 
(SDj2) by subtraction of SDA2 from the observed dispersion (equal to SDj2 + SDA2). 
Subtracting SDi2 + SDA2 from the overall variance of the set of first results 
determined the interindividual variance (SDG2). The intraindividual (SDj) and 
interindividual (SDo) variations were estimated as square roots of the respective 
variance component estimates. Coefficient of variation was calculated from mean 
divided by standard deviation. For all analysis, a two-tailed P < 0.05 was considered 
to indicate statistical significance.
Results:
The clinical and biochemical details of the individual subjects were shown in Table 5.1. 
No significant difference in BMI was observed between any of the four groups, p = 0.37. 
As anticipated, PCOS/premenopausal controls were younger than T2DM7 
postmenopausal controls (p O.0001). When the mean HOMA-IRs for each PCOS 
patient were combined as a group they did not differ from patients with T2DM 
(3.1±1.2 and 1.9±0.9, respectively). However, both groups were higher than in their 
matched controls (p = 0.005) (pre-menopausal women, 1.0±0.2; postmenopausal 
women 1.3±0.5).
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Table 5.1 Clinical and biochemical features of subjects. Data with Gaussian 
distribution are presented as means ± SD while those with non-Gaussian distribution 
are presented as median (interquartile ranee). ND: test not done, HOMA-IR: 
calculated insulin resistance, HOMA %B: calculated beta cell function, T: total 
testosterone, SHBG: sex hormone binding globulin
Parameter
Age (yr)
Body mass 
index (kg/m2)
Fasting 
glucose 
(mmol/L)
Fasting Insulin 
(uU/ml))
HOMA-IR
HOMA %B
T (nmol/litre)
Mean 
intraindividual 
variance for IR
Healthy post- 
menopausal 
(n=ll)
56.2±6.1 b' c
32.4 ±5.3
5.0 ±0.5
9.6 (6.8-1 1.5)c
2.0(1.6-2.7)a' c
111.9
ND
O.IS3' 0
Post- 
menopausal 
T2DM (n=12)
61.7±7.0d' e
31.1 ±3.3
7.6 ± 2.3
13.4(8.3- 
15.2)d' e
3.7(2.7-5.3)a' (1
62.3
ND
LOS3-"
Healthy pre- 
menopausal 
(n=ll)
28.4 ± 4.7"' a
29.9 ±3.25
4.8 ± 0.3
8.1 (6.3-9.0)"' '
1.7(1. 3-2.0)"' '
106.5
2.7 ±0.9*
0.23d' 1
PCOS
(n=12)
26.3±4.6C' 6
33.2 ±6.3
5.0 ±0.6
23.5(16.1-
33.3)c' e' f
4.9(3. 8-8.0)c' 1
208.8
4.7 ±0.8*
1.190' 1
3 denotes p< 0.05 between healthy postmenopausal and postmenopausal T2DM
b denotes p< 0.05 between healthy postmenopausal and healthy premenopausal
c denotes p<0.05 between healthy postmenopausal and PCOS
d denotes p<0.05 between postmenopausal T2DM and healthy premenopausal
e denotes p<0.05 between postmenopausal T2DM and PCOS
f denotes p<0.05 between healthy premenopausal and PCOS
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There was no difference in IR between the pre and postmenopausal controls. Insulin 
levels were higher for PCOS than T2DM and both significantly higher than the control 
populations (pO.OOOl). Percentage beta cell function were 208.8%, 62.3%, 106.5% and 
111.9% respectively in PCOS, postmenopausal women with T2DM, healthy 
premenopausal and healthy postmenopausal women. Mean intraindividual variation of 
IR for PCOS, postmenopausal T2DM, healthy pre-menopausal and healthy post­ 
menopausal were 1.19,1.05, 0.3, 0.15 respectively (pO.OOl).
Discussion:
This is the first analysis to compare the mean and biological variation of insulin 
resistance in PCOS with that of type 2 diabetes. These data showed that the mean IR 
and its biological variability did not differ between PCOS and T2DM, although 
insulin concentrations in the PCOS group were considerably greater. All the 
parameters were higher than the respective matched control subjects.
These findings have several implications. Firstly, they suggested that the progression 
from PCOS to the development of T2DM was unlikely to be due to a further increase 
in insulin resistance (or variability), but rather the progressive failure of pancreatic 
beta cells that was recognised in T2DM(241). The HOMA beta calculation for beta 
cell function supported this hypothesis in the fact that percentage beta cell function 
was much reduced in postmenopausal women with T2DM compared to other groups. 
Although similarly insulin resistant, beta cell function was much increased in patients 
with PCOS, with a corresponding reduction in insulin sensitivity. This increased 
workload against insulin resistance, in some women may lead to a subsequent failure
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of beta cells and consequently T2DM. Gungor et al had shown that adolescents with 
T2DM had impairment in first phase insulin secretion (FPIS) and second phase 
insulin secretion (SPIS)(241). Other studies by the same group suggested that 
adolescent PCOS with normal glucose tolerance (NOT) were more hyperinsulinaemic 
than matched obese girls (242), and those with impaired glucose tolerance (IGT) had 
impaired FPIS with no derangement in SPIS (243). Comparing across their studies, 
Gungor et al proposed that the essential metabolic determinant of the progression 
from NOT to IGT to T2DM was due to pancreatic beta cell failure(241) and the 
findings presented here were consistent with this suggestion.
Insulin resistance had been shown to be an independent risk factor for cardiovascular 
disease(244) and patients with PCOS may have an increased cardiovascular risk(109, 
124-126, 245). That the mean IR was as high in T2DM implied that women with 
PCOS may have a cardiovascular risk comparable to T2DM despite not being 
hyperglycaemic. While biological variability in IR has not been proven to add to the 
risk already present in patients with high mean IR values, glucose variability has 
recently been found to be associated with increased risk of free radical damage, 
independent of mean glucose in patients with type 2 diabetes(246). It remained 
possible that an increase in biological variability of IR may be associated to or in fact 
is an independent risk for cardiovascular risk.
The data also showed that in individuals with the same BMI and ethnicity(247-249) 
both the mean level and the intraindividual variation of IR were both low and did not 
differ between the BMI matched premenopausal and postmenopausal controls, 
indicating that IR and its biological variation did not change substantially with age
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and was independent of menopausal status.. A limitation of this study is that the data 
from two different studies were used for comparison.
In conclusion, insulin levels were lower in patients with T2DM compared to PCOS 
although the mean and biological variations of IR were comparable; suggesting that 
beta cell dysfunction may determine the progression of PCOS to T2DM.
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Chapter 6:
Effect of Metformin and Pioglitazone on 
Endothelial function in women with Polycystic
Ovary Syndrome
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Introduction:
There is currently new evidence to suggest that insulin resistance seen in metabolic 
syndrome, which includes diabetes and polycystic ovary syndrome, causes endothelial 
dysfunction (250-253) and vascular endothelium plays an active role in 
cardiovascular disease(254, 255). Endothelial dysfunction is an important factor in 
the pathogenesis of atherosclerosis and assessing the degree of this dysfunction and its 
changes with medication can be non-invasively performed with techniques such as 
flow mediated dilation (FMD)(253).
Women with PCOS had been found to have altered vascular function(256) and this 
was variably associated with IR, hyperandrogenism and other factors such as lipids or 
inflammatory markers such as C-reactive protein(121, 250). IR had been proposed to 
be associated with endothelial dysfunction through mechanisms including insulin 
stimulating NO synthase gene expression(257) and endothelin-1 expression through 
activation of the mitogen-activated protein kinase pathway. Both metformin and 
pioglitazone are insulin sensitizers commonly used for the treatment of patients with 
PCOS and there were suggestions that metformin is effective in improving endothelial 
function in women with PCOS as measured by flow mediated vasodiliatation(122, 
124, 150, 258). However, there had not been any previous studies comparing the 
efficacy of pioglitazone to metformin on its effect on endothelial function. Therefore 
the aim of this study was to investigate the effect of vascular function in women with 
PCOS on treatment with pioglitazone as compared to metformin.
Research Design and Method:
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This is a randomised parallel controlled trial to assess the change in endothelial 
function with metformin and pioglitazone in women with PCOS. Subjects aged 
between 30-50 years were recruited from the endocrine clinics and those with 
impaired glucose tolerance and diabetes were excluded using the 2 hour OGTT test as 
per WHO criteria. PCOS was diagnosed using the Rotterdam criteria. The number of 
patients to be recruited was based on a previous study(158) and powered for 10 
patients in each treatment arm for study completion. NQuery version 4 was used for 
sample size determination. After randomisation, subjects were advised not to modify 
their eating habits throughout the study. Clinical and biochemical assessments were 
performed at randomisation and at the end of the 4-month period. The primary end 
point of the study was the change in flow mediated vasodilatation and secondary 
outcome measure was the change in androgen levels, hs-CRP, lipid profile and blood 
pressure.
All subjects gave their informed written consent that had been approved by the local 
research ethics committee. The clinical trial registration number for this study was 
ISRCTN58369615. Patients who meet the criteria for inclusion were randomised by a 
computer generated randomisation list. Fasting blood were withdrawn for insulin and 
blood glucose between 8-9 am for each subject before and 4 months after treatment 
with metformin (SOOmg t.d.s) or pioglitazone (45mg daily). The homeostasis model 
assessment (HOMA) was used as the method to assess insulin resistance. Assessment 
of endothelial-dependent flow-mediated vasodilatation of the brachial artery diameter 
was measured from B mode ultrasound images captured on an ATL5000 HDI 
machine using a 10-MHz transducer, where an electrocardiogram trace was 
simultaneously recorded. Measurements were done before and 4 months after
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therapy. To create a flow stimulus in the brachial artery, a sphygmomanometric 
(blood pressure) cuff was first placed on the forearm 1 cm below the antecubital 
fossa. A baseline rest image was identified on longitudinal scanning of the brachial 
artery with the probe at 5cm above the antecubital fossa, and measurement recorded 
for 1 minute. Thereafter, arterial occlusion was created by cuff inflation to 
suprasystolic pressure (200mmHg) for 5 minutes. This caused ischaemia and 
consequent dilatation of downstream resistance vessels via autoregulatory 
mechanisms. Subsequent cuff deflation induced a brief high-flow state through the 
brachial artery (reactive hyperaemia) to accommodate the dilated resistance vessels. 
The resulting increased in sheer stress of the artery was recorded continuously for 5 
minutes after cuff deflation. Vessel diameter was measured during every systole and 
mid-artery pulsed Doppler signal was obtained upon immediate cuff release to assess 
hyperaemic velocity. A computer software package (Vascular Tools v4, by Medical 
Imaging Applications LLC, USA) was used to calculate the average baseline diameter 
and peak dilatation. FMD was determined as the percentage change from baseline to 
60 sec after ischemia, the point of maximal dilation. The FMD was performed at the 
same time pre and post treatments and patients were advised to avoid stimulants like 
coffee the morning of the test.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows, version 14.0. 
Comparison of percentage change from baseline in the metformin and pioglitazone 
groups were calculated using paired t test in data showing Gaussian distribution and 
paired Wilcoxon in those that were non Gaussian when tested using the Kolmogorov-
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Smirnov test. For all analysis, a two-tailed P < 0.05 was considered to indicate 
statistical significance.
Results:
Twenty two subjects were recruited for the study and all were overweight (BMI >28 
kg/m2). Eleven patients were ramdomised to receive metformin and eleven to 
pioglitazone. Table 6.1 showed the baseline parameters and treatment effects for each 
group of patients. Improvement in peak flow mediated vasodilatation (FMD) was 
observed in pioglitazone [baseline of 3.9±0.8 (mean±SD) to 8.0±1.0] after 4 months 
of treatment with a percentage increase of 105% whereas metformin showed a trend 
towards improvement [baseline of 6.0±1.7 to 11.3±6.0]. There was no significant 
change in BMI with metformin whereas BMI in the pioglitazone treated group 
increased by 7.8% (P < 0.05). FAI and IR reduced with both treatments, hs-CRP 
significantly reduced with pioglitazone but not with metformin and there was no 
significant change in other parameters.
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Table 6.1 Clinical and biochemical parameters of PCOS subjects at baseline and 4 
months after treatment with metformin and pioglitazone. Data presented as 
mean±SD. (all parameters were calculated from 11 patients in each arm except for 
FMD data which was calculated from 6 patients on metformin and 5 patients on 
pioglitazone).
Parameters
FMD (%)
Hs-CRP (mg/L)
BMI (kg/mz)
HOMA-IR
Tanita
Waist (cm)
Hip (cm)
Systolic BP
Diastolic BP
Fasting glucose 
(mmol/L)
FAI (%)
SHBG (nmol/L)
Androstenedione 
(nmol/L)
DHEAS (umol/L)
ALT (IU/L)
Total cholesterol 
(mmol/L)
Metformin
baseline
6.0±1.7
3.9±2.9
32.6±6.1
2.3±0.9
44.6±3.7
99.6±12.5
117.0±9.2
124±16.9
73.7±14.3
4.9±0.3
19.9±7.8
24.1±6.5
14.6±3.7
7.3±2.5
23.6±7.0
5.0±1.2
4 months
11.3±6.0
3.3±2.6
33.6±5.9
2.0±0.9
45.4±3.7
97.6±11.5
115.7±9.0
120.2±21.4
71.7±16.0
4.8±0.3
18.0±9.4
25.7±12.3
10.6±2.2
5.2±0.1
29.4±15.9
4.9±0.8
Pioglitazone
baseline
3.9±0.8
4.2±5.3
30.6±5.8
2.5±0.9
46.2±5.2
98.9±8.7
112.9±11.3
118.3±6.7
69.5±6.3
4.8±0.3
16.5±7.2
26.5±10.3
16.0±5.8
6.5±1.8
20.4±7.0
5.2±0.8
4 months
8.0±1.0*
1.1±0.5*
33.0±4.7*
1.7±1.1
46.0±4.9
100.6±10.6
113.9±13.0
111.3±8.1
67.0±8.0
4.8±0.3
13.9±9.2
31.6±12.1
16.1±7.0
5.1±1.7
18.3±4.1
5.2±0.6
* p<0.05 compared to baseline value in the same group
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Discussion:
Apart from being an inert barrier to elements contained in the blood, the endothelium is 
an active biological interface between the blood and all other tissues. Endothelial 
dysfunction were thought to be associated with the development of atherosclerosis(l 17) 
through the reduced synthesis and release of NO(259,260), a potent inhibitor of platelet 
aggregation(261). This impaired availability of NO may directly facilitate the 
development of coronary ischemia(259). Apart from two studies that reported no 
difference in endothelial function between PCOS and weight matched controls(118, 
119), many others showed an abnormal endothelial function and arterial stiffness in 
women with PCOS(112, 120-123). A recent case controlled study of 100 patients 
showed that overweight women with PCOS had increased arterial stiffness (measured 
by pulse wave velocity (PWV)) and reduced endothelial function (measured by brachial 
artery flow mediated vasodilatation (FMD)) compared to weight-matched 
controls(124). Several subsequent studies showed improvement in FMD in patients 
with PCOS on treatment with metformin (122, 124, 150, 258) and rosiglitazone(262) 
but no studies had so far compared the change in endothelial function on treatment with 
metformin and pioglitazone.
This study showed significant improvement in endothelial function after 4 months 
treatment with pioglitazone but only a trend towards improvement with metformin. 
The lack of significant response seen with metformin might have been due to the short 
duration of study of 4 months as compared to 6 months in studies by others. 
Pioglitazone significantly reduced hs-CRP despite a significant increase in BMI. The 
improvement in endothelial function and reduction in hs-CRP, both surrogate markers
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of cardiovascular risk, implicated a beneficial effect of pioglitazone on cardiovascular 
risk, to a higher efficacy compared to metformin. The increased in BMI seen was 
likely due to an increased in overall total body water rather than body fat(263) and 
pioglitazone had also been demonstrated to shift fat distribution from visceral to 
subcutaneous adipose depots(264). The mechanism by which metformin and 
pioglitazone act to improve endothelial function is still unclear, although the 
suppressive effects on circulation androgens and insulin as well as improvement in 
insulin sensitivity were probably important components.
This study was however limited by several external factors. It had been difficult to 
maintain a constant room temperature throughout the procedure as well as between 
the different seasons (winter and summer months) when the FMD study was 
conducted due to the lack of a climate controlled room. In this study, the room 
temperature at the time of the baseline FMD study had always been recorded and 
attempts made to ensure the room temperature at the second visit was at a similar 
range to the first by cooling down through opening the windows (in summer months). 
A further set back to the study was the change in the ultrasound machine halfway 
through the study and thus results from earlier patients had to be discarded, reducing 
the overall size of data suitable for analysis. At the end of the time allocated for the 
study, FMD results were based on 6 patients on metformin and 5 patients on 
pioglitazone, all from the new ultrasound machine.
In summary, this study showed that treatment with pioglitazone had resulted in a 
significantly greater improvement in endothelial function and reduction in hs-CRP
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compared to metformin. This suggests that pioglitazone may be a more potent agent in 
reducing cardiovascular risks in PCOS compared to metformin.
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Chapter 7:
Effect of Metformin, Orlistat and Pioglitazone 
Treatment in Polycystic Ovary Syndrome
Introduction:
Increased insulin resistance (IR) is an important feature in polycystic ovary syndrome 
(PCOS) that contributes to the increased risk of developing Type 2 diabetes and is a 
feature of the adverse cardiovascular risk profile seen in the metabolic syndrome(8, 
10). Jayagopal et al had shown that the absolute and intraindividual variation in IR 
were much greater in overweight women with PCOS compared to weight matched 
women without PCOS(221), but it remained unknown if this innate variation of IR is 
modified following treatment and whether treatments such as insulin sensitisation or 
weight loss have the largest impact. Therefore, this study had compared the effects of 
insulin sensitisation with metformin, pioglitazone, to that of weight loss (with orlistat) 
on mean IR and its biological variability in women with PCOS. The secondary 
endpoints were the changes in lipid profile and hs-CRP.
Research Design and Method:
This was a randomised, open labelled, parallel study comparing treatment with 
metformin (500mg three times a day), orlistat (120mg three times a day) and 
pioglitazone (45mg once daily). Thirty obese hyperandrogenic, anovulatory 
Caucasian women with PCOS [BMI 36.0±1.2 kg/m2 and age of 26.4±1.5 yrs (mean ± 
SEM)] were recruited from the Hull Royal Infirmary endocrinology clinic where they 
were referred by their primary care physicians for investigation of menstrual 
abnormalities, with or without hirsutism. PCOS was diagnosed by the ESRM 
Rotterdam criteria(15); all patients had oligomenorrhea or amenorrhoea, 
hyperandrogenemia and polycystic ovaries on transvaginal ultrasound. None were on 
any medications that would alter their insulin resistance at the time or for the 
preceding three months of entering the trial. Diabetes was excluded by a 75g oral
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glucose tolerance test as per WHO criteria. All subjects gave their informed written 
consent that had been approved by the local research ethics committee. The clinical 
trial registration number for this study is ISRCTN58369615 and the study was funded 
by University of Hull.
After initial screening, all women began with an 8-wk run-in period where they were 
given dietary advice and compliance checked. At the end of the run-in phase, they 
were randomized using a computer program. The number of patients to be recruited 
was based on a previous study(158) Using NQuery version 4 and powered for insulin 
resistance, a sample size of 10 patients in each treatment arm was determined for 
study completion. The dose of metformin was in accord with a previous study 
showing the beneficial effect of metformin in PCOS(143) and increased step-wise, 
from 500 mg once daily for the first week to 500 mg twice daily for the next week, 
and to 500 mg three times daily for the remainder of the study period. The dose of 
orlistat was 120 mg three times daily before each meal. Pioglitazone was started at 30 
mg daily for the first 2 weeks and further increased to 45mg for the remainder of the 
study period. After randomisation, the subjects were advised not to modify their 
eating habits throughout the study. Clinical and biochemical assessments were 
performed at each visit on 10 consecutive occasions at 4 day intervals before and 12- 
weeks after treatment.
Study measurements
After an overnight fast, weight and blood pressure were measured and blood samples 
were taken at screening, randomization, and on completion of the study period. 
Compliance was monitored based on counting returned medication. Fasting venous
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blood was collected into serum gel tubes (Becton Dickinson) and one fluoride oxalate 
tube at the same time each day (0800-0900) on 10 consecutive occasions at 4 day 
intervals before and 12-wk after treatment. Samples were separated by centrifugation 
at 2000g for 15 minutes at 4°C, and two aliquots of the serum were stored at -20°C 
within 1 hour of collection. Plasma glucose was analysed within four hours of 
collection. The serum samples were split before assay.
Reagents
Serum insulin was assayed using a competitive chemiluminescent immunoassay, 
supplied by Euro/DPC, Llanberis, UK. The assay was performed on a DPC Immulite 
2000 analyser (Euro/DPC, Llanberis, UK), using the manufacturer's recommended 
protocol. There was no stated cross-reactivity with proinsulin. Plasma glucose was 
measured using a Synchron LX 20 analyser (Beckman-Coulter, High Wycombe, UK), 
using the manufacturer's recommended protocol. The coefficient of variation for this 
assay was 1.2% at a mean glucose value of 94.6 mg/dl (5.3 mmol/liter). The IR was 
calculated using the homeostasis model assessment (HOMA) method (HOMA-IR = 
(insulin x glucose)/22.5)(220). Serum testosterone was measured by isotope dilution 
liquid chromatography- tandem mass spectromentry (Waters Corporation, 
Manchester, UK) and SHBG was measured by immunometric assay with fluorescence 
detection on the DPC Immulite 2000 analyzer using the manufacturer's recommended 
protocol. The free androgen index was obtained as the quotient 100 T/SHBG. Before 
analysis, all the serum samples were thawed and thoroughly mixed. The duplicate 
samples (ie. two per visit) were randomized and then analysed in a single continuous 
batch using a single batch of reagents.
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Statistical Analysis
Statistical analysis was performed using SPSS for Windows, version 14.0. 
Comparisons of percentage changes from baseline in the metformin, orlistat and 
pioglitazone groups were carried out using the paired t test in data showing a 
Gaussian distribution. In data where distribution between individuals violated the 
assumptions of normality when tested using the Kolmogorov-Smirnov test, 
differences were calculated by paired Wilcoxon method. Biovariability data was 
analysed by calculating analytical, within subject, and between subject variances
*? *} "y(SDA , SDj , SDo , respectively) according to the methods of Fraser and Co- 
workers(176, 202). Using this technique, analytical variance (SDA2) was calculated
ry ryfrom the difference between duplicate results for each specimen (SDA = 2d /2N, 
where d is the difference between duplicates, and N is the number of paired results). 
The variance of the first set of duplicate results for each subject on the ten assessment 
days was used to calculate the average biological intraindividual variance (SDj2) by 
subtraction of SDA2 from the observed dispersion (equal to SDj2 + SDA2). Subtracting 
SDi2 + SDA2 from the overall variance of the set of first results determined the 
interindividual variance (SDo2). The intraindividual (SDi) and interindividual (SDo) 
variations were estimated as square roots of the respective variance component 
estimates. For all analysis, a two-tailed P < 0.05 was considered to indicate statistical 
significance.
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Results:
All subjects completed the study and the results were shown in Table 7.1. Baseline 
differences between the three groups were non-significant (ANOVA test).
Table 7.1: Percentage change for each parameter after 3 months of treatment.
HOMA-IR
BV HOMA
Insulin
((j,U/ml)
SHBG
(nmol/L)
[range 35-
100]
BMI (kg/mj)
FAI (%)
[range 0-3.0]
Metformin (n=10)
Baseline
vs. 12
weeks
3.6±0.5
vs.
3.1±0.6
1.1±0.5
vs.
0.7±0.4
16.8±2.3
vs.
15.1±2.9
22.1±2.5
vs.
25.3±3.2
34.3±1.8
vs.
33.2±1.9
7.9±0.9
vs.
6.1±0.9
% change
-16.1±6.8
-23. 7± 17.0
-12.8±7.7
13.3±3.1 *
-3.4±1.0*
-22.9±7.4 *
Orlistat(n=10)
Baseline 
vs. 12
weeks
5.0±0.8
vs.
3.7±0.5
3.9±2.0
vs.
1.0±0.5
23.6±3.9
vs.
17.7±2.3
25.U3.5
vs.
29.5±5.1
37.4±2.7 
vs.
35.2±2.4
8.7±1.9
vs.
6.9±1.6
% change
-19.7±6.4*
-41.8±11.6*
-18.4±5.6*
14.3±5.0*
-5.7±0.8 *
-20.8±5.8 *
Pioglitazone (n=10)
Baseline 
vs. 12
weeks
4.5±0.8
vs.
2.5±0.4
1.2±0.5
vs.
0.5±0.2
20.0±2.9
vs.
12.0±1.5
22.3±1.6
vs.
32±3.2
36.2±1.8
vs.
37.3±1.8
6.1±1.2
vs.
4.7±0.6
% change
-41.0±4.1*
-28.5±18.0
-37.6±4.2 *
43. 7± 10.2*
3.1±1.4
-16.1±5.1*
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Total
testosterone
(nmol/L)
[range 0-1. 56]
Androstenedi
one (nmol/L)
[range 2-11]
Hs-C-
reactive
protein
(mg/L)
[range 0-8]
Total
cholesterol
(mmol/L)
Triglyceride
(mmol/L)
HDL
cholesterol
(mmol/L)
LDL
cholesterol
(mmol/L)
Systolic BP
(mmHg)
Diastolic BP
(mmHg)
1.6±0.2
vs.
1.4±0.2
7.1±1.1
vs.
6.5±0.9
S.lil.O
vs.
4.8±1.1
5.0±0.3
vs.
4.9±0.3
1.8±0.4
vs.
1.6±0.3
1.2±0.08
vs.
1.2±0.08
3.0±0.2
vs.
2.9±0.2
122±3
vs.
117±1
71±1 vs.
69±1
-14.7±7.3 a
-5.0±8.7
-8.5±6.8
-3.2±2.5
-5.6±6.5
0.08±2.0
-3.6±2.6
-3.8±1.4 a
-3.2±l.l a
1.7±0.2
vs.
1.5±0.2
6.1±0.8
vs.
5.8±0.6
6.2±2.0
vs.
5.6±2.0
5.1±1.2
vs.
4.6±0.2
1.8±0.2
vs.
1.7±0.2
1.2±0.05
vs.
1.2±0.03
3.1±0.2
vs.
2.7±0.2
125±4 vs.
123±4
71±2 vs.
68±2
-11.5±4.7
-2.8±4.8
-7.8±7.5
-9.3±2.2 a
-1.3±5.1
-2.1±3.2
-13.5±2.6 a
-1.3±1.8
-4.6±1.2 a
1.2±0.2
vs.
1.4±0.2
5.9±0.9
vs.
5.2±0.7
7.2±1.8
vs.
3.1±0.8
5.0±0.4
vs.
5.1±0.4
1.4±0.2
vs.
1.2±0.2
1.2±0.06
vs.
1.4±0.1
3.1±0.3
vs.
3.2±0.4
123±2
vs.
115±3
71±2 vs.
65±2
19.2±7.1
-7.5±4.9
-59.4±4.8 a
3.0±3.7
-14.2±7.3
16.5±3.3 a
1.3±3.1
-6.7±l.l a
-8.0±0.9 a
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Data were presented as mean ± SEM and local laboratory reference range given in 
brackets. All serum results were obtained from fasting variables. BV HOMA denotes 
biological variation of HOMA. 
* p<0.05 for changes compared to baseline
Insulin resistance
HOMA-IR reduced significantly in both the orlistat (p= 0.013) and pioglitazone (p= 
0.005) treated groups. Women treated with metformin did not show significant 
reduction in HOMA-IR (p= 0.17) for the period studied. Comparison between the 
three treatments showed a significant reduction in HOMA-IR favouring the 
pioglitazone group (p=0.04). The differences between the groups for percentage 
change in HOMA-IR remained significant after correction for percentage change hi 
BMI (pO.OOOl).
Biological variability of HOMA-IR
Figure 7.1, 7.2 and 7.3 showed the changes in biological variability (BV) of HOMA- 
IR after 12 weeks of treatment for all the three groups. Biological variability reduced 
significantly only in the orlistat treated group compared to baseline (p= 0.015). 
Women in the metformin and pioglitazone treated groups showed a trend to reduction 
of BV of IR but did not reach statistical significance for the period studied. A 
discrepant HOMA-IR of 19.6 in one patient on orlistat was included in the analysis 
that caused a greater pre-treatment variance, but had no influence on our overall 
findings. BV HOMA-IR was significantly correlated to HOMA-IR, the Pearson 
correlation coefficient was 0.72 and its p-value 0.001 (2-tailed).
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The change in BV HOMA-IR significantly correlated with changes in HOMA-IR 
(correlation coefficient 0.39, p=0.035) and changes in FAI (correlation coefficient 
0.57, p=0.001). There were no significant correlations between changes in BV 
HOMA-IR with changes in BMI or SHBG.
Figure 7.1: Changes in biological variability of insulin resistance in women with 
PCOS pre and post treatment with Metformin:
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Figure 7.2: Changes in biological variability of insulin resistance in women with 
PCOS pre and post treatment with Orlistat:
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Figure 7.3: Changes in biological variability of insulin resistance in women with 
PCOS pre and post treatment with Pioglitazone:
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BMI
BMI reduced significantly with both metformin (p= 0.013) and orlistat (p= 0.005), 
with a trend to an increase with pioglitazone after 12 weeks of treatment. There was 
no difference between the decrease in BMI with metformin to that of orlistat, p=0.07.
Biochemical hyperandrogenaemia
FAI reduced significantly in all the three groups (p= 0.017 in metformin, p= 0.007 in 
orlistat and p= 0.012 in pioglitazone). There was no difference between the three 
treatments for the change in FAI, p=0.85 (Kruskal Wallis test).
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Hs-CRP
Only the pioglitazone treated group showed a significant reduction in hs-CRP when
compared to baseline with a reduction from 7.2±1.8 mg/L to 3.1 ±0.8 mg/L, a total
reduction of 59.4%. Treatment with metformin and orlistat for 12 weeks showed a
trend to reduction by 8.5% and 7.8%, respectively that was not statistically
significant.
Lipids
In the orlistat treated group, 12 weeks of treatment resulted in a significant reduction 
in total cholesterol with a reduction of 9.3±2.2% that was largely contributed by a 
reduction in LDL cholesterol (13.5±2.6%). HDL cholesterol increased significantly 
in the pioglitazone treated group (16.5±3.3%) but had no overall effect on total 
cholesterol. There was no significant improvement in any of the lipid parameters on 
treatment with metformin.
Blood pressure
There was a significant improvement in systolic blood pressure in both the metformin 
and pioglitazone treated groups, but did not differ in the magnitude of the reduction 
between the two groups, p=0.165. All the three treatments significantly reduced 
diastolic blood pressure with a greater reduction seen in the pioglitazone group.
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7.1 Effect on Mean Insulin Resistance (IR) and its Biological 
Variability
Metformin therapy has been shown to have beneficial short-term effects on insulin 
resistance in non diabetic women with PCOS(138-145) and its use in women with 
PCOS is now regarded as acceptable practice. Pioglitazone(152, 265-267) and 
orlistat(158) had also been shown to improve the metabolic and hormonal 
consequence of PCOS.
This study showed that weight reduction with orlistat was comparable to insulin 
sensitisation with pioglitazone in leading to a significant reduction of IR over the time 
course of the study while treatment with metformin showed a trend to reduction. The 
apparent lack of effect by metformin may have been due to its reduced efficacy in 
subjects with a high BMI(268). The percentage reduction of IR was largest with 
pioglitazone compared to metformin and orlistat, but with respect to the reduction in 
hyperandrogenism, the effect of pioglitazone was comparable to the other two 
treatments.
Insulin resistance was much more variable in women with PCOS compared to weight 
matched controls(221), and this study had shown that only weight reduction through 
orlistat reduced IR variability of the HOMA-IR measurements, whilst insulin 
sensitisation had no effect. This suggested that physiological reversal of both mean 
and variability of IR occured with weight loss, whilst only mean IR was reduced with 
insulin sensitisation. The reduction in variability within the same individual by 
weight loss also indicated that the large variability in HOMA-IR was likely to be a
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true reflection of fluctuant insulin resistance in these patients, rather than an artefact. 
The HOMA model itself is a validated technique of assessing IR(220) and studies 
comparing it to other measures of IR such as clamp studies have shown it to be a good 
measure of IR(269, 270), and in practical terms the only method for such frequent 
sampling to determine biological variability.
Why should weight loss reduce the biological variability of HOMA when insulin 
sensitization does not? It has to be accepted that the cause for such a large degree of 
variability in IR amongst PCOS patients is currently unknown. However, 
speculatively, insulin sensitization by metformin and pioglitazone is unidimentional, 
in that both reduce insulin resistance largely through a single mechanism which, in 
turn, would seem to predominantly influence only mean IR rather than its variability. 
In comparison, weight loss (in this case with orlistat) is more likely to have a 
multidimentional effect by modulating several factors associated with IR and hence 
the reducing both mean IR and its biological variability.
While variability in IR has not been proven to add to the risk already present in 
patients with high mean IR values, glucose variability has certainly been found to be 
associated with increased free radical damage independently of mean glucose in type 
2 diabetes (T2DM)(246) . However it is not known if this relationship is actually a 
reflection of the inherent variability of IR found in T2DM and PCOS.
In summary, only weight reduction with orlistat resulted in a significant reduction in 
IR and its variability whist insulin sensitisation with metformin and pioglitazone had
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no effect on IR variability despite a significant reduction in mean IR seen with 
pioglitazone.
7.2 Effect on Lipids and Cardiovascular risk profile
I have shown that of the three treatments, orlistat was most effective in improving 
total lipid profile whereas pioglitazone was the best agent in improving subclinical 
inflammation like hs-CRP.
The use of metformin in treatment of PCOS had been well described but current 
experience in treating PCOS with thiazolidinedione is still limited. The largest study 
on the use of thiazolidinediones were on troglitazone where a prospective, placebo 
controlled study with 305 subjects with PCOS were treated with placebo or 300 or 
600mg of troglitazone(271). This study showed a significant improvement hi 
ovulation rates, biochemical and clinical hyperandrogenism and glycaemic parameters 
in subjects receiving troglitazone compared to placebo. However, the use of 
troglitazone had to be withdrawn from the market due to its association with 
numerous reports of fatal liver toxicity. Newer generations of thiazolidinedione like 
rosiglitazone and pioglitazone had subsequently been widely used in type 2 diabetes 
with no such association of liver toxicity. Effect of pioglitazone on PCOS had been 
studied in a randomised double blind controlled trial by Brettenthaler et al (152) 
where in doses of 30mg/day for 3 months, it significantly improved insulin sensitivity, 
hyperandrogenism, and ovulation rates thereby resulting in both metabolic and 
reproductive benefit. A recent study by Ortega-Gonzalez(265) showed that
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pioglitazone is as effective as metformin in improving insulin sensitivity and 
hyperandrogenism, despite an increase in body weight, body mass index, and the 
waist to hip ratio associated with pioglitazone. Mitkov et al (272) on the other hand 
showed that comparing metformin versus pioglitazone in the treatment of PCOS, after 
a 3 months therapy, testosterone reduced to a greater degree with metformin (9.2%) 
compared to rosiglitazone (7.3%) whereas, serum insulin reduced more with 
rosiglitazone (26.6%) than metformin (17.6%). hi contrast to the above mentioned 
studies where the effect of metformin was compared to either pioglitazone or 
rosiglitazone, this study compares the cardiovascular parameters on treatment with the 
three most common agents used in women with PCOS, mainly metformin, 
pioglitazone and orlistat.
Modest elevations in inflammatory parameters such as hs-CRP(97, 99) indicating 
subclinical inflammation and independent of degree of obesity, had been noted in 
PCOS. The earlier study in this thesis had shown the large biological variability of hs 
CRP and its unreliability as a marker. In this study, the effect of biological variability 
was accounted for through repeated testing over a period of 5 weeks for each 
individual prior to treatment and 12 weeks post treatment. The mean CRP value of 
the 10 samples pre and post treatments were used for the calculations. The result 
showed that CRP reduced significantly with pioglitazone but not with metformin or 
orlistat. This was in accord with current findings that pioglitazone is effective in 
reducing CRP(273-275) and that weight loss per se has no effect on CRP(276).
The lipoprotein profile in obese patients with PCOS were characterised by elevated 
plasma triglyceride, and reduced high density lipoprotein cholesterol (HDL-C)
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concentrations, which mirrored those seen in subjects with type 2 diabetes(27, 277, 
278). Women with PCOS have higher LDL compared to age matched controls 
whereas increased plasma triglyceride and reduced high density lipoprotein is 
influenced by BMI and thus commonly seen in obese women with PCOS. In this 
study, of the three treatments, only orlistat significantly reduced total cholesterol 
level. The improvement in the lipid profile seen with orlistat was also consistent with 
data reporting the reduction of LDL cholesterol by the drug as predicted by its 
mechanism of action in blocking dietary fat absorption(279-282). Pioglitazone 
reduced HDL with no effect on LDL nor overall change in total cholesterol, in accord 
with a recent meta-analysis(283).
All three treatments reduced the free androgen index (FAI), but apparently through 
different mechanisms. In metformin and orlistat treated patients the change comprised 
of fairly equal contributions from both the reduction in total testosterone and increase 
in SHBG while that seen with pioglitazone was largely contributed to by the increase 
in SHBG alone. This perhaps not surprising in view that pioglitazone is the most 
effective insulin sensitizer among the three drugs. The reductions in FAI contrast 
with the less marked and non-significant changes in androstenedione, suggesting that 
the improvement in hyperandrogenism may not be solely due to the effects of 
treatment on ovarian androgen production.
In conclusion, despite the significant reduction in hyperandrogenism seen with all 
three treatments, only orlistat significantly reduced total cholesterol through a 
reduction in LDL. Pioglitazone increased HDL but had no overall effect on total 
cholesterol.
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Chapter 8:
Insulin Resistance variability in women with
Anovulatory and Ovulatory Polycystic Ovary
Syndrome, and Normal Controls
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6-7% 
of women in the reproductive age(2-5). It is characterised by chronic anovulatory 
infertility and hyperandrogenism with the clinical manifestation of oligomenorrhoea, 
hirsutism and acne(l). Insulin resistance (IR) and its biological variability has been 
shown to be increased in women with PCOS(238) but it is unknown if this variability 
differs within the group of women who are anovulatory and those who are ovulatory. 
My study was conducted to investigate if this difference in IR and its biological 
variability exists between these two groups of women with PCOS.
Patients and Methods:
Fifty three Caucasian women with PCOS were recruited from the endocrinology 
clinic. All subjects were diagnosed to have PCOS by the ESRM Rotterdam 
criteria(15), where all patients had evidence of hyperandrogenemia, amenorrhea 
(cycle length >35 days; <8 cycles per year) and polycystic ovaries on transvaginal 
ultrasound. Non classical 21-hydroxylase deficiency, hyperprolactinemia, and 
androgen secreting tumours were excluded by appropriate tests before the diagnosis 
of PCOS was made. Diabetes was excluded in all subjects by a 75g oral glucose 
tolerance test. No subjects were on oral contraceptive pills nor taking any 
medications that could alter their insulin resistance at the time or for the preceding 
three months of entering the trial. Patients who had menstruation just before or 
during the study period were excluded from the study. Twenty two normal 
menstruating women were recruited from staff volunteers as controls. All subjects 
gave their informed written consent prior to entering the study that had been approved
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by the local research ethics committee. The clinical trial registration number for this 
study is ISRCTN58369615 and is funded by the University of Hull.
Fasting venous blood was collected into serum gel tubes (Becton Dickinson, Cowley, 
Oxfordshire, UK) at the same time each day (0800-0900) on 10 consecutive occasions 
at 3-4 day intervals to include measurements over a period of 5 weeks which included 
at least a complete menstrual cycle. Ovulation was defined by a progesterone level 
greater than 20nmol/L(181). Samples were separated by centrifugation at 2000 g for 
15 minutes at 4°C, and two aliquots of the serum were stored at -20°C within 1 h of 
collection. Plasma glucose was analysed within four hours of collection.
Reagents
Aliquots were thawed and analyzed in a single continuous batch of reagents. Serum 
insulin was assayed using a competitive chemiluminescent immunoassay, supplied by 
Euro/DPC, Llanberis, UK. The assay was performed on a DPC Immulite 2000 
analyser (Euro/DPC, Llanberis, UK), using the manufacturer's recommended 
protocol. There was no stated cross-reactivity with proinsulin. Plasma glucose was 
measured using a Synchron LX 20 analyser (Beckman-Coulter, High Wycombe, UK), 
using the manufacturer's recommended protocol. The coefficient of variation for this 
assay was 1.2% at a mean glucose value of 5.3 mmol/liter (94.6 mg/dl). The IR was 
calculated using the homeostasis model assessment (HOMA) method (HOMA-IR = 
(insulin x glucose )/22.5)(220). Serum testosterone was measured by isotope dilution 
liquid chromatography- tandem mass spectromentry (Waters Corporation, 
Manchester, UK) and SHBG was measured by immunometric assay with fluorescence 
detection on the DPC Immulite 2000 analyzer using the manufacturer's recommended
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protocol. The free androgen index was obtained as the quotient 100 T/SHBG. Before 
analysis, all the serum samples were thawed and thoroughly mixed.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows, version 14.0. In data 
where distribution between individuals violated the assumptions of normality when 
tested using the Kolmogorov-Smirnov test, differences were calculated by Mann- 
Whitney-U method. These parameters include HOMA-IR and insulin. Correlation 
was calculated by Pearson's method where non Gaussian data was log transformed 
prior to analysis. Biovariability data was analysed by calculating analytical, within 
subject, and between subject variances (SDA2, SDi2, SDo2, respectively) according to 
the methods of Fraser and Co-workers(176, 202). Using this technique, analytical 
variance (SDA2) was calculated from the difference between duplicate results for each 
specimen (SDA2 = 2d2/2N, where d is the difference between duplicates, and N is the 
number of paired results). The variance of the first set of duplicate results for each 
subject on the ten assessment days was used to calculate the average biological 
intraindividual variance (SDj2) by subtraction of SDA2 from the observed dispersion 
(equal to SDj2 + SDA2). Subtracting SDj2 + SDA2 from the overall variance of the set 
of first results determined the interindividual variance (SDo2). The intraindividual 
(SDi) and interindividual (SDo) variations were estimated as square roots of the 
respective variance component estimates. For all analysis, a two-tailed P < 0.05 was 
considered to indicate statistical significance.
Results:
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Although all patients were clinically amenorrhea, analysis of progesterone level 
showed twenty two of fifty three women with PCOS to have an ovulatory cycle 
(42%). An ovulatory cycle was defined as the presence of a progesterone surge of 
above 20nmol/L within the 5 weeks of study period. Biochemical parameters of 
patients are shown in Table 8.1 and all data presented as mean±SEM for consistency. 
BMI were non-significantly different between the ovulatory and anovulatory groups. 
One outlier (patient 19) from the ovulatory group was excluded from calculations as 
the HOMA-IR lies above two standard deviations from the overall mean in the group. 
Women with anovulatory PCOS were found to be significantly more insulin resistant 
compared to ovulatory PCOS, and both significantly higher than controls 
(meaniSEM; HOMA-IR 4.7±0.2 vs 3.9±0.1 vs 1.6±0.05 respectively). This is 
reflected by a lower SHBG in the anovulatory group compared to ovulatory, and both 
lower than controls. Biological variability of IR was greater in anovulatory PCOS 
compared to ovulatory PCOS and both were higher than the biological variability of 
IR in controls. This is shown in Figure 8.1.
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Table 8.1: Biochemical parameters of subjects with anovulatory PCOS, ovulatory 
PCOS and controls. Data are presented as mean ± SEM and local laboratory reference 
range given in brackets. All serum results are obtained from fasting variables. BV 
HOMA denotes biological variation of HOMA.
To convert values for insulin to picomoles per liter, multiply by 6. To convert values 
for SHBG to micrograms per deciliter, divide by 34.7.
Insulin (uU/ml)
HOMA-IR
BV HOMA
SHBG (nmol/L) 
[range 35-100]
Glucose (mmol/L)
BMICkg/m3 )
Anovulatory PCOS 
(n=31)
21.3±0.7 a' t)
4.7±0.2 a' b
5.9±4.8 "• "
24.6±0.7 a' b
4.9±0.02
34.3±1.3 b
Ovulatory PCOS 
(n=21)
17.6±0.5 a' c
S^iO.l 3- 0
l.O±OA^ c
26.9±0.5 a' c
4.9±0.03
33.7±l.l c
Controls 
(n=22)
7.8±0.2"' c
1.6±0.05 b' c
0.2±0.02 b' c
59.5±1.8 b' c
4.7±0.02
29.5±1.2 b' c
a denotes p< 0.05 between anovulatory and ovulatory 
b denotes p< 0.05 between anovulatory and controls 
c denotes p<0.05 between ovulatory and controls
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Figure 8.1: Mean and range of HOMA-IR in subjects with anovulatory PCOS, 
ovulatory PCOS and controls.
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Discussion:
Studies have suggested that insulin insensitivity in polycystic ovary syndrome 
occured in oligo or amenorrhoea but not when the menstrual cycle is regular(284). 
However, there were no previous studies comparing IR and its biological variability 
between women with anovulatory PCOS to those who have an ovulatory cycle but 
clinically amenorrhea. My data showed that 42% of women with PCOS who were 
clinically not menstruating had an ovulatory cycle at the time of study. Women with 
anovulatory PCOS had higher mean and biological variability of IR compared to 
those having ovulatory cycle, and both were higher than women without PCOS. 
However, it is unknown whether this was a transient feature associated with an 
ovulatory cycle or a feature of this group of ovulatory patients. As there were no
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differences between the numbers of menses between groups, it suggests that the 
former is more likely. Should this be true then it would also suggest that women with 
PCOS with a longer duration of anovulation may have a higher cardiovascular risk. 
The variation in the spectrum of risk depending on the frequency of ovulatory cycles 
may help explain why the data on cardiovascular events in PCOS remains 
inconclusive as this variable has not been accounted for. However, in the Nurses 
Health Study for subjects followed through for cardiovascular events, a history of 
menstrual cycle irregularity was associated with an increased risk of nonfatal and fatal 
coronary heart disease(125).
Carmina et al have reported that ovulatory women with hyperandrogenaemia exhibit 
a mild insulin resistance and altered lipid profile, similar to that of patients with 
classic (anovulatory) PCOS(285). The same group suggested that ovarian blood 
velocity in PCOS was higher than in healthy women during the follicular phase, and 
women with anovulatory PCOS were more insulin resistant (286). Their most recent 
study found that central fat distribution was increased in anovulatory PCOS compared 
to ovulatory and matched controls, and this was associated with a lower level of 
adiponectin(175). Others reported that ovulatory women with PCOS have lower 
levels of progesterone in the early luteal phase and that may have resulted in reduced 
fertility(287). These studies are difficult to compare as they used subjects with 
ovulatory PCOS who clinically had a normal menstrual cycle that differed to our 
study where all of our subjects were clinically anovulatory.
It was previously shown that women with PCOS have a higher and more variable IR 
compared to controls(221). In this study, I found that women with anovulatory PCOS
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have higher biological variability in IR compared to ovulatory PCOS and both higher 
than normal menstruating women. While biological variability in IR has not been 
proven to add to the risk already present in patients with high mean IR values, glucose 
variability has recently been found to be associated with increased risk of free radical 
damage, independent of mean glucose in patients with type 2 diabetes(246). It 
remained possible that an increase in biological variability of IR may be associated to 
or in fact is an independent risk for cardiovascular risk. Whether the association 
between a high biological variability in IR is the cause or effect of the state of 
anovulation, this is still yet to be determined. However, if it is true that the difference 
in biological variability of IR is the key to the differences in the ovulatory status in 
this group of clinically anovulatory woman with PCOS, then, modification of this 
state through the use of medication would be an interesting area to pursue for the 
future.
In conclusion, the mean and biological variability of IR, were higher in women with 
anovulatory PCOS compared to ovulatory PCOS, and both were higher than controls. 
This suggests that those patients who ovulate may be better protected against future 
cardiovascular consequences.
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Chapter 9:
Summary Discussion
115
This thesis critically evaluates several aspects of polycystic ovary syndrome from the 
diagnosis of the condition itself, the reliability of diagnostic biochemical markers and 
its biological variation to the treatment from the perspective of cardiometabolic risk.
This thesis presents a review of the literature relating to the cardiometabolic risks in 
PCOS and describes studies that have contributed to further understanding of this 
topic and further treatment options. The data presented here showed that on an 
individual basis the median and range of the LH/FSH ratio do not differ significantly 
between patients with or without clinical PCOS, indicating that the test does not have 
robust diagnostic utililty. This unreliability of the LH/FSH ratio was supported by 
the proposed Rotterdam criteria although there still lack clarity within the criteria on 
which androgen should be measured, what is a normal androgen and which analytical 
technique should be employed. This thesis evaluated the index of individuality, 
critical difference and individual variation among the three commonly used 
measurements of androgens in the diagnosis and management of women with PCOS 
i.e. total testosterone, free androgen index and calculated bioavailable testosterone 
and demonstrated the relative suitability of each in detecting hyperandrogenism in 
PCOS. The data in this thesis showed that among the three methods of measurement, 
none were ideal diagnostic markers for detecting hyperandrogenism in patients with 
PCOS. This further illustrated the difficulty in patient selection in a research setting 
mainly due the fact that measurements of androgens were not particularly sensitive at 
low values as seen in women. Tandem mass spectrometry would have been an ideal 
choice but this may not be a realistic option in many laboratories in the United 
Kingdom due to financial restrain. From the available method, the data in this thesis
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suggested that FAI may seem a better marker in identifying patients with PCOS and 
once the diagnosis is made, all three were useful in monitoring progression.
A surrogate marker for cardiovascular disease which is reproducible, stable and 
relatively easy to measure would be invaluable in both research setting and clinical 
practice, particularly in monitoring the response to treatment. This thesis evaluated 
the inter and intra-individual variability of hs-CRP and its suitability as a marker for 
cardiovascular disease in patients with PCOS. The results showed that hs-CRP 
values were widely variable in women with PCOS as well as in normal controls and 
the critical difference for sequential CRP values in PCOS was -64% and +179% 
suggesting that only changes above or below these values will be considered 
significantly different from the first. The lack of concordance between this variability 
and that of IR suggested that hs-CRP cannot be used as a direct surrogate marker to 
establish the presence of IR in this group of patients and the possibility that in fact 
inflammation may itself not be the centre for the development of IR in PCOS. 
Instead, it is likely that both IR and inflammation were separate products of a 
common source, possibly an altered secretion of adipocytokines.
Insulin resistance in PCOS has been linked to later development of impaired glucose 
tolerance and type 2 diabetes(49). Evidence from small long-term cohort studies, 
case-control studies and case series, points to a risk of type 2 diabetes in middle age 
of 10-20% (11, 50, 288), with a high rate of impaired glucose tolerance suggesting 
that further cases of diabetes will develop later. This thesis compared the mean and 
biological variation in IR and beta cell function in PCOS to that of Type 2 diabetes 
and to age and weight matched controls and found that the progression from PCOS to
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the development of T2DM is unlikely to be due to a further increase in insulin 
resistance (or variability), but rather the progressive failure of pancreatic beta cells 
with a decrease in insulin production.
It has been suggested that women with PCOS may have a higher cardiovascular risk 
than weight-matched controls with normal ovarian function(289) as they have 
increased cardiovascular risk factors such as obesity, hyperandrogenism, 
hyperlipidaemia and hyperinsulinaemia. The elevation of risk factors in young 
women with PCOS may therefore put them at increased risk of developing 
accelerated atherosclerosis(32, 51, 290) Despite the increase in cardiovascular risk 
factors and surrogate markers, morbidity and mortality per se from coronary heart 
disease among women with PCOS has not been shown to be as high as 
predicted(125, 245). Studies to date are small in size, and randomised controlled 
trials and prospective end point studies are lacking. Nevertheless, from a clinical 
perspective, clinicians were advised to identify cardiovascular risk factors in women 
with PCOS and treat these accordingly. This has caused renewed interest in the use 
insulin sensitising agents such as metformin and the thiazolidinediones (troglitazone, 
rosiglitazone and pioglitazone) to reduce insulin resistance and thereby reduce risk of 
developing diabetes and other metabolic sequelae. To evaluate the efficacy of these 
two groups of insulin sensitizers on cardiometabolic risk, this thesis compared the 
changes in endothelial function on treatment with pioglitazone and metformin in 
women with PCOS. Through the measurement of flow mediated vasodilatation as a 
surrogate marker for endothelial function, the data suggested that pioglitazone may be 
a more effective agent in improving endothelial function compated to metformin.
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There has been a shift in the approach to the treatment of women with PCOS. There 
is now a recognition that women with PCOS are more IR and at a greater risk of 
developing T2DM and cardiovascular disease. This has resulted in increased interest 
in the condition that is increasing in prevalence within the western population. The 
aetiology of PCOS is likely to be a combination of an increased intrinsic 
susceptibility coupled with an external trigger, like obesity and therefore both IR and 
obesity would have seem appropriate targets for treatment. In the study presented in 
this thesis, the metabolic effect of insulin sensitisation with metformin and 
pioglitazone was compared to weight reduction with orlistat. Nevertheless, although 
used extensively, it must be emphasized that both metformin and the 
thiazolidinediones are unlicensed for use in PCOS and patients should be counselled 
before initiating therapy. In the studies presented here, the results showed that of the 
three treatments, only orlistat, through weight reduction, successfully reduced insulin 
resistance and its variability within a 3-month period. This is in association with an 
overall reduction in total cholesterol and LDL level. The interesting and as yet 
unanswered questions are firstly whether the increased biological variation is an 
independent factor that contributes to the increased cardiovascular risk and a 
reduction of this variability reduces the risk. With the increased risk of 
cardiometabolic syndrome and type 2 diabetes, it may seem prudent that we are 
vigilant in identifying the most at risk patients and instituting the most appropriate 
treatment to target the specific risks factors. The encouraging trend noted following 
treatment with orlistat suggested that this therapeutic option needs to be explored 
further in the treatment in targeting the cardiometabolic aspects of women with 
PCOS. It appeared that weight reduction rather insulin sensitisation may be a more 
effective treatment option to improve cardiometabolic profile and to prevent future
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development of T2DM. This would have been in accord with the result seen in the 
Diabetes Prevention Programme where weight reduction is as effective ,if not better 
than insulin sensitisation with metformin in preventing progression to T2DM in those 
with impaired glucose tolerance(291).
IR was found to be increased in women with PCOS but it was unknown if the mean 
IR and its biological variation differ between women with and without an ovulatory 
cycle, and whether ovulation itself reduces IR in women with PCOS compared to that 
found in normal women with regular ovulatory cycle. The last study in this thesis 
compared the biological variability of IR in women with ovulatory and anovulatory 
PCOS. Women with anovulatory PCOS were found to have higher mean and 
biological variability of IR compared to those having an ovulatory cycle, and both 
were higher than women without PCOS suggesting that those patients who ovulate 
may be better protected against future cardiovascular consequences.
The information gained from the studies presented in this thesis has opened fresh 
avenues to be explored in the coming years. Adiponectin had been widely used as a 
marker for metabolic syndrome and surrogate marker for cardiometabolic risk. 
Before its routine use in clinical practice, the biological variability of adiponectin 
should be determined to allow informed interpretation of results. This thesis had 
shown that weight reduction may be more effective than insulin sensitisation in 
improving the cardiometabolic profile of women with PCOS, possibly through its two 
dimensional approach. It would therefore be interesting to explore the changes in 
these parameters with other agents like rimonabant, GLP-1 analogues (e.g. exenetide) 
and DPP-IV antagonists (e.g. sitagliptin and vidagliptin) all of which had shown
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beneficial effects in patients with T2DM, but their roles in PCOS is yet to be 
explored. Non alcoholic fatty liver disease (NAFLD) and non alcoholic 
steatohepatitis (NASH) in women with PCOS remained a clinical challenge as 
treatment options remained to be established. Further studies comparing the effects 
of insulin sensitisers and weight reduction agents mentioned above as 
pharmacological options for treatment of NAFLD and NASH may provide new 
avenues for exploration in the future.
The different phenotypes of PCOS, whether ovulatory or anovulatory may have very 
different cardiometabolic risk profiles and response to treatment. The next few years 
may allow these differences to be explored further and the establishment of better 
criteria in stratifying future risk profile in women with PCOS.
Future direction for future research:
As shown in my thesis, weight loss is an important component in the treatment of 
PCOS and current treatment options are limited, especially when rimonabant has now 
been withdrawn from the market. Future research on the effect of new treatments like 
GLP-1 analogues and PYY in patients with PCOS should be encouraged. Although 
NAFLD and NASH are relatively common in PCOS, there is currently no consensus 
on treatment options. Therefore studies on the treatment of NAFLD, NASH and the 
spectrum of obesity cardiometabolic syndrome would be of great interest.
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2 Disorders of male and female sex hormones
Management of polycystic 
ovarian syndrome
LW. CHO AND STEPHEN L. ATKIN
Patients with polycystic ovarian syndrome can be challenging as they usually present with multiple problems that may 
include weight gain, irregular periods, acne, hirsutism or infertility. Treatment should be tailored to the needs of the 
patient in a holistic manner. In this review, the authors detail the reproductive, metabolic and cardiovascular aspects of 
polycystic ovarian syndrome and how these features can be managed in general practice.
Or L.W. Cho, MRCP, Specialist Registrar in Diabetes and 
Endocrinology, Hull Royal Infirmary; Professor S.L. Atkin, FRCP, 
PhD, Head of Academic Endocrinology, Diabetes and Metabolism, 
University of Hull.
polycystic ovarian syndrome (PCOS) is a common 
I endocrine disorder affecting 6-7 per cent of women of 
reproductive years. 1-4 It is likely to be increasing in line 
with the expected increase in obesity seen in the popula­ 
tion. It is a heterogeneous clinical syndrome characterised 
by chronic anovulation leading to irregular periods, and 
clinical or biochemical hyperandrogenism resulting in hir­ 
sutism and acne.5 Many women with PCOS may appear to 
have metabolic syndrome in view of the higher reported 
incidence of hypertension, abnormal lipids, visceral obesi­ 
ty and elevated insulin levels in diis population.6
Diagnosis of PCOS
A diagnosis of PCOS can be made only after other condi­ 
tions have been excluded (Box 1). We would recommend 
a baseline screen of diyroid function tests, serum pro- 
lactin, 17-hydroxyprogesterone, and a free androgen 
index (FAI = total testosterone divided by sex hormone- 
binding globulin [SHBG] x 100 to give a calculated free 
testosterone level). Only if there is a suspicion of 
Cushing's syndrome should two 24-hour urinary cortisol 
measurements be performed. If these results are unre­ 
markable (diough the FAI may be elevated), you can 
progress to establishing die diagnosis of PCOS.
In 2003, a consensus on the diagnostic criteria for 
PCOS was drawn up: the presence of two out of the three 
features listed in Box 2 indicates a diagnosis of PCOS. 7
Many women with PCOS have a total testosterone level 
at the upper limit of normal, but an elevated FAI as a 
result of low SHBG. The elevation of the free 
component of testosterone can therefore contribute to a 
clinical presentation of hyperandrogenism. The official
Box 1. Conditions to be excluded before making a diagnosis of 
PCOS.
• Thyroid dysfunction
• Congenital adrenal hyperplasia
• Hyperprolactinaemia
• Androgen-secreting tumours
• Cushing's syndrome
Box 2. Criteria for the diagnosis of PCOS. 7
The presence of two of:
• Oligo- and/or anovulation
• Clinical and/or biochemical features of hyperandrogenism
• Polycystic ovaries 
And exclusion of other aetiologies (see Box 1)
definition of die polycystic ovary is either 12 or more 
peripheral follicles, or increased ovarian volume >10cm3 
(Figures 1 and 2). If the ultrasound scan shows a follicle 
>10mm in diameter, it should be repeated at a time of 
ovarian quiescence in order to calculate volume and 
area.7 In our unit we tend to diagnose on the basis of a his­ 
tory of irregular periods and a raised FAI as this is cheap­ 
er and easier, reserving ultrasound for difficult cases or for 
research purposes.
It is important to note that the raised luteinising hor­ 
mone/follicle-stimulating hormone (LH/FSH) ratio is no 
longer a diagnostic test for PCOS due to its inconsistency, 
and should not be requested.8
Pathophysiology
The cause of PCOS is unknown, but it is very likely to have 
a genetic component The underlying problem appears to 
be insulin resistance, which is an important target for the 
treatment of the condition. Simplistically, the high insulin 
levels9 reduce the SHBG and increase androgens from the
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figure 1. Ultrasound of a polycystic ovary showing multiple follicles in a 
peripheral distribution.
ovary, leading to higher testosterone levels and irregular 
periods, infertility, acne and hirsutism (Figure 3). This is 
compounded by obesity, which causes an increase in 
insulin resistance, making the problem worse.
Manifestations of PCOS
Symptoms often begin around puberty, or after weight 
gain or stopping the oral contraceptive pill, but can pres­ 
ent at any time. Patients widi PCOS normally have amen- 
orrhoea or oligomenorrhoea widi fewer than eight peri­ 
ods per year and, as die cycles are often anovulatory, infer­ 
tility results. Hirsutism is common and can be accurately 
documented using die Ferriman-Gallwey criteria, 10 
though in clinical practice diis is of little use. Twenty-five 
per cent of women also suffer from acne or male-pattern 
alopecia, but virilisation is not a feature of PCOS. The 
prevalence of obesity in PCOS varies widely and may be 
responsible in some instances for die PCOS phenotype 
'coming out'.
The chronic anovulation of PCOS may be associated 
with an increased risk for endometrial hyperplasia and 
endometrial cancer,11 but this remains controversial: in a 
study of women 22-31 years after an ovarian wedge biop­ 
sy for PCOS, none had any endometrial problems. 12
It would appear diat many women widi PCOS fulfil die 
criteria for metabolic syndrome in view of a higher report­ 
ed incidence of hypertension, dyslipidaemia, visceral obe­ 
sity, insulin resistance and hyperinsulinaemia in diis pop­ 
ulation.6 They have a high risk of progression to impaired 
glucose tolerance and type 2 diabetes, as shown in one 
study where 35 per cent of patients widi PCOS had 
impaired glucose tolerance and 10 per cent had type 2 dia­ 
betes by die age of 40. 13 Sleep apnoea is an independent 
risk factor for cardiovascular disease and is found to be 
more common in PCOS, 14'15 so it may be worth asking die 
partner if die patient snores. The presence of cardiovascu-
Figure 2. Gross anatomical specimen showing peripheral follicles in a 
polycystic ovary.
lar risk factors of obesity, insulin resistance and an abnor­ 
mal lipid profile may predispose women widi PCOS to 
coronary heart disease, although diis remains controver­ 
sial. Cardiovascular disease studies in PCOS have been 
inconclusive, widi some suggesting increased cardiac 
events and odiers suggesting no increase compared widi 
women without PCOS.
Investigations
The aims of die investigations are to exclude serious 
underlying disorders, confirm die diagnosis and screen 
for complications.
History and examination
Virilisation is more likely if testosterone is >5nmol/l and 
diere has been rapid progression of hirsutism. If virilisa­ 
tion is present and die testosterone is >7nmol/l, an andro- 
gen-secreting tumour needs to be excluded before PCOS 
can be confirmed. Gynaecological examination is 
required rarely and only to exclude other causes of, for 
example, abnormal bleeding.
Ultrasound scanning
Whedier die presence of polycystic ovaries on ultrasound 
scanning should be used to diagnose PCOS is still debatable. 
About 20 per cent of normal women have polycystic ovaries 
on ultrasound16 and more dian 10 per cent of women widi 
PCOS do not have polycystic ovaries. 1 ^ However, ultrasound 
may be necessary if there is doubt regarding die diagnosis or 
die possibility of an androgen-secreting tumour, which is 
usually eidier adrenal or ovarian in origin. For adequate 
visualisation of die ovaries, a transvaginal ultrasound would 
be preferred if there are no contraindications.
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Figure 3. Insulin resistance in polycystic ovarian syndrome.
Biochemical tests
We tend to measure the FAI to confirm biochemical hyper- 
apHrogenaemia, as in many cases total testosterone may be 
ai upper limit of the normal assay in these women, but 
because of a reduced SHBG they have a higher level of 
bioactive testosterone. A glucose tolerance test should be 
considered to exclude type 2 diabetes if the patient has a 
fasting blood glucose level >5.6mmol/l, is over the age of 
40 years and obese (body mass index [BMI] >30kg/m2), or 
is obese with a family history of type 2 diabetes. 
Endometrial biopsy is not routinely requested, but may be 
used to investigate unexplained vaginal bleeding.
Management of PCOS
Effective treatment of patients with PCOS requires that 
the specific goal(s) of therapy be first established. 
Individual goals may include weight management, fertili­ 
ty, treatment for hirsutism and/or acne, achieving a regu­ 
lar menstrual cycle, and the prevention of the 
long-term consequences associated with PCOS (type 2 dia­ 
betes and possibly cardiovascular disease).
Obesity
It should be emphasised that weight management is the 
cornerstone in the treatment of PCOS. 18 Although obesi­ 
ty is not thought to be the cause of PCOS, it can make the 
individual features worse or reduce the effect of therapy. 19 
It has been reported that loss of around 5 per cent of body 
weight results in spontaneous resumption of ovulation,20
improvement in fertility, 21 increased SHBG and reduced 
basal level of insulin.22 '23
Anti-obesity drugs such as orlistat and sibutramine 
have been shown to reduce hyperandrogenaemia24'2^ and 
would be a suitable add-on to insulin sensitisers such as 
metformin in the treatment of patients with PCOS. 
Rimonabant, which is a new endocannabinoid receptor 
blocker, has shown promise in reducing weight and 
improving cardiovascular risk profile in obese subjects,26 
but there are currently no data on its use in PCOS.
Menstrual dysfunction
Amenorrhoea may be associated with endometrial carci­ 
noma and therefore it is recommended that women 
should have at least four menstrual bleeds per year. This 
can be achieved by using the low-dose combined oral con­ 
traceptive. Alternatively, a short course of either medroxy- 
progesterone or norethisterone will give a withdrawal 
bleed every three months (but will obviously not provide 
contraception). Metformin treatment is increasingly used 
to restore regular periods and will give an ovulatory rate of 
around 60 per cent The levonorgestrel intrauterine 
device (Mirena) can be used as first-line treatment for cor­ 
rection of the anovulatory unopposed proliferative 
endometrial change, circumventing the significant prob­ 
lems associated with the oral products (acne, bloating, 
mood depression, ovarian cysts), although these symp­ 
toms are uncommonly seen for progestagens given for 10 
days every three months.
Infertility
It should be remembered that there are three potential 
causes of infertility among patients with PCOS: the first 
might be directly related to the PCOS through a lack of 
ovulation as follicles fail to develop beyond 10mm;27 the 
second might be an additional factor, such as tubal prob­ 
lems; and the third might be due to a male factor.
As most cycles are anovulatory, induction of ovulation 
may be required. However, it cannot be emphasised 
enough that encouragement of weight loss may help any 
treatment strategy and a weight loss of about 5 per cent 
can restore ovulation.28 '29
The next line of treatment that is increasingly used is 
the insulin sensitiser metformin. Not all GPs are comfort­ 
able using metformin as it is not licensed for use in the 
treatment of PCOS and a referral to secondary care may 
be warranted. Studies have suggested that metformin will 
result in an ovulatory rate of between 29 and 75 per cent. 
It should be noted that women with a BMI greater than 
37kg/m2 may respond less well to metformin treatment. 
Other treatments used, particularly in secondary care,
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include clomiphene citrate, with or without met- 
formin,30 '31 and thiazolidinediones such as pioglitazone 
and rosiglitazone as a method to reduce insulin resistance 
in place of metformin.
Metformin is often used as first-line therapy to see if 
ovulatory cycles can be restored, as it is not associated with 
ovarian hyperstimulation and the need for ultrasound 
monitoring for the first cycle. If this fails, the fertility agent 
clomiphene is usually initiated. Studies have suggested that 
the combination of metformin and clomiphene is more 
effective than either alone. This was not found, however, in 
a recent study that suggested that clomiphene added to 
metformin, which had been recently started, had no addi­ 
tional benefit on ovulatory rate over clomiphene alone.32 
In patients who remain anovulatory or fail to achieve preg­ 
nancy with clomiphene and metformin, treatment such as 
ovarian drilling (for slim patients) or gonadotrophin ther­ 
apy may be considered. Wedge resection of the ovaries has 
now been abandoned due to the risk of pelvic adhesions, 
subfertility and loss of ovarian tissue.
Hirsutism
Hirsutism should ideally be quantified using the 
Ferriman-Gallwey score,10 with a score of over eight indi­ 
cating hirsutism, although this is often not practicable. 
Licensed treatments include:
• oral contraceptive pills;
• oestrogen plus cyproterone acetate (Dianette);
• cosmetic measures (eglaser, electrolysis, bleaching, wax­ 
ing and shaving);
• eflornidiine (Vaniqa) for facial hirsutism. 
Usually, a combination of methods is required to achieve 
an acceptable cosmetic result. Non-licensed treatments 
that may be used depending on individual practice, but 
are often seen more in specialist centres, include:
• spironolactone, initially 50mg twice daily - check 
biochemical profile two weeks after initiating dierapy;
• anti-androgens, eg flutamide (25mg three times daily) 
and finasteride (5mg daily) - adequate contraceptive 
measures are essential;
• metformin as an insulin sensitiser - this has been shown 
to be an effective option for treatment of hirsutism, with 
an 11 per cent reduction in testosterone levels. 33
Use of insulin sensitisers
It should be emphasised dial metformin is not licensed 
for use in PCOS. Patients need to be advised of this, and it 
should be documented in die notes dial diis has been dis­ 
cussed. Metformin (500mg diree times daily) is effective 
in improving die metabolic aspects of PCOS as well as 
increasing menstrual regularity and hirsutism.33 However,
metformin causes a significantly high incidence of nausea 
and vomiting. To minimise these side-effects, we would 
recommend a starting dose of SOOmg taken widi a meal 
for the first week; if tolerated, the dose can be increased to 
SOOmg twice daily for die second week, and finally three 
times daily on the diird week at breakfast, lunch and din­ 
ner. There are inadequate data to recommend die use of 
metformin during pregnancy, aldiough no specific neona­ 
tal complications have been described in die literature.
The diiazolidinediones, troglitazone (removed from 
clinical use due to its association with liver failure), piogli­ 
tazone (up to 45mg daily) and rosiglitazone (up to 8mg 
daily), have been shown to have positive cardiometabolic 
effects and to reduce hyperandrogenaemia and hirsutism, 
as well as regulating die menstrual cycle in women widi 
PCOS.34"36 However, diey cause weight gain, which can be 
an undesirable side-effect in diis population. These treat­ 
ments are again unlicensed and tend to be restricted to 
specialist units.
Long-term management
It has been suggested dial women with PCOS may have a 
higher cardiovascular risk dian weight-matched controls 
widi normal ovarian function.37 They have increased car­ 
diovascular risk factors such as obesity, hyperandrogenism, 
hyperlipidaemia and hyperinsulinaemia. Their abnormal 
lipid profiles consist mainly of raised triglycerides and 
total and low-density lipoprotein cholesterol.38"^0 The 
effect of PCOS on high-density lipoprotein cholesterol, 
however, is controversial,38'39 '41' and evidence on hyper­ 
tension is also less consistent.41 The elevation of risk fac­ 
tors in women widi PCOS at an earlier age dian among 
women widiout PCOS may dierefore put diem at an 
increased risk of developing accelerated adierosclerosis, 
resulting in myocardial infarction.38 '40 '42 In die Nurses' 
Healdi Study, menstrual cycle irregularity was associated 
widi an increased risk of non-fatal and fatal coronary heart 
disease, aldiough no clinical or biochemical androgen 
data were available for confirmation of a diagnosis of 
PCOS.43
In spite of die increase in cardiovascular risk factors, 
morbidity and mortality from coronary heart disease 
among women widi PCOS in a long-term study have not 
proved to be as high as predicted.44 Furthermore, die 
available studies to date are small in size - non- 
randomised controlled trials and prospective end-point 
studies are lacking. Neverdieless, from a clinical perspec­ 
tive, clinicians should continue to identify cardiovascular 
risk factors in women widi PCOS and treat diese accord­ 
ingly. While it seems prudent to assess die cardiovascular 
risk factors of a patient widi PCOS (including blood pres-
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sure, cholesterol, triglycerides and high-density lipopro- 
tein cholesterol), it should be borne in mind that the con­ 
ventional cardiovascular risk calculators have not been val­ 
idated in this group of patients.
Women with PCOS are, however, at risk of developing 
type 2 diabetes. Fasting blood sugars have been shown to 
be insensitive at diagnosing diabetes and therefore it 
seems sensible to perform an oral glucose tolerance test 
on women at particularly high risk (see section on bio­ 
chemical tests). It has been suggested that high-risk 
Southeast Asian women should be considered for an oral 
glucose tolerance test if they have a BMI of more than 
25kg/m2 because of their increased insulin resistance at a 
lower BMI compared to a Caucasian population. For those 
patients diagnosed with impaired glucose tolerance, annu­ 
al fasting blood glucose would be warranted.
Summary
Patients with PCOS may be referred to an endocrinologist, 
gynaecologist or dermatologist depending on their main 
presenting complaint. PCOS is a multisystem condition 
and therefore treatment will involve a multidisciplinary 
approach.
The UK-based PCOS support group can be found 
through the website http://www.verity-pcos.org.uk
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Is a Routine Ultrasound Scan 
Necessary for the Diagnosis of 
Polycystic Ovarian Syndrome?
Li Wei Cho1, Anne Marie Coady2, Eric S Kilpatrick3 & Stephen L Atkin 1 
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Polycystic ovarian syndrome (PCOS) is common among 
women of reproductive years and patients with this condi­ 
tion may be referred to an endocrinologist, a gynaecologist 
or a dermatologist, depending on their main presenting 
complaint. A recently mailed questionnaire to endocrinolo- 
gists and gynaecologists showed a lack of consensus 
between the two specialties in the definition, diagnosis 
and treatment of PCOS. Can routine ultrasound for the 
imaging of polycystic ovaries be dispensed with? In large 
measure, the answer is 'yes'. First, polycystic ovaries are 
common in women without PCOS and not all women with 
PCOS have polycystic ovaries. Secondly, if the patient has 
irregular periods and biochemical hyperandrogenism, why 
scan? Thirdly, the operator dependence of the technique 
may give false positive and negative scan results. 
Economically and practically, ultrasound scanning in PCOS 
should be limited to cases of diagnostic uncertainty 
performed by a recognized expert in pelvic ultrasonography.
Introduction
Polycystic ovarian syndrome (PCOS) is a common endocrine 
disorder affecting 6-7% of the population. 1^1 It is character­ 
ized by chronic anovulation and hyperandrogenism with the 
clinical manifestation of oligomenorrhoea, hirsutism and acne. 5 
Many women with PCOS may appear to have metabolic 
syndrome in view of the higher reported incidence of 
hypertension, dyslipidaemia, visceral obesity, insulin resis­ 
tance and hyperinsulinaemia in this population. 6 Therefore, 
appropriate diagnosis and risk stratification is important in this 
group of patients.
Whether the presence of polycystic ovaries on ultrasound 
scanning should be used to diagnose polycystic ovarian 
syndrome routinely, is still debatable. A recent study involving 
questionnaires to endocrinologists and gynaecologists to 
compare their clinical practices in the management of patients 
with PCOS suggested that ovarian ultrasound was requested 
by almost all gynaecologists (91%), but by less than half of the 
endocrinologists (44%)? This difference in opinion is indica­ 
tive of the controversies over the inclusion of the ultrasound 
findings in the diagnostic criteria for PCOS. Polycystic ovaries 
are a common finding even in women without PCOS.8"11 In a 
study where an ultrasound scan was performed in normal 
volunteer women of reproductive age, of the 158 subjects who 
were not on oral contraceptives, 23% had polycystic ovaries. 12 
Furthermore, the appearance of polycystic ovaries on ultra­ 
sound has been shown to have no impact on fertility13 and 
neither morphology nor volume of the ovaries is associated 
with distinctive metabolic or reproductive phenotypes in 
women with PCOS. 14 In addition, about 10% of women with
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PCOS do not have polycystic ovaries on ultrasound scanning. 
A recent study in Germany found polycystic ovaries in only 
78% of women in a cohort of 212 PCOS patients previousl? 
recruited using the NIH criteria. Nevertheless, it should be 
noted that some of the studies above were done using the 
older criteria for polycystic ovaries and relevance of diagnosis 
made using the new criteria remains to be determined.
The definition of PCOS was first suggested in 1990 from an 
expert conference sponsored by the National Institutes of 
Health (NIH). In essence, these criteria define PCOS as a 
disorder of ovarian androgen excess as characterized by 
hyperandrogenism and oligo/amenorrhoea after exclusion of 
disorders that include Cushing's syndrome, congenital adre­ 
nal hyperplasia, thyroid dysfunction, hyperprolactinaemia and 
androgen secreting tumours. However, in 2003, a consensus 
workshop was held in Rotterdam, sponsored in part by the 
European Society for Human Reproduction and Embryology 
and the American Society for Reproductive Medicine where a 
new criteria was drawn up. 15 According to the Rotterdam 
criteria, PCOS can be diagnosed if two out of three features 
are present:
• hyperandrogenism;
• oligo/amenorrhoea;
• polycystic ovaries on ultrasound, after excluding other 
disorders.
If we look at it closely, the Rotterdam criteria does not replace 
but in fact expands the NIH definition of PCOS to include two 
extra subgroups, i.e. those with polycystic ovaries and 
hyperandrogenism (with normal regular periods), and those 
with polycystic ovaries and irregular periods (with no clinical or 
biochemical evidence of elevated testosterone levels).
What is biochemical hyperandrogenism? Patients with poly­ 
cystic ovarian syndrome often have a raised serum testoster­ 
one above the upper limit of the local assay. Serum 
testosterone levels more than 7-0 nmol/l raises concerns 
about alternative diagnoses, such as androgen secreting 
tumours. However, in addition to the testosterone the sex 
hormone binding globulin (SHBG) is often requested. The 
SHBG binds and carries testosterone, and in that form 
testosterone is inactive; however, the SHBG levels are often 
lower in PCOS as hyperinsulinaemia (commonly found in 
PCOS) is associated with a reduction in SHBG. Commonly, the 
testosterone level is expressed as a relative proportion of the 
SHBG concentration to derive a 'free androgen index (FAI)' 
that is a calculated estimate of the amount of 'free' (unbound) 
testosterone, that may be increased in PCOS when the total 
testosterone alone is not raised.
Two new phenotypes are proposed by the Rotterdam 
2003 criteria for PCOS that is irregular periods without 
hyperandrogenism, but with polycystic ovaries and secondly 
regular periods, but with polycystic ovaries and hyperandro­ 
genism. It is not known if these two variants are the same as 
the most common presentation of irregular periods with
DOI: 10.1179/174313406X150113
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hyperandrogenism. For example, whilst it is unclear if poly- 
cystic ovaries confers an increase in insulin resistance. 16-18 
the classical phenotype of insulin resistance, hyperandrogen­ 
ism and menstrual irregularity are associated with an 
increased risk of type 2 diabetes, but as yet, we do not have 
data to suggest this in the two new phenotypes suggested.
There are also practical and economic issues involved with 
including ultrasound scanning routinely in the diagnosis. The 
variable findings of polycystic ovaries in those with and without 
the syndrome may, in part, be due to inexpert scanning and 
varying techniques. It is recognized that, for obese patients, 
transvaginal scanning is far superior to transabdominal 
scanning and is the modality of choice. Should a dominant 
follicle be seen, then it is recommended to bring the patient 
back at the beginning of the next cycle as this could lead to a 
false negative scan. However, transvaginal ultrasound scan­ 
ning does have significant intra- and inter-observer variability, 
and as such must be considered subjective. 19 Therefore, 
transvaginal ultrasonography alone may not therefore be a 
reliable method of diagnosing or excluding PCOS.20 
Economically, in other health care systems outside the UK, 
ultrasound scanning puts the diagnosis into a higher remu­ 
neration band for the practitioner and, therefore, it may be 
preferable to perform a scan, rather than a routine blood test. 
Locally, in our UK laboratory, the total cost of a testosterone is 
approximately £7 and the cost of a sex hormone binding 
globulin £9: venesection can be done within minutes at the 
point of contact at the initial consultation and minimal expertise 
to perform it and the samples are measured by automated 
systems. Conversely, the cost of a transvaginal ultrasound is 
£32, requires .an additional expert professional and often has 
an inherent wait for an appointment in another location.
In conclusion, polycystic ovaries on ultrasound are found 
commonly in 20% of normal women, whereas 10% of those 
with polycystic ovarian syndrome (defined by NIH criteria) do 
not have polycystic ovaries on ultrasound. The combination of 
irregular periods with a raised testosterone or FAI makes an 
ultrasound examination unnecessary in the majority of women 
and should be reserved for cases of uncertainty or research. In 
these days of-financial constraint and the strain on diagnostic 
services through increased demand, the routine use of 
ultrasound in the diagnosis of PCOS, in these authors' opinion, 
is limited.
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Abstract:
Background: The LH/FSH ratio is often requested to help diagnose polycystic
ovarian syndrome (PCOS) despite a recent consensus recommending against its use.
Therefore, this study aimed to compare the variability of the LH/FSH ratio in PCOS
with that of normal menstruating women over a full cycle in order to establish the
diagnostic utility, or otherwise, of the test.
Methods: Twelve women with PCOS and 11 matched controls had blood collected at
4-day intervals on 10 consecutive occasions over a complete menstrual cycle.
Results: The median LH/FSH ratio for individual subjects did not differ significantly
between the PCOS and the non-affected group (1.6 vs. 1.2, p=0.14). Only 7.6% of
samples from PCOS patients had a LH/FSH ratio above 3 compared with 15.6% of
samples from normal subjects.
Conclusion: This study confirms that measurement of the LH/FSH ratio is of limited
use in the diagnosis of PCOS.
Introduction
An elevated luteinising hormone/follicle stimulating hormone (LH/FSH) ratio has 
been used as a diagnostic test for polycystic ovarian syndrome (PCOS) for many 
years. 12 Despite its continued use, concerns about the clinical utility of the ratio have 
led to the recent Rotterdam ESHRE/ASRM consensus statement on PCOS 
recommending against its inclusion. Only one previous study has evaluated the 
variation of the LH/FSH ratio in PCOS3 and this was only from specimens collected 
at monthly intervals. Therefore, this study aimed to determine the variability of the 
ratio in women with PCOS in comparison with normal controls throughout the time 
period of a full menstrual cycle.
Methods
Twelve overweight Caucasian women with PCOS (median age 28 y, range 18-31 y) 
and 11 weight-matched non-affected Caucasian women (median age 30 y, range 19- 
33,) with regular menses (every 28-30 d) and normal free andogen index (FAI) 
participated in the study. PCOS was diagnosed using the Rotterdam criteria.4 The 
body mass index (BMI, calculated as weight (kg)/height (m)2) in the PCOS group was 
not significantly different from that in the non-affected group (mean±SD, 33.2±6.3 vs. 
29.9±3.3, p=0.151 using Mann-Whitney U test). Fasting venous blood was collected 
into serum gel tubes (Becton Dickinson, Cowley, Oxfordshire, UK) at the same time 
each day (0800-0900) on 10 consecutive occasions at 4-day intervals to encompass 
measurement over at least a complete menstrual cycle. Samples were separated by 
centrifugation at 2000 g for 15 minutes at 4°C, and stored at -20°C within 1 h of 
collection. All subjects gave their informed written consent that had been approved by 
the local research ethics committee.
Aliquots were thawed and analyzed in a single continuous batch of reagents. Serum 
FSH, LH and testosterone were measured using a two-step procedure that used 
microparticle immunoassay technology (Abbott Diagnostics, Maidenhead, UK). Sex 
hormone binding globulin (SHBG) and insulin were measured using a 
chemiluminescent immunometric assay on the DPC Immulite 2000, (Euro/DPC, 
Llanberis, UK). Plasma glucose was measured using a hexokinase method on the 
Synchron LX 20 analyzer (Beckman Coulter, Inc., High Wycombe, UK). The FAI 
was calculated from total testosterone xlOO /SHBG. Statistical analysis was 
performed using SPSS, version 11.5.
Results
Four patients from the PCOS group showed biochemical evidence of ovulation 
(progesterone >16 nmol/L)5 during the collection period, so a third comparison group 
of anovulatory PCOS patients (n=8) was added (table 1). Overall, the median 
LH/FSH ratio for individual subjects did not differ significantly between the clinical 
PCOS and the non-affected groups (1.6 vs. 1.2, p=0.14 using Mann-Whitney U test), 
although the median ratio was higher in the anovulatory group compared to controls 
(1.8 vs. 1.2, p=0.013). LH concentrations alone were significantly higher in both 
clinical and anovulatory PCOS compared to controls (table 1). Tukey's test for 
indices of heterogeneity applied to the clinical PCOS and non-affected group showed 
no significant differences. LH/FSH ratio exceeded 3 in only 9/119 (7.6%) of samples 
in the clinical PCOS patients and in 17/109 (15.6%) of the controls. (x2=2.047, 
p=0.153) Two non-affected women had testosterone concentrations between 4.0 and 
7.0 nmol/L among their 10 samples but have no clinical evidence of abnormal 
menstrual cycle or hyperandrogenism.
Discussion
This study has shown that on an individual basis the median and range of the LH/FSH 
ratio do not differ significantly between patients with or without clinical PCOS, 
indicating that the test does not have robust diagnostic utililty. Although the median 
of the LH/FSH ratio in the anovulatory PCOS group was statistically higher than in 
controls (1.8 vs. 1.2), it is still much lower than the conventionally recommended cut 
off of 3.O.2 Indeed, numerically, there were fewer samples from PCOS patients with a 
ratio in excess of 3 than in the group of normally menstruating subjects. In fact,
repeated measurement of just LH seemed better than the LH/FSH ratio at 
discriminating clinical PCOS from controls, although it would be premature to use 
our data to advocate such a use.
Confirmation of the unreliability of the LH/FSH ratio is important as whilst the 
Rotterdam consensus4 now does not recommend it as a diagnostic test, it is still often 
requested for that purpose. For example, in our institution approximately 20% of the 
12,000 annual requests for LH and FSH measurement indicated PCOS as a reason for 
the request, on at a cost of over £20,000.
Our data is the first to look at the LH/FSH ratio over a complete menstrual cycle and 
is in accord with a previous study by Oei and Kazer3 that looked at the LH/FSH ratio 
variability by repeating LH and FSH concentrations once monthly for four 
consecutive months. Like ourselves they concluded that the LH/FSH ratio was too 
unreliable in distinguishing between PCOS and normal menstruating women in 
clinical practice.
The reasons for the apparently poor performance of the ratio must remain speculative. 
However, it is possible that the test has become less useful than it used to be because 
of changes to the diagnostic criteria for PCOS (leading to the inclusion of more 
ovulatory patients) as well as changes in the specificity of gonadotrophin assays.
In conclusion, our data has shown that variability in the LH/FSH ratio is at least as 
large for normal women as it is for those with clinical PCOS. In support of the recent 
Rotterdam consensus this study therefore confirms that the ratio has little diagnostic 
utility in clinical practice.
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Table 1. Biochemical features of clinical PCOS, anovulatory PCOS and non-affected 
group. Data presented as median (range), n denotes number of samples. LH 
luteinising hormone, FSH follicle stimulating hormone, SHBG sex hormone binding 
globulin and FAI free androgen index.
Parameter
(reference
range)
Fasting glucose
mmol/L (3.5-
5.0mmol/l)
Fasting insulin
mU/L
Testosterone
nmol/L
(0-4.1nmol/L)
FAI (0-8%)
SHBG nmol/L
LHU/L
FSHU/L
LH/FSH ratio
Non-affected
group
(n=109)
4.7 (3.6-5.7)
7.8 (2.0-19.2)
3.0(1.4-7.7)
5.3 (1.7-22.5)
53.8 (18.9-
153.0)
5.9 (0.7-82.6)
5.2(1.3-13.2)
1.2(0.3-11.0)
Clinical
PCOS
(n=119)
4.9 (4.0-9.0)
19.8 (5.6-
153.0)
3.8 (2.2-6.0)
13.6 (2.6-
40.1)
24.8 (12.8-
141.0)
9.3(1.1-54.8)
5.6(1.7-11.0)
1.6(0.3-6.2)
) value
clinical PCOS
/s. non-
iffected)
O.001
<0.001
<0.001
<0.001
<0.001
0.003
0.127
0.136
\novulatory
'COS (n=80)
4.9 (4.0-6.2)
22.0 (4.6-
153.0)
3.8 (2.3-6.0)
13.0 (2.6-
40.1)
25.8 (12.8-
141.0)
11.1 (1.4-
22.2)
5.8 (3.3-8.4)
1.8(0.4-4.0)
> value
anovulatory
'COS vs. non-
iffected)
0.034
0.001
O.001
O.001
<0.001
O.001
0.017
0.013
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Summary
Objective Hyperandrogenaemia is one of the three Rotterdam 
consensus diagnostic criteria for polycystic ovarian syndrome 
(PCOS) and may be measured by estimation of total testosterone, 
free androgen index (FAI) or bioavailable testosterone (BioT). The 
aim of this study was to compare the biological variability of total 
testosterone with that of the biological variability of both the FAI and 
BioT, to determine the least variable measurement for clinical practice. 
Design Comparative study.
Patients Blood samples were collected after an overnight fast at 
4-day intervals on 10 consecutive occasions from 12 PCOS patients 
and 11 weight- and age-matched control women. 
Measurements Duplicate samples of stored serum were analysed 
for total testosterone, SHBG and BioT in a single batch. 
Results The PCOS group had a significantly higher median BioT, 
FAI and total testosterone than controls. In both the PCOS and con­ 
trol groups, the intraindividual variance was small and similar for 
BioT and FAI. There was no significant difference between the within- 
subject biological coefficient of variation (CV,) for BioT, FAI and 
total testosterone. The maximum and minimum critical differences were 
+58% and -37% for BioT and +70% and -40% for FAI, respectively. 
Conclusion FAI appears to be the better diagnostic marker to 
distinguish hyperandrogenism in patients with PCOS, but once 
diagnosis has been made, all three methods should be equally good 
in monitoring further changes in the androgen status.
(Received 26 March 2007; returned for revision 8 June 2007; finally 
revised 15 August 2007; accepted 16 August 2007)
Introduction
Polycystic ovarian syndrome (PCOS) is a common disorder of 
women of reproductive age and is characterized by chronic anovulation
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220-236 Anlaby Road, Hull HU3 2RW, UK. Tel.: +44(0)1482 675385; 
Fax- +44(0)1482 675395; E-mail: l.cho@hull.ac.uk
and androgen excess. As a consequence, the Rotterdam consensus 
2003 has recommended hyperandrogenism as one of the three diag­ 
nostic criteria for diagnosis of PCOS. 1 Hyperandrogenism presents 
as hirsutism, acne or male pattern alopecia; serum concentrations 
of total testosterone are often at the upper limit of normal or mod­ 
estly elevated, but free testosterone (direct measurement or using the 
free androgen index, FAI) is usually elevated.2 This is recognized as 
being due to the clearance and bioavailability of testosterone, which is 
affected by the serum concentration of SHBG; hence, the diagnostic 
utility of an isolated serum testosterone measurement is question­ 
able and probably adds to the heterogeneity of diagnostic criteria 
used in PCOS. Bioavailable testosterone (BioT) measurement 
(which excludes SHBG-bound testosterone) and the FAI, which 
accounts for the sex hormone-bound fraction of testosterone, are 
assumed to be inherently superior estimates of hyperandrogenism 
compared with the measurement of total testosterone concentration 
alone. While the biological variability of total testosterone has been 
studied previously3'4 in normal individuals, no comparative data 
currently exist on the biological variation of BioT and FAI. These data 
are crucial for determining the relative suitability and/or superiority 
of these measures in both the initial and subsequent follow-up of 
the biochemical assessment of androgen excess in PCOS.
Materials and methods
Subjects were recruited initially for a study to assess the biological 
variation of insulin resistance in individuals with PCOS.5 Twelve 
overweight Caucasian women diagnosed to have PCOS (median age 
28 years, range 18-31) and 11 weight-matched Caucasian women 
(controls) having regular menses (every 28-30 days) and without 
PCOS (median age 30 years, range 19-33) participated in the study. 
The diagnosis of PCOS was based on evidence of a history of oligo- 
menorrhoea and either hirsutism or acne, together with hyperandro­ 
genaemia (FAI > 8). FAI was defined as testosterone x 100/SHBG, 
with both units in nmol/1. Nonclassical 21-hydroxylase deficiency, 
hyperprolactinaemia and androgen-secreting tumours were 
excluded by appropriate tests before the diagnosis of PCOS was 
made.6 No subject was taking any medication at the start of the study, 
nor during the preceding 6 months, and there was no concurrent ill­ 
ness. All subjects were on an unrestricted diet and were instructed
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Table 1. Baseline clinical and biochemical features of study subjects
Parameter PCOS (n = 12) Controls (n = 11) P-value
Age (years) 
BMI (kg/rn2) 
Testosterone (nmol/1)
SHBG (nmol/1)
BioT (nmol/1)
FAI(%)
Non-SHBG-bound
T (nmol/1)
26-3 ± 4-58 
33-2 ± 6-32 
3-9 (3-1-4-6)
22-9 ± 5-06
1-3 (1-0-1-6)
16-1 (11-6-21-1)
0-19 (0-13-0-26)
28-4 ± 4-72 
29-9 ± 3-25 
3-2 (2-6-4-0)
64-5 + 7-65
0-9 (0-7-1-1)
7-4 (5-9-9-4)
0-07(0-06-0-11)
ns 
ns 
< 0-001
<Q-001
< 0-001
0-001
0-001
PCOS, polycystic ovarian syndrome; BMI, body mass index;
BioT, bioavailable testosterone; FAI, free androgen index;
T, testosterone; ns, not significant.
Data presented as mean ± SD or as median (range) due to non-Gaussian
distribution.
not to modify their usual eating patterns during the period of 
sampling. Fasting plasma glucose, age and body mass index (BMI) 
were obtained. Patients and controls were matched for BMI (Table 1). 
Fasting venous blood was collected into serum gel tubes (Becton 
Dickinson, Oxford, UK) at the same time each day (0800-0900 h) 
on 10 consecutive occasions at 4-day intervals. Samples were 
separated by centrifugation at 2000 g for 15 min at 4 °C, and aliquots 
of the serum were stored at-20 °C within 1 h of collection. The study 
was conducted in accordance with the guidelines in the Declaration 
of Helsinki. All subjects gave their informed written consent prior 
to entering the study, which had been approved by our local ethics 
committee. The clinical trial registration number for this study is 
ISRCTN65353256.
Reagents
Before analysis, all the serum samples were thawed and mixed thor­ 
oughly. The duplicate samples (i.e. two per visit) were randomized 
and then analysed in a single continuous batch using a single batch 
of reagents. Duplicate aliquots of stored serum were analysed for 
SHBG, total testosterone (T) and BioT and analysed in singleton. 
The FAI was obtained as the quotient 100T/SHBG. Serum testoster­ 
one was measured on an Architect analyser (Abbott Laboratories, 
Maidenhead, UK) and SHBG was measured on a DPC Immulite 
2000 (Euro/DPC, Llanberis, UK) analyser using the manufacturer's 
recommended protocol. The intra-assay coefficients of variation 
(CVs) for total testosterone and SHBG as determined from duplicate 
study samples were 4-9% and 5-8%, respectively. BioT was measured 
using minor modifications of the method of Tremblay and Dube7 
and is widely reported as a measure of non-SHBG-bound testoster­ 
one.8"11 In brief, this technique uses 3H-labelled testosterone as a 
tracer, where SHBG is precipitated from charcoal-stripped serum 
using saturated ammonium sulfate and the radiolabelled testoster­ 
one measured in the supernatant as an estimate of the percentage 
non-SHBG-bound fraction. The concentration of BioT can then be 
calculated as this fraction of the total testosterone. Interassay preci­ 
sion was 5-25% at a concentration of 5-0 nmol/1.
Statistical analysis
Statistical analysis was performed using SPSS version 14. Biovari- 
ability data were analysed by calculating analytical, within-subject and 
between-subject variances (SD2 , SD2 and SD^ respectively) 
according to the methods of Fraser and co-workers.12'13 Using this 
technique, analytical variance (SD2 ) was calculated from the differ­ 
ence between duplicate results for each specimen (SD\ = Ztf/2N, 
where d is the difference between duplicates, and N is the number 
of paired results). The variance of the first set of duplicate results for 
each subject on the 10 assessment days was used to calculate the aver­ 
age biological intraindividual variance (SD2) by subtraction of SD2 
from the observed dispersion (equal to SD2 + SD2 ). Subtracting 
SD2 + SD2 from the overall variance of the set of first results deter­ 
mined the interindividual variance (SD2 ). The intraindividtfal 
(SD,) and interindividual (SDG) variations were estimated as square 
roots of the respective variance component estimates. The reference 
change value, or critical difference between two consecutive samples 
in an individual subject (i.e. the smallest percentage change unlikely 
to be due to biological variability), was calculated using the formula 
2-77(CV[), where CV, is the within-subject biological coefficient of 
variation. 12 The index of individuality (lol) was derived from the 
ratio of intra- and interindividual variation (SD/SDJ. 1 When the 
lol for a particular test is 0-6 or less, conventional population-based 
reference intervals are of limited value in the detection of unusual 
results for a particular individual. When the lol is 1-4 or more, the 
variation in an individual will fit the population reference limits 
more closely, thus being suitable as a screening test.
A power calculation based on our previous biological variability 
studies3"5 suggested that a total number of eight patients per arm was 
sufficient to achieve statistical significance, P < 0-05.
Results
The baseline clinical and biochemical details of the subjects are 
shown in Table 1. Figures 1, 2 and 3 show the median and range of 
BioT, FAI and total testosterone for the individuals in the three 
groups. The PCOS group had significantly higher median BioT, total 
T and FAI than the control group [median (range), 1-3 (1-0-1-6) vs. 
0-9 (0-7-1-1) nmol/1, P = 0-001; 3-9 (3-1-4-6) vs. 3-2 (2-6-4-0) nmol/1, 
P = 0-001; and 16-1 (11-6-21-1) vs. 7-4 (5-9-9-4), P = 0-001, respec­ 
tively]. The distribution of both BioT and FAI in controls and 
patients with PCOS were non-Gaussian using the Kolmogarov- 
Smirnov test. Data were therefore log-transformed before calcula­ 
tions were performed. In both the PCOS and control groups the 
intraindividual variance was small and similar for BioT and FAI 
(Table 2).
lol values for FAI, BioT and total testosterone were 0-87,0-91 and 
0-69, respectively, for PCOS and 0-61, 0-71 and 0-43 for controls. 
There was no significant difference between CV, of BioT, FAI and 
total testosterone.
In the group with PCOS, a strong correlation was seen between 
the BioT values and FAI (r = 0-9, P = 0-001). However, this correla­ 
tion was not observed in the control group (r = 0-2, P = 0-079). The 
minimum and maximum critical difference between two consecu­ 
tive BioT samples in an individual patient with PCOS was -37% or
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Fig. 1 Median and range of values (unadjusted for analytical variation) for 
bioavailable testosterone (BioT) in PCOS and controls.
Fig. 3 Median and range of values (unadjusted for analytical variation) for 
total testosterone in PCOS and controls.
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Table 2. Percentages of contribution from analytical, intra- and 
interindividual variance to total variance in PCOS and controls
% analytical % intraindividual % interindividual 
variance from variance from variance from 
total variance total variance total variance
PCOS 
BioT 2-8 28-8 68-4 
FAI 1-8 29-0 69-2 
Total T 5-2 30-7 64-1
Non-SHBG-bound T 1-6 21-8 76-6
Controls 
BioT 3-5 5-6 90-8 
FAI 1-1 5-4 93-5 
Total T 1-5 15-1 83-4 
5 Non-SHBG-bound T 1-0 7-4 91-6
Fig. 2 Median and range of values (unadjusted for analytical variation) for 
FAI in PCOS and controls.
PCOS, polycystic ovarian syndrome; BioT, bioavailable testosterone; 
FAI, free androgen index; T, testosterone.
+58% of any initial level of BioT. This indicates that a subsequent 
sample must rise by greater than 58% or fall by more than 37% to 
be considered significantly different from the first.
In comparison, the critical difference for FAI was -41% and 
+70%. Total testosterone was normally distributed and the critical 
difference was ±33%.
Discussion
This is the first study to systematically examine and compare the 
biological variability of BioT and FAI to total testosterone in PCOS, 
and demonstrates the relative suitability of each measure in detecting 
hyperandrogenism in PCOS. Indeed, one of the advantages in
specifically assessing the biological variability of these tests is that any 
differences found between them can be attributed more to the test 
itself rather than to analytical limitations of the assays involved.
There were high between-subject variations for BioT and FAI in 
both PCOS and controls, limiting their potential use as a measure 
to assess the degree of androgen excess present from a single estimate. 
However, if we consider the range of values in PCOS women, there 
was an overlap in values between women with PCOS and controls 
in total testosterone and BioT but no overlaps in FAI, making it a 
potentially better marker in identifying patients with PCOS than 
total testosterone alone.
Testosterone circulates in blood bound to both albumin and to 
the specific binding protein SHBG, with about 1% in women present
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in the free, nonprotein state. 14"16 The bioactive component includes 
the free plus albumin-bound fraction testosterone but not the 
SHBG-bound testosterone. Therefore, variation in the concentration 
of SHBG will influence the total concentration of testosterone and 
thus present difficulty in interpretation of results. SHBG concentra­ 
tion increases during pregnancy, oral contraceptive (oestrogen) 
usage, hyperthyroidism, administration of antiepileptic drugs and 
weight loss. However, it decreases with hypothyroidism, obesity or 
androgen excess. 17 As BioT measures only the bioactive and not the 
SHBG-bound component and the FAI is a calculated measure of 
testosterone adjusted for abnormalities in SHBG, they are presumed 
to be a more reliable index of measurement for hyperandrogenism.
The low lol value for all three tests in control subjects suggest that 
none are ideal diagnostic markers for detecting hyperandrogenism 
in patients with PCOS. This is because a low lol means that healthy 
individuals have androgen values that repeatedly remain close to 
their 'set point' within the population reference range rather than 
moving within the reference range. As a consequence, it means that 
individuals who usually have their set point at the lower end of the 
reference range can develop significant hyperandrogenaemia (in 
relation to themselves) but be regarded as 'normal' because their 
result still falls within the population reference range. By contrast, 
use of a low lol test to follow up patients already known to have the 
disease can in fact be of advantage as it means that a relatively small 
change in their test result will probably be of significance. 18
In this respect, the lol and CV, of total testosterone, BioT and FAI 
in PCOS patients were relatively similar, suggesting that all three are 
as useful (or otherwise) in monitoring androgen levels once diag­ 
nosis has been made. Both the strong correlation seen between BioT 
levels and FAI in the group with PCOS and the similar intra/inter- 
individual variance suggest that when the diagnosis of PCOS has 
been made, measurement of either BioT or FAI could be used with 
equal utility when assessing androgen status using a single measure. 
This correlation was not seen in the control groups, possibly because 
of the much smaller range of results among the healthy participants 
compared to those with PCOS. The critical difference value deter­ 
mined in this study means that, for any given individual, when serial 
measures of BioT are used to assess change in androgen status, a 
subsequent value must rise by more than 58% or fall by more than 
37% to be considered significantly different from the first (i.e. the 
change is greater than that explained by biological variation alone). 
The same argument applies for FAI, where the value should be greater 
than 70% or less than 41%. The Rotterdam criteria suggested the use 
of hyperandrogenaemia as a means of diagnosing PCOS. However, 
once the diagnosis is made, monitoring in response to treatment 
may be useful to assess a treatment effect.
We also calculated the non-SHBG-bound testosterone according 
to the method of Pearlman and Crepy, 19 which was found to have 
a good correlation with that of the direct radioimmunoassay of 
testosterone in ammonium sulfate-precipated plasma.20 The results 
are also included in Tables 1 and 2. As expected, the calculated 
non-SHBG-bound testosterone and its variability was found to be 
closely correlated to FAI as both represent an indirect measure of 
free testosterone.
There are limitations to this study. First, this study was executed 
and analysis performed before solvent extraction of raised testosterone
samples was routinely performed by the local laboratory. A recent 
publication by two of our authors suggested that the Abbott testo­ 
sterone assay is prone to interference by dehydroepiandrosterone sul- 
fate (DHEAS), which can be removed by a solvent extraction and 
reanalysis method.21 This, in turn, could potentially have an influ­ 
ence on our study findings. However, DHEAS interferes not only in 
the Abbott testosterone assay but also in most other immunoassay 
methods.22 Therefore, our results should be comparable to those 
measured on women in most routine clinical laboratories in the UK, 
although the proportion of laboratories that would investigate a 
raised result further by either solvent extraction or referral to another 
laboratory is unknown. It should be noted, however, that these find­ 
ings may only be relevant for the defined methodology and caution 
is necessary for general application. Second, by selecting patients for 
the study as having PCOS on the basis of a raised FAI, this cotfld 
itself have introduced a bias in establishing which test was superior 
at identifying the disease. Nonetheless, any androgen cut-off used for 
diagnosis, whether it is total testosterone, BioT or FAI, is necessarily 
arbitrary and our routine use of FAI does not detract from the fact 
that the overlap between measurements of total testosterone and 
BioT in healthy and PCOS subjects was far greater than with FAI.
In conclusion, FAI appears to be a better diagnostic marker for 
hyperandrogenism in patients with PCOS as there is less overlap with 
normality, but once the diagnosis is made, then all three methods 
have equal utility for monitoring changes in the androgen status.
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and functional sensitivity was calcu­ 
lated to be the dose in the equation 
with a total CV of 20%. We found the 
functional sensitivity, using reagent 
lots 26 and 29, to be 0.012 mlU/L. 
This value is considerably lower than 
that of Rawlins and Roberts (1), al­ 
though the same reagent lots were 
used. For the two newer in-date lots, 
functional sensitivity was calculated 
to be 0.022 mlU/L. Both determina­ 
tions are consistent with the manu­ 
facturer's claim of 0.019 mlU/L for 
the ADVIA Centaur TSH-3.
In summary, we believe that the 
data support our functional sensitiv­ 
ity claim for the third-generation 
ADVIA Centaur TSH-3 method and 
that this claim has been demon­ 
strated in other studies (4-6).
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Dr. Roberts responds:
To the Editor:
We appreciate the information pro­ 
vided by Waskiewicz et al. in their 
letter. They are correct that the study 
by Ognibene et al. (1) refers to a 
second-generation thyrotropin (TSH) 
assay on the ADVIA Centaur and not 
to a third-generation TSH assay. We 
regret this error. The study by Vo­ 
geser et al., cited as Ref. 4 by 
Waskiewicz et al., did not actually 
include an estimate of the functional 
sensitivity, but rather imprecision 
was 22.3% at a TSH concentration of 
0.014 mlU/L and 3.9% at 0.26 mlU/L 
(2). These are not sufficient data to 
estimate functional sensitivity.
The major issue is why our study 
yielded a higher functional sensitiv­ 
ity than theirs did. They indicate that 
each pool was tested with all reagent 
lots in one run. Our study used each 
of two reagent lots sequentially, 
which might in part account for the 
higher imprecision (3). The instru­ 
ment in their study was used for 
various patient sample evaluations 
in support of Centaur customers. The 
instrument in our study was used for 
routine testing of patient samples in 
a reference laboratory setting with 
—10000 patient results reported 
monthly, and TSH-3 was one of the 
analytes being routinely reported. 
The differing environments and use 
of the ADVIA Centaur analyzers in 
these 2 studies may have contributed 
to differences in imprecision. We 
maintain that our experimental con­ 
ditions are more representative of 
what will be encountered in routine 
clinical testing.
It is unclear whether authors of 
previous studies have performed im­ 
precision studies in a research setting 
or in a clinical testing environment. 
To our knowledge, no one has re­
ported on the effects of increasing 
workload on assay imprecision, but 
this may be a factor affecting the 
precision of some analyzers. A better 
understanding of which variables are 
most important and how they affect 
assay imprecision could lead to bet­ 
ter assay performance during routine 
clinical use. In the study by 
Waskiewicz et al., the functional sen­ 
sitivity of lots 38 and 41 of TSH-3 
reagent was 0.022 mlU/L, whereas 
that of lots 26 and 29 (the ones used 
in our study) was 0.012 mlU/L. It 
would be interesting to field-test lots 
38 and 41 to see whether the in­ 
creased functional sensitivity exhib­ 
ited by these two lots in a controlled 
setting would also be evident in rou­ 
tine clinical testing.
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The Biological Variation of C-Reactive 
Protein in Polycystic Ovarian Syndrome
To the Editor:
An inverse relationship between in­ 
creased C-reactive protein (CRP) 
concentrations and insulin sensitiv­ 
ity has occurred in individuals with 
polycystic ovarian syndrome (PCOS) 
(1) and is thought to contribute to an
1906 Letters
increased risk of coronary heart dis­ 
ease (2). However, no data currently 
exist on the biological variability of 
CKP and insulin resistance within 
the same individuals with PCOS, in­ 
formation that is essential to assess 
the full relationship between the two 
measures. We describe a study to 
establish whether a PCOS patient's 
CRP concentration remains within 
narrow biological limits or varies 
more widely over a given time pe­ 
riod, as well as to correlate its vari­ 
ability to that of insulin resistance.
Twelve overweight [mean (SD) 
body mass index (BMI), e.g., 33.2 (6.3) 
kg/m2] Caucasian women, diagnosed 
with PCOS [median (range) age, 
28(18-31) years], and 11 weight- 
matched Caucasian women [controls; 
mean(SD) BMI, 29.9(3.3) kg/m2], 
with regular menses (every 28-30 
days) and without PCOS [median 
(range) age, 30 (19-33) years], partici­ 
pated in the study. The BMI in the 
PCOS group was not significantly 
greater (P = 0.151) than that of the 
control group. Diagnosis of PCOS was 
based on evidence of hyperandrogen- 
emia [defined as free androgen index 
>8; mean(SD) index: PCOS group, 
21.85 (7.95); controls, 4.68 (2.05)], with 
a history of oligomenorrhea and hir- 
sutism or acne. Mean (SD) concentra­ 
tions of testosterone and sex hormone- 
binding globulin (SHBG) in the PCOS 
group compared with the control 
group were 4.69(0.76) vs 2.66(0.87) 
nmol/L (P <0.001) and 22.87 (5.06) vs 
64.51(7.65) nmol/L, respectively (P 
<0.001). Fasting venous blood was col­ 
lected into serum gel tubes (Becton 
Dickinson) and 1 fluoride oxalate tube 
at the same time each day (0800-0900) 
on 10 consecutive occasions at 4-day 
intervals. Samples were separated by
centrifugation at 2000g for 15 min at 
4 °C, and 2 aliquots of the serum were 
stored at -20 °C within 1 h of collec­ 
tion. Plasma glucose was analyzed in 
singleton within 4 h of collection. The 
serum samples were split before assay. 
All participants gave informed written 
consent before entering the study, 
which had been approved by the Hull 
and East Riding Local Research Ethics 
Committee.
Serum CRP was measured by the 
high-sensitivity method on a DPC 
Immulite analyzer (Euro/DPC), us­ 
ing the manufacturer's recommended 
protocol. The interassay CV was 4% 
using the study samples. Serum in­ 
sulin was assayed by a competitive 
chemiluminescent immunoassay, sup­ 
plied by Euro/DPC. The assay was 
performed on a DPC Immulite 2000 
analyzer (Euro/DPC), according to 
the manufacturer's recommended 
protocol. The CV of this method was 
8%, calculated as below, for study 
samples. The detection limit was 2 
milliunits/L, and there was no stated 
cross-reactivity with proinsulin. 
Plasma glucose was measured with a 
Synchron LX 20 analyzer (Beckman- 
Coulter), according to the manufac­ 
turer's recommended protocol. The 
CV for this assay was 1%, with a 
mean glucose value of 5.3 mmol/L 
during the study period. Fasting glu­ 
cose in the PCOS group [mean (SD), 
4.98 (0.58) mmol/L] was not signifi­ 
cantly different from the control 
group [4.81 (0.32) mol/L]. Fasting in­ 
sulin was much higher in the PCOS 
group than in the control group 
[mean (SD), 23.56 (8.54) vs 7.70 (1.83) 
jumol/L; P <0.001].
Statistical analysis was performed 
using SPSS for Windows NT, Ver. 9.0 
(SPSS Inc.). We analyzed biovariabil-
ity data by calculating both intra- 
and interindividual analytical vari­ 
ances (SDA2, SDr2, SDG2, respec­ 
tively), according to the methods of 
Fraser and Harris (3). The insulin 
resistance was calculated by use of 
the Homeostasis Model Assessment 
(HOMA) method [resistance = (insu­ 
lin X glucose)/22.5] (4).
Before analysis, all serum samples 
were thawed and thoroughly mixed. 
The duplicate samples (i.e., 2 per 
visit) were randomized and then an­ 
alyzed in a single continuous batch 
with a single batch of reagents. The 
distribution of CRP was found to be 
log-gaussian (by Kolmogorov-Smir- 
nov) in both the women with PCOS 
and the control group and conse­ 
quently was logarithmically trans­ 
formed before statistical analysis.
The CRP concentration in the 
PCOS group was greater than in the 
control group [median (range), 
3.54 (0.80-61.35) mg/L vs 1.07 (0.18- 
9.24) mg/L; P = 0.0001, Mann-Whit- 
ney test; Fig. 1)]. For the group with 
PCOS, the analytical variance con­ 
tributed 0.2% to the total test variance, 
intraindividual variance contributed 
30.2%, and interindividual variance 
contributed 69.6%. For the control 
group, the analytical variance con­ 
tributed 1% to the total test variance; 
intraindividual variance, 36.8%; and 
interindividual variance, 62.2%. Af­ 
ter accounting for analytical varia­ 
tion, the mean intraindividual varia­ 
tion was similar in both the group 
with PCOS and the control group 
(mean, 1.63 vs 1.76). In contrast, as 
reported previously for the same in­ 
dividuals (5), the HOMA-IR was not 
only greater in the group with PCOS 
[mean (range), 5.85 (1-42.1) units vs 
1.67 (0.48-3.49) units; P = 0.001], but
Fig. 1. Median and range of CRP concentra­ 
tions in the PCOS and control groups.
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was also more variable than in the 
control group (mean, 1.19 vs 0.23). 
The interindividual variation in CRP 
in its natural log for both groups was 
similar, at 0.5. The critical difference 
between 2 consecutive CRP samples 
in an individual patient with PCOS, 
calculated using the formula 
2.77(CV!) (3) on the log-derived data, 
was -64% or +179% of any initial 
concentration of CRP. This indicates 
that a subsequent sample must in­ 
crease by >179% or decrease by 
>64% to be considered significantly 
different from the first.
This is the first study to examine 
the biological variation of CRP in 
women with PCOS, and it shows that 
although the mean concentration of 
CRP is higher in individuals with 
PCOS compared with healthy con­ 
trols, the intraindividual variation of 
CRP is similarly large in both groups. 
Indeed, the potential utility of CRP 
as a marker of cardiovascular risk 
may be limited by the magnitude of 
this variability in both health and 
disease, as there can be substantial 
overlap between PCOS and control 
individuals. Our control group data 
are in accord with results demon­ 
strated by previous studies suggest­ 
ing a similarly wide intraindividual 
variability in CRP of ~30%-40% (6- 
9). In contrast, Ockene et al. (10) 
have suggested that high-sensitivity 
CRP has a degree of measurement 
stability similar to that of total cho­ 
lesterol, therefore providing evi­ 
dence of potential clinical utility of 
high-sensitivity CRP screening as a 
tool for vascular risk prediction. This 
issue of clinical usefulness, therefore, 
has yet to be resolved.
The lack of concordance between 
the variability of CRP concentration 
and the variability of insulin resis­ 
tance in PCOS, compared with the 
controls, indicates that despite the 
known inverse relationship, the mag­ 
nitude of CRP changes in the same 
individual does not closely mirror 
that of insulin resistance. Therefore, 
an increased CRP concentration can­ 
not be used as a direct surrogate 
marker to establish the presence of 
insulin resistance in this group. 
There has also.been the assumption 
that, in patients with PCOS, CRP
values may reflect the presence of the 
metabolic syndrome (11,12); indeed 
it still might, but insulin resistance 
alone would not be the sole cause or 
the main factor. It seems more likely 
that CRP may reflect or be a marker 
of many factors that contribute to the 
syndrome.
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Pseudocholinesterase Activity In 
Organophosphate Poisoning after 
Storage of Unseparated Blood 
Samples at Room Temperature for 
3 Weeks
To the Editor:
Suppressed pseudocholinesterase ac­ 
tivity is a well-established laboratory 
finding in patients with serious or­ 
ganophosphate poisoning (1). Re­ 
cently, a 48-year-old man with sus­ 
pected ingestion of methyl parathion 
died, and the postmortem examina­ 
tion was not indicative. After 3 
weeks, an overlooked specimen was 
discovered that had been collected 
from the patient ~1 h after the sus­ 
pected poisoning. The determination 
of pseudocholinesterase activity was 
requested. The blood sample, which 
showed complete hemolysis, was 
separated by centrifugation, and the 
pseudocholinesterase activity was 
determined. The result of 4.21 kU/L 
indicated the presence of only minor 
organophosphate poisoning without 
suppression of pseudocholinesterase 
activity.
Data regarding pseudocholinester­ 
ase activity in unseparated blood af­ 
ter storage at room temperature are 
rare, however, with the longest re­ 
ported duration (48 h) showing only 
negligible differences (2). Because 
one would expect enzyme activities 
to be extensively changed after stor­ 
age for 3 weeks at room temperature, 
we performed a limited study with
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The mean and the biological variation of insulin resistance does 
not differ between polycystic ovary syndrome and type 2 diabetes
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Abstract
Background: There is an assumption that the mean and biological variation of insulin resistance (IR) is less in polycystic
ovary syndrome (PCOS), and intuitively higher in type 2 diabetes (T2DM). To test this hypothesis we compared the mean
and biological variation in IR in PCOS to that of T2DM and to age- and weight-matched controls.
Methods: Twelve PCOS, 11 matched healthy women; 12 postmenopausal diet-controlled T2DM and 11 matched healthy
postmenopausal women were recruited. Blood samples were collected at 4-d intervals on 10 consecutive occasions.
The biological variability of IR was derived on duplicate samples.
Results: Mean and biological variability of HOMA-IR for PCOS did not differ from T2DM. Both measures were higher than
the matched controls. There was no difference in insulin or IR measures between the body mass index matched pre- and
postmenopausal women. Percentage 3 cell function were 208.8%, 62.3%, 106.5% and 111.9%, respectively, in PCOS,
postmenopausal women with T2DM, healthy premenopausal and healthy postmenopausal women.
Conclusions: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR
(or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production.
The clinical trial registration number for this study is ISRCTN65353256.
Ann Clin Biochem 2009; 00:1-4. DOI: 10.1258/acb.2008.008146
Introduction
Patients with polycystic ovarian syndrome (PCOS) have an 
increased risk of developing type 2 diabetes (T2DM),1 and 
both conditions are characterized by insulin resistance 
(IR). Increased IR is thought to be central to PCOS and 
may play a pathogenic role. 2 There is strong epidemiologi- 
cal evidence that IR is an independent cardiovascular risk 
factor.3 The factors underlying the progression of PCOS to 
T2DM are unclear and may be due to an increase in the 
underlying IR, perhaps due to increasing age, that may 
differ in both its mean and by its increased variability 
within the same individual.4"5 The aim of this study was 
to compare the mean and biological variation in IR concen­ 
trations in patients with PCOS to that of T2DM, together 
with age- and body mass index (BMI)-matched control 
subjects.
Patients and methods
This is a re-analysis of data derived from two studies.4'5 The 
biological variation of IR was assessed by measuring IR at
4-d intervals on 10 consecutive occasions in 12 overweight 
patients (BMI > 25) with PCOS (BMI means ± SD; 33.2 ± 
6.3), 12 postmenopausal Caucasian subjects with diet- 
controlled T2DM with previous normal menstrual cycles 
(31.1 ± 3.3), 11 healthy women with normal menstrual 
periods (every 28-30 d) (29.9 + 3.25) and 11 healthy post­ 
menopausal women (32.4 ± 5.3). Diagnosis of PCOS was 
based on the Rotterdam criteria 2003.6 All patients with 
PCOS had evidence of hyperandrogenaemia (free androgen 
index >8), with a history of oligomenorrhoea and hirsutism 
or acne: all patients had a normal oral glucose tolerance test. 
Diabetes was diagnosed on a fasting venous plasma glucose 
concentration >7.0mmol/L (126mg/dL) or a 2-h concen­ 
tration >ll.lmmol/L (200mg/dL) after a 75 g oral 
glucose tolerance test. Women were considered postmeno­ 
pausal if they had amenorrhoea for >1 y and 
follicle-stimulating hormone concentrations >20 IU/L. 
Exclusion criteria included any secondary cause of hyper- 
glycaemia, current or previous (in the preceding 6 months) 
use of oestrogen therapy, treatment with insulin or oral 
hypoglycaemic agents, untreated hypothyroidism, history 
of drug or alcohol abuse or smoking. Subjects on
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medications unrelated to diabetes took their medication as 
usual with no changes reported during the sampling 
period. Fasting venous blood was collected at the same 
time each day (08:00-09:00 h). Samples were separated by 
centrifugation at 4°C, and two aliquots of the serum were 
stored at -20°C within lh of collection. Plasma glucose 
was analysed in singleton within 4h of collection. The 
serum samples were split before assay. All subjects gave 
their informed written consent and the study had been 
approved by the local ethics committee.
Serum insulin was assayed using a competitive chemi- 
luminescent immunoassay, and plasma glucose measured 
Ql using a Synchron LX 20 analyser. Before analysis, all the 
serum samples were thawed and thoroughly mixed. 
Duplicate samples (i.e. two per visit) were randomized 
and analysed in a single continuous batch. IR was derived 
using the Homeostasis Model Assessment method 
(HOMA-IR) from fasting measures of serum insulin and 
plasma glucose, calculated using the homeostasis model 
assessment (HOMA) method (HOMA-IR = (insulin x 
glucose)/22.5).7 Percentage beta cell function were calcu­ 
lated using the computer-based programme.7'8
Statistical analysis was performed using SPSS for 
Ql Windows, version 11.0. Data on insulin and HOMA-IR 
was non-Gaussian and therefore non-parametric calcu­ 
lations were used. Group differences were compared by 
analysis of variance. Where significant differences were 
indicated Scheffe's post hoc test was applied.
Biovariability data were analysed by calculating analyti­ 
cal, within-subject and between-subject variances (SD^, 
SD?, SDc, respectively) according to the methods of Fraser 
and co-workers.9'10 Using this technique, analytical variance 
(SDi) was calculated from the difference between duplicate 
results for each specimen (SDA = Srf2/2N, where d is the 
difference between duplicates and N the number of paired 
results). The variance of the first set of duplicate results 
for each subject on the 10 assessment days was used to cal­ 
culate the average biological intraindividual variance (SD?) 
by subtraction of SDi from the observed dispersion (equal 
to SD?+SDi). Subtracting SD? + SDi from the overall
variance of the set of first results determined the interindivi- 
dual variance (SDc), The intraindividual (SDi) and inter- 
individual (SDc) variations were estimated as square roots 
of the respective variance component estimates. Coefficient 
of variation was calculated from mean divided by standard 
deviation. For all analysis, a two-tailed P < 0.05 was con­ 
sidered to indicate statistical significance.
Results
The clinical and biochemical details of the individual sub­ 
jects are shown in Table 1. No significant difference in 
BMI was observed between any of the four groups (P = 
0.37). As anticipated, PCOS/premenopausal controls were 
younger than T2DM/postmenopausal controls *(P< 
0.0001). When the mean HOMA-IRs for each PCOS 
patient were combined as a group they did not differ from 
patients with T2DM (3.1 + 1.2 and 1.9 + 0.9, respectively). 
However, both groups were higher than in their matched 
controls (P = 0.005) (premenopausal women, 1.0 ± 0.2; 
postmenopausal women, 1.3 + 0.5). There was no difference 
in IR between the pre- and postmenopausal controls. Insulin 
concentrations were higher for PCOS than T2DM and both 
significantly higher than the control populations (P< 
0.0001). Percentage beta cell function were 208.8%, 62.3%, 
106.5% and 111.9%, respectively, in PCOS, postmenopausal 
women with T2DM, healthy premenopausal and healthy 
postmenopausal women. Mean intraindividual variation 
of IR for PCOS, postmenopausal T2DM, healthy premeno­ 
pausal and healthy postmenopausal were 1.19, 1.05, 0.23, 
0.15, respectively (P < 0.001).
Discussions
This is the first analysis to compare the mean and biological 
variation of IR in PCOS with that of T2DM. These data show 
that the mean IR and its biological variability do not differ 
between PCOS and T2DM, although insulin concentrations 
in the PCOS group were considerably greater (Figure 1).
Table 1 Clinical and biochemical features of subjects
Parameter
Age (yr)
Body mass index (kg/m2)
Fasting glucose (mmol/L) 
Fasting Insulin (|jLLI/mL))
HOMA-IR
HOMA %B
T (nmol/L)
Mean intraindividual
variance for IR
Healthy postmenopausal 
(n = 11)
56.2 + 6.1 *•*
32.4 + 5.3
5.0 + 0.5 
9.6(6.8-11.5)*
2.0(1.6-2.7)T'tt
111.9
ND
0.15^
Postmenopausal 
T2DM (n = 12)
61.7±7.0*'§
31.1 +3.3
7.6 ± 2.3 
13.4 (8.3- 15.2)*'5
3.7 (2.7-5.3)*'Tt
62.3
ND
1.05*'n
Healthy premenopausal 
(n = 11)
28.4 + 4.7"*
29.9 ± 3.25
4.8 ± 0.3 
8.1 (6.3-9.0)*'**
1.7(1.3-2.0)*'"
106.5
2.7 ± 0.9**
0.23*'**
PCOS (n = 12)
26.3 + 4.6tl§
33.2 + 6.3
5.0 + 0.6 
23.5 (16.1 -33.3)^'**
4.9 (3.8-8.0)^**
208.8
4.7 + 0.8**
1.19*"'
Data with Gaussian distribution are presented as means + SD while those with non-Gaussian distribution are presented as median (interquartile range). ND, test 
not done; HOMA-IR, calculated insulin resistance; HOMA %B, calculated beta cell function; T, total testosterone; SHBG, sex hormone-binding globulin
•Denotes P< 0.05 between healthy postmenopausal and healthy premenopausal 
Denotes P < 0.05 between healthy postmenopausal and PCOS
*Denotes P < 0.05 between postmenopausal T2DM and healthy premenopausal
§Denotes P < 0.05 between postmenopausal T2DM and PCOS
"Denotes P< 0.05 between healthy premenopausal and PCOS
nDenotes P< 0.05 between healthy postmenopausal and postmenopausal T2DM
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premenopausal, 4 = PCOS
Figure 1 Box plot of median and range of insulin resistance in each group
All the parameters were higher than the respective matched 
control subjects.
These findings have several implications. First, they 
suggest that the progression from PCOS to the development 
of T2DM is unlikely to be due to a further increase in IR 
(or variability), but rather the progressive failure of pancrea­ 
tic beta cells that is recognized in T2DM.11 The HOMA beta 
calculation for beta cell function supported this hypothesis 
by the fact that percentage beta cell function was much 
reduced in postmenopausal women with T2DM compared 
with other groups. Although, similarly insulin resistant 
beta cell function was much increased in patients with 
PCOS, with a corresponding reduction in insulin sensitivity. 
This increased workload against IR, in some women may 
lead to a subsequent failure of beta cells and consequently 
T2DM. Gungor et al.11 had shown that adolescents with 
T2DM have impairment in first phase insulin secretion 
(FPIS) and second phase insulin secretion (SPIS). Other 
studies by the same group suggest that adolescent PCOS 
with normal glucose tolerance (NGT) are more hyperinsulin- 
aemic than matched obese girls,12 and those with impaired 
glucose tolerance (IGT) have impaired FPIS with no 
derangement in SPIS.13 Comparing across their studies, 
Gungor et al.n proposed that the essential metabolic deter­ 
minant of the progression from NGT to IGT to T2DM is 
due to pancreatic beta cell failure and our findings are con­ 
sistent with this suggestion.
IR has been shown to be an independent risk factor for 
cardiovascular disease14 and patients with PCOS may 
have an increased cardiovascular risk.15 " 19 That the mean 
IR is as high in T2DM implies that women with PCOS 
may have a cardiovascular risk comparable with T2DM 
despite not being hyperglycaemic. While biological variabil­ 
ity in IR has not been proven to add to the risk already 
present in patients with high mean IR values, glucose vari­ 
ability has recently been found to be associated with 
increased risk of free radical damage, independent of 
mean glucose in patients with T2DM.20 It remained possible 
that an increase in biological variability of IR may be
associated to or in fact is an independent risk for cardio­ 
vascular risk.
The data also showed that in individuals with the same 
BMI and ethnicity21 " 23 both the mean concentration and 
the intraindividual variation of IR were both low and did 
not differ between the BMI-matched premenopausal and 
postmenopausal controls, indicating that IR and its biologi­ 
cal variation does not change substantially with age and is 
independent of menopausal status. A limitation of this 
study is that the data from two different studies were 
used for comparison.
In conclusion, insulin concentrations were lower in 
patients with T2DM compared to PCOS although the 
mean and biological variations of IR were comparable; 
suggesting that beta cell dysfunction may determine the 
progression of PCOS to T2DM.
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ORIGINAL ARTICLE
Effect of metformin, orlistat and pioglitazone treatment on 
mean insulin resistance and its biological variability in 
polycystic ovary syndrome
L W. Cho*, E. S. Kilpatrickt, B. G. Keevilt, A. M. Coady§ and S. L. Atkin*
*Department of Medicine University of Hull, Hull, UK, ^Department of Clinical Biochemistry, Hull Royal Infirmary, Hull, 
UK, ^Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester, UK, ^Department of Radiology, 
Hull Royal Infirmary, Hull, UK
Summary
Context Mean insulin resistance (IR) is greater and it is also more
variable in overweight women with polycystic ovarian syndrome
(PCOS) compared to weight matched controls. Whilst treatment will
reduce the mean IR, it is not known if the IR variability is also
reduced,
Objective To compare the change in IR and its variability before
and after treatment with insulin sensitization through metformin
and pioglitazone, compared to that induced by weight loss with orlistat
Design Randomized, open labelled parallel study.
Setting Endocrinology outpatient clinic at a referral centre.
Patients Thirty obese PCOS patients [BMI 36-0 ± 1-2 kg/m2
(mean ± SEM)] participated in the study.
Intervention The change in biological variability (BV) was
assessed by measuring IR (homeostasis model assessment method)
at 4-day intervals on 10 consecutive occasions before and 12 weeks
after randomization to metformin, pioglitazone or orlistat.
Outcome measured The primary end point of the study was a
change in BV of IR.
Results Treatment with pioglitazone, orlistat and metformin
reduced the overall IR by 41-0 + 4-1%, 19-7 ± 6-4% and 16-1 ± 6-8%
(P = 0-005, P = 0-013, P = 0-17, respectively) and IR variability by
28-5 ± 18-0%, 41-8 ± 11-6% and 23-7 ± 17-0 (P = 0-20, P = 0-015 and
P = 0-28, respectively). Free androgen index reduced significantly
with all treatments.
Conclusion Only orlistat reduced both IR and its variability
significantly, though all three drugs were effective in reducing
hyperandrogenism within the 12-week period of the study.
(Received 18 February 2008; returned for revision 14 March 2008; 
finally revised 31 March 2008; accepted 19 May 2008)
Correspondence: Li Wei Cho, Centre for Diabetes and Endocrinology, 
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Introduction
Increased insulin resistance (IR) is an important feature in polycystic 
ovary syndrome (PCOS) that contributes to the increased risk of 
developing type 2 diabetes and is a feature of the adverse cardiovascular 
risk profile seen in the metabolic syndrome. 1 '2 Jayagopal etal. have 
shown that the absolute and intra-individual variation in IR are 
much greater in overweight women with PCOS compared to weight 
matched women without PCOS, but it is unknown if this innate 
variation of IR is modified following treatment and whether treatments 
such as insulin sensitization or weight loss have the largest impact. 
Therefore, this study has compared the effects of insulin sensitization 
with metformin, pioglitazone, to that of weight loss (with orlistat) 
on mean IR and its biological variability (BV) in women with PCOS.
Research design and methods
This was a randomized, open labelled, parallel study comparing 
treatment with metformin (500 mg three times a day), orlistat 
(120 mg three times a day) and pioglitazone (45 mg once daily). 
Thirty obese hyperandrogenic, anovulatory Caucasian women with 
PCOS [BMI 36-0 + 1-2 kg/m2 and age of 26-4 ± 1-5 year (mean + 
SEM)] were recruited from the Hull Royal Infirmary endocrinology 
clinic, where they were referred by their primary care physicians for 
investigation of menstrual abnormalities, with or without hirsutism. 
PCOS was diagnosed by the ESRM Rotterdam criteria;4 all patients 
had oligomenorrhea or amenorrhoea, hyperandrogenaemia and 
polycystic ovaries on transvaginal ultrasound. None were on any 
medications that would alter their IR at the time or for the preceding 
3 months of entering the trial. Diabetes was excluded by a 75-g oral 
glucose tolerance test. All subjects gave their informed written consent 
that had been approved by the local research ethics committee. The 
clinical trial registration number for this study is ISRCTN58369615 
and the study is funded by University of Hull.
After initial screening, all women began with an 8-week run-in 
period where they were given dietary advice and compliance 
checked. At the end of the run-in phase, they were randomized using 
a computer program. The number of patients to be recruited was 
based on a previous study.5 Using NQuery version 4 and powered 
for IR, a sample size of 10 patients in each treatment arm was
© 2009 The Authors
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determined for study completion. The dose of metformin was 
in accord with a previous study showing the beneficial effect of 
metformin in PCOS6 and increased step-wise, from 500 mg once 
daily for the first week to 500 mg twice daily for the next week, and 
to 500 mg three times daily for the remainder of the study period. 
The dose of orlistat was 120 mg three times daily before each meal. 
Pioglitazone was started at 30 mg daily for the first 2 weeks and 
further increased to 45 mg for the remainder of the study period. 
After randomization, the subjects were advised not to modify 
their eating habits throughout the study. Clinical and biochemical 
assessments were performed at each visit on 10 consecutive occasions 
at 4-day intervals before and 12-weeks after treatment. The primary 
end points of the study were the change in IR and its biological 
variability.
Study measurements
After an overnight fast, weight and blood pressure were measured 
and blood samples were taken at screening, randomization, and on 
completion of the study period. Compliance was monitored based 
on counting returned medication. Fasting venous blood was 
collected into serum gel tubes (Becton Dickinson) and one fluoride 
oxalate tube at the same time each day (08-00-09-00) on 10 consecutive 
occasions at 4-day intervals before and 12-week after treatment. 
Samples were separated by centrifugation at 2000 g for 15 min at 
4 °C, and two aliquots of the serum were stored at -20 °C within 
1 h of collection. Plasma glucose was analysed within 4 hours of 
collection. The serum samples were split before assay.
Reagents
Serum insulin was assayed using a competitive chemiluminescent 
immunoassay, supplied by Euro/DPC, Lknberis, UK. The assay was 
performed on a DPC Immulite 2000 analyser (Euro/DPC, Llanberis, 
UK), using the manufacturer's recommended protocol. There was 
no stated cross-reactivity with proinsulin. Plasma glucose was 
measured using a Synchron LX 20 analyser (Beckman-Coulter, High 
Wycombe, UK), using the manufacturer's recommended protocol. 
The coefficient of variation for this assay was 1 -2% at a mean glucose 
value of 94-6 mg/dl (5-3 mmol/1). The IR was calculated using 
the homeostasis model assessment (HOMA) method (HOMA- 
IR = (insulin x glucose)/22-5).7 Serum testosterone was measured by 
isotope dilution liquid chromatography-tandem mass spectromentry 
(Waters Corporation, Manchester, UK) and SHBG was measured by 
immunometric assay with fluorescence detection on the DPC 
Immulite 2000 analyser using the manufacturer's recommended 
protocol. The free androgen index was obtained as the quotient 100 
T/SHBG. Before analysis, all the serum samples were thawed and 
thoroughly mixed. The duplicate samples (i.e. two per visit) were 
randomized and then analysed in a single continuous batch using 
a single batch of reagents.
Statistical analysis
Statistical analysis was performed using SPSS for Windows, version 
14-0. Comparisons of percentage changes from baseline in the
metformin, orlistat and pioglitazone groups were carried out using 
the paired (-test in data showing a Gaussian distribution. In data 
where distribution between individuals violated the assumptions of 
normality when tested using the Kolmogorov-Smirnov test, differences 
were calculated by paired Wilcoxon method. Biovariability data was 
analysed by calculating analytical, within subject, and between 
subject variances (SD^, SDp SD^, respectively) according to the 
methods of Eraser and Co-workers.8'9 Using this technique, analytical 
variance (SD^) was calculated from the difference between duplicate 
results for each specimen ( SD^ = £//2N where d is the difference 
between duplicates, and N is the number of paired results). The 
variance of the first set of duplicate results for each subject on the 
10 assessment days was used to calculate the average biological intra- 
individual variance (SD2 ) by subtraction of SD^ from the observed 
dispersion (equal to SD2 + SD^). Subtracting SD2 + SD2 from the 
overall variance of the set of first results determined the inter- 
individual variance (SD2,). The intra-individual (SD,) and inter- 
individual (SDG) variations were estimated as square roots of the 
respective variance component estimates. For all analysis, a two- 
tailed P < 0-05 was considered to indicate statistical significance.
Results
All subjects completed the study and the results are shown in Table 1. 
Baseline differences between the three groups were nonsignificant 
(ANOVA test).
Insulin resistance (IR)
HOMA-IR reduced significantly in both the orlistat (P = 0-013) and 
pioglitazone (P = 0-005) treated groups. Women treated with 
metformin did not show significant reduction in HOMA-IR 
(P = 0-17) for the period studied. Comparison between the three 
treatments showed a significant reduction in HOMA-IR favouring 
the pioglitazone group (P = 0-04). The differences between the 
groups for percentage change in HOMA-IR remained significant 
after adjustment for percentage change in BMI (P < 0-0001).
Biological variability (BV) of HOMA-IR
Figures 1-3 show the changes in BV of HOMA-IR after 12 weeks of 
treatment for all the three groups. BV reduced significantly only in 
the orlistat treated group compared to baseline (P = 0-015). Women 
in the metformin and pioglitazone treated groups showed a trend 
to reduction of BV of IR at but did not reach statistical significance 
for the period studied. A discrepant HOMA-IR of 19-6 in one 
patient on orlistat was included in the analysis that caused a 
greater pretreatment variance, but had no influence on our overall 
findings.
BV HOMA-IR was significantly correlated to HOMA-IR, the 
Pearson correlation coefficient was 0-72 (P = 0-001; two-tailed). The 
change in BV HOMA-IR significandy correlated with changes in 
HOMA-IR (correlation coefficient 0-39, P = 0-035) and changes in 
FAI (correlation coefficient 0-57, P = 0-001). There were no significant 
correlations between changes in BV HOMA-IR with changes in BMI 
or SHBG.
© 2009 The Authors 
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TUble 1. Percentage change for each parameter after 3 months of treatment
HOMA-IR 
BVHOMA 
Insulin (nU/rnl) 
SHBG (nmol/1) [range 35-100] 
BMI (kg/m3) 
FAI (%) [range 0-3-0]
Metformin
Baseline vs. 12 weeks
3-6 ±0-5 vs. 3-110-6 
M ±0-5 vs. 0-7 ±0-4 
16-8 ±2-3 vs. 15-1 ±2-9 
22-1 ±2-5 vs. 25-3 + 3-2 
34-3 ±1-8 vs. 33-211-9 
7-9 ± 0-9 vs. 6-1 ± 0-9
% change
-16-1 ±6-8 
-23-7 ± 17-0 
-12-8 ±7-7 
13-313-1* 
-3-4 ±1-0* 
-22-9 ± 7-4*
Orlistat
Baseline vs. 12 weeks
5-0 1 0-8 vs. 3-7 ± 0-5 
3-9 ±2-0 vs. 1-010-5 
23-6 1 3-9 vs. 17-7 1 2-3 
25-1 13-5 vs. 29-515-1 
37-4 1 2-7 vs. 35-2 1 2-4 
8-7 1 1-9 vs. 6-9 1 1-6
% change
-19-7 1 6-4* 
-41-8111* 
-18-4 1 5-6* 
14-3 1 5-0* 
-5-7 1 0-8* 
-20-8 ± 5-8*
Pioglitazone
Baseline vs. 12 weeks
4-5 1 0-8 vs. 2-5 1 0-4 
1-2 10-5 vs. 0-510-2 
20-0 1 2-9 vs. 12-0 1 1-5 
22-3 1 1-6 vs. 32 1 3-2 
36-2 11-8 vs. 37-311-8 
6-1 11-2 vs. 4-710-6
% change
-11-0 ±4-1* 
-28-5 ± 18-0 
-37-6 ± 4-2* 
43-7 1 10-2* 
3-1 1 1-4 
-16-115-1*
Data are presented as mean 1 SEM and local laboratory reference range given in brackets. All serum results are obtained from fasting variables. BV HOMA
denotes biological variation of HOMA. Baseline differences between groups were nonsignificant (ANOVA).
*P < 0-05 for changes compared to baseline.
To convert values for insulin to picomoles per litre, multiply by 6. To convert values for SHBG to micrograms per decilitre, divide by 34-7.
Fig. 1 Changes in biological variability of insulin 
resistance in women with PCOS pre- and 
post-treatment with metformin.
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BMI
BMI reduced significantly with both metformin (P = 0-013) and 
orlistat (P = 0-005), with a trend to an increase with pioglitazone 
after 12 weeks of treatment. There was no difference between the 
decrease in BMI with metformin to that of orlistat, P = 0-07.
Biochemical hyperandrogenaemia
FAI reduced significantly in all the three groups (P = 0-017 in 
metformin, P = 0-007 in orlistat and P- 0-012 in pioglitazone). 
There was no difference between the three treatments for the change 
in FAI, P = 0-85 (Kruskal-Wallis test).
Discussion
Metformin therapy has been shown to have beneficial short-term 
effects on IR in nondiabetic women with PCOS,6' 10"16 and its use
in women with PCOS is now regarded as acceptable practice. 
Pioglitazone " and orlistat have also been shown to improve the 
metabolic and hormonal consequence of PCOS. This study aimed 
to contrast and compare the metabolic changes and BV of IR that 
followed treatment with these three medications in women with 
PCOS.
We have shown that weight reduction with orlistat was comparable 
to insulin sensitization with pioglitazone in leading to a significant 
reduction of IR over the time course of the study while treatment 
with metformin showed a trend to reduction. The apparent lack of 
effect by metformin may have been due to its reduced efficacy in 
subjects with a high BMI.21 The percentage reduction of IR was 
largest with pioglitazone compared to metformin and orlistat, but 
with respect to the reduction in hyperandrogenism, the effect of 
pioglitazone was comparable to the other two treatments.
IR is much more variable in women with PCOS compared to 
weight matched controls3 and this study has shown that only weight 
reduction through orlistat reduced IR variability of the HOMA-IR
© 2009 The Authors
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Fig. 2 Changes in biological variability of insulin 
resistance in women with PCOS pre- and 
post-treatment with orlistat.
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Fig. 3 Changes in biological variability of insulin 
resistance in women with PCOS pre- and 
post-treatment with pioglitazone.
measurements, whilst insulin sensitization had no effect This suggests 
that physiological reversal of both mean and variability of IR occurs 
with weight loss, whilst only mean IR is reduced with insulin 
sensitization. The reduction in variability within the same individual 
by weight loss also indicates that the large variability in HOMA-IR 
is likely to be a true reflection of fluctuant IR in these patients, rather 
than an artefact. The HOMA model itself is a validated technique 
of assessing IR7 and studies comparing it to other measures of IR 
such as clamp studies have shown it to be a good measure of IR ' 
and in practical terms the only method for such frequent sampling 
to determine BV.
Why should weight loss reduce the BV of HOMA when insulin 
sensitization does not? It has to be accepted that the cause for such 
a large degree of variability in IR amongst PCOS patients is currently
unknown. However, speculatively, insulin sensitization by metformin 
and pioglitazone is unidimensional, in that both reduce IR largely 
through a single mechanism which, in turn, would seem to pre­ 
dominantly influence only mean IR rather than its variability. In 
comparison, weight loss (in this case with orlistat) is more likely to 
have a multidimensional effect by modulating several factors associated 
with IR and hence the reducing both mean IR and its BV.
While variability in IR has not been proven to add to the risk 
already present in patients with high mean IR values, glucose 
variability has certainly been found to be associated with increased 
free radical damage independently of mean glucose in type 2 diabetes 
(T2DM).24 However, it is not known if this relationship is actually 
a reflection of the inherent variability of IR found in T2DM and 
PCOS.
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In summary, only weight reduction with orlistat resulted in a 
significant reduction in insulin resistance and its variability whist 
insulin sensitization with metformin and pioglitazone had no effect 
on insulin resistance variability despite a significant reduction in 
mean insulin resistance seen with pioglitazone.
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LONG-TERM CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME
This is the second edition of this guideline, which was previously published in May 2003 under the same title.
1. Purpose and scope
This guideline has been produced to provide information, based on clinical evidence, to assist clinicians with 
a special interest and for updating the generalist who manages women with polycystic ovary syndrome, to 
allow them to advise women about the long-term health consequences of the syndrome.This guideline does 
not cover infertility associated with polycystic ovary syndrome (PCOS), which has been extensively reviewed 
elsewhere. 12
2. Introduction
PCOS is a common disorder, often complicated by chronic anovulatory infertility and hyperandrogenism with 
the clinical manifestation of oligomenorrhoea, hirsutism and acne.3 Many women with this condition are 
obese and have a higher prevalence of impaired glucose tolerance, type 2 diabetes and sleep apnoea than is 
observed in the general population. They exhibit an adverse cardiovascular risk profile, characteristic of the 
cardiometabolic syndrome as suggested by a higher reported incidence of hypertension, dyslipidaemia, 
visceral obesity, insulin resistance and hyperinsulinaemia.4 PCOS is frequently diagnosed by gynaecologists 
and it is therefore important that there is a good understanding of the long-term implications of the diagnosis 
in order to offer a holistic approach to the disorder.
3. Identification and assessment of evidence
This RCOG guideline was developed in accordance with standard methodology for producing RCOG Green- 
top Guidelines. The Cochrane Library (including the Cochrane Database of Systematic Reviews, DARE and 
EMBASE),TRIP,Medline and PubMed (electronic databases) were searched for relevant randomised controlled 
trials, systematic reviews and meta-analyses.The search was restricted to articles published between 1966 and 
October 2006.The databases were searched using the relevant MeSH terms including all subheadings and this 
was combined with a keyword search. MeSH heading search included 'polycystic ovary', 'metabolic', 
'diabetes', 'cardiovascular' and 'glitazone' and the search limited to humans and the English language. The 
computer search was complemented by hand searching from original references and reviews.
The definitions of the types of evidence used in this guideline originate from the US Agency for Health Care 
Policy and Research. Where possible, recommendations are based on, and explicitly linked to, the evidence 
that supports them.Areas lacking evidence are highlighted and annotated as 'Good Practice Points'.
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4> Prevalence of PCOS
Estimation of the 'true' prevalence has to be made with caution as many of the data available were collected 
prior to the new Rotterdam diagnostic criteria. Most clinical data suggests a prevalence of 6-7% of the 
population.5-8 The present Rotterdam criteria are current best practice but it is recognised that PCOS 
encompasses a wide spectrum of disorder, overlapping with normality.
The prevalence of PCOS may differ according to ethnic background; for example, in women of South Asian 
origin, PCOS presents at a younger age, has more severe symptoms and a higher prevalence.' 10
5. Diagnosis
How is PCOS diagnosed?
Diagnosis of PCOS can only be made when other aetiologies have been excluded (thyroid dysfunction, 
congenital adrenal hyperplasia, hyperprolactinaemia, androgen-secreting tumours and Gushing 
syndrome).
A consensus definition using precise diagnostic criteria should be used when diagnosing PCOS to 
facilitate effective patient care and robust clinical research.
The National Institutes of Health (NIH) 1990 preliminary consensus definition has now been replaced by a 
more recent definition by the Rotterdam European Society for Human Reproduction and Embryology 
(ESHRE) and the American Society of Reproductive Medicine (ASRM) PCOS Consensus Workshop Group." 
This has suggested a broader definition for PCOS, with two of the three following criteria being diagnostic of 
the condition:
• polycystic ovaries (either 12 or more peripheral follicles or increased ovarian volume (greater than 10 cm3)
• oligo- or anovulation
• clinical and/or biochemical signs of hyperandrogenism.
A raised luteinising hormone/follicle-stimulating hormone ratio is no longer a diagnostic criteria 
for PCOS owing to its inconsistency. 12 It should be noted that the diagnosis of PCOS can only be 
made when other aetiologies have been excluded. The recommended baseline screening tests 
are thyroid function tests, a serum prolactin and a free androgen index (total testosterone divided 
by sex hormone binding globulin (SHBG) x 100 to give a calculated free testosterone level). In 
cases of clinical evidence of hyperandrogenism and total testosterone greater than 5 nmol/1, 
17-hydroxyprogesterone should be sampled and androgen-secreting tumours excluded. If there is 
a clinical suspicion of Cushing syndrome, this should be investigated according to local practice.
These new diagnostic criteria have affected the value of a number of systematic reviews, as the majority of 
the reviews are based on the NIH 1990 criteria, which may not be entirely representative of those patients 
diagnosed by the new Rotterdam criteria in use today, in particular where ultrasound was used as the main 
diagnostic criterion.
6. Counselling
How should women be counselled?
Evidence 
level Kb
Women diagnosed with PCOS should be informed of the possible long-term risks to health that are 
associated with their condition. They should be advised regarding weight control and exercise.
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7- Long-term consequences
7.1 Metabolic consequences ofPCOS
What is the risk of developing type II diabetes in women with PCOS?
Women presenting with PCOS, particularly if they are obese (body mass index greater than 30), have a 
strong family history of type 2 diabetes or are over the age of 40 years, are at increased risk of type 2 
diabetes and should be offered a glucose tolerance test.
Insulin resistance in PCOS has been linked to later development of impaired glucose tolerance and 
type 2 diabetes. 13 Evidence from small long-term cohort studies, case-control studies and case 
series points to a risk of type 2 diabetes in middle age of 10-20%, M-'s with a high rate of impaired 
glucose tolerance, suggesting that further cases of diabetes will develop later. Increased body mass, 
particularly truncal obesity, and a strong family history of diabetes (up to 83% in one study) increase 
the risk of developing type 2 diabetes in the presence of polycystic ovary phenotype. 16 However, 
the frequency of type 2 diabetes is also increased in women with PCOS who are not obese (body 
mass index less than 27 kg/m2), 15 ''6 suggesting that PCOS is an independent risk factor for type 2 
diabetes in middle age.A sensible approach to ensuring early detection of diabetes might be to offer 
screening to women with PCOS with measurement of fasting blood glucose, on a regular basis, 
perhaps annually. However, if the fasting blood glucose is 5.6 mmol/1 or greater, body mass index is 
greater than 30 or a strong family history of diabetes, then an oral glucose tolerance test should be 
arranged.Although fasting glucose was poorly discriminatory for type 2 diabetes in studies to date, 
it is a more appropriate test for routine screening. Fasting insulin and HOMA-IR are not measured 
routinely in clinical practice in the UK and exhibit considerable variability that limits their 
usefulness only to population-based studies. These tests are not sensitive enough to be useful in 
individual cases and are not included in the diagnosis of the condition.
Guidance on the management of diabetes in pregnancy is available in the National Institute for Health and 
Clinical Excellence guideline, Diabetes in pregnancy: management of diabetes and its complications from 
pre-conception to the postnatal period (expected publication date March 2008).
7.2 PCOS and obstructive sleep apnoea
What is the risk of developing sleep apnoea in women with PCOS?
Evidence 
level IV
Women diagnosed with PCOS (or their partners) should be asked about snoring and daytime 
fatigue/somnolence and informed of the possible risk of sleep apnoea, and offered investigation and 
treatment when necessary.
Sleep apnoea is an independent cardiovascular risk factor and has been found to be more common 
in PCOS. The difference in prevalence of sleep apnoea between PCOS and controls remained 
significant even when controlled for BAIL 1718 It has been reported that the strongest predictors for 
sleep apnoea were fasting plasma insulin levels and glucose-to-insulin ratios. 19
7.3 PCOS and cardiovascular risk
What is the risk of developing cardiovascular disease in women with PCOS?
Clinicians need to be aware that conventional cardiovascular risk calculators have not been validated in 
women with PCOS.
Evidence 
levelIH
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In clinical practice, hypertension should be treated but lipid-lowering treatment is not recommended 
routinely and should only be prescribed by a specialist.
While it seems prudent to assess the cardiovascular risk factors of a woman with PCOS (including 
measurement of blood pressure, cholesterol, triglycerides and high-density lipoprotein cholesterol), it should 
be borne in mind that the conventional cardiovascular risk calculators have not been validated in this group.
It has been suggested that women with PCOS may have a higher cardiovascular risk than weight-matched 
controls with normal ovarian function.20-22 They have increased cardiovascular risk factors such as obesity, 
hyperandrogenism, hyperlipidaemia and hyperinsulinaemia. Their abnormal lipid profiles mainly consist of 
raised triglycerides, total and low-density lipoprotein cholesterol. 23-25 The effect of PCOS on high-density 
lipoprotein cholesterol (HDL-Q, however, is controversial, 23242S and evidence on hypertension is also less 
consistent.26 The elevation of risk factors in young women with PCOS may therefore put them at increased 
risk of developing accelerated atherosclerosis resulting in myocardial infarction. 142425 In the Nurses' Health 
Study, menstrual cycle irregularity was associated with an increased risk of nonfatal and fatal coronary heart 
disease, although no data were available for confirmation of a diagnosis of PCOS.27
Despite the increase in cardiovascular risk factors, morbidity and mortality from coronary heart 
disease among women with PCOS has not been shown to be as high as predicted.28 Studies to date 
are small in size and randomised controlled trials and prospective endpoint studies are lacking. 
Nevertheless, from a clinical perspective, clinicians should continue to identify cardiovascular risk 
factors in women with PCOS and treat these accordingly. In clinical practice, hypertension should 
be treated according to the Joint British Society Guidelines, which should be referred to. 29 These 
guidelines suggest that persistent blood pressures greater or equal to 140 mmHg systolic and or 90 
mmHg diastolic, not responding to lifestyle measures, need to be considered for drug therapy 
(women with diabetes or other high risk factors with blood pressure greater than 130 mmHg 
systolic and or 80 mmHg diastolic may require drug therapy). Lipid-lowering treatment is not 
recommended routinely and should be prescribed by a specialist.
8. PCOS and pregnancy
What are the implications of PCOS for pregnancy?
Women who have been diagnosed as having PCOS before pregnancy (such as those requiring ovulation 
induction for conception) should be screened for gestational diabetes before 20 weeks of gestation, 
with referral to a specialist obstetric diabetic service if abnormalities are detected
Metformin is currently not licensed for use in pregnancy in the UK and is not recommended for use in 
pregnancy.
Evidence 
level ID.
There is a higher risk of gestational diabetes in women with PCOS.3031 The risk is believed to be greatest in 
obese women with PCOS who required ovulation induction in order to conceive. Such women should be 
screened for abnormal glucose tolerance in pregnancy and, if appropriate, referred for antenatal management 
by an obstetrician with special interest in diabetes in pregnancy. A recent meta-analysis concluded that 
women with PCOS have a significantly higher risk of pregnancy complications compared to controls.32
Metformin taken throughout pregnancy had been suggested to reduce the risk of miscarriage and gestational 
diabetes in women with PCOS.33 34 Another meta-analysis provided reassurance that metformin is safe, with 
suggestive data that it may reduce incidence of miscarriage if taken in the first trimester of pregnancy.35 
However, the methodology of these studies was poor and metformin is currently not licensed for use in 
pregnancy in the UK. We do not recommend its use in pregnancy at present until further randomised 
prospective study results are available to provide adequate evidence of safety and efficacy of its use in this
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context.A larger multicentre trial, the MiG trial, is due to report on the use of metformin in pregnancy soon. 
Nevertheless, being a class B drug, metformin has no reported evidence of animal or fetal toxicity or 
teratogenicity.
Comparing metformin-treated PCOS and control groups, no differences in height, weight and motor-social 
development in infants has been noted during the first 18 months of life.36 Even though metformin is excreted 
in breast milk, it is at a very low level,37-39 and there have been no concerns to date with its use.^There may 
still be unanticipated risks to the baby from the postnatal use of metformin by breastfeeding women.40 Further 
studies are therefore needed before recommending the use of metformin in the puerperium.
Evidence 
level Db
Women who have been diagnosed in pregnancy with gestational diabetes have been found to have 
a high prevalence of PCOS on subsequent screening. This association is more common in women 
with raised body mass index.41 "2
9. Cancer and PCOS
What are the risks of cancer in women with PCOS?
Oligo- or amenorrhoea in women with PCOS may predispose to endometrial hyperplasia and later 
carcinoma. It is good practice to recommend treatment with progestogens to induce a withdrawal bleed 
at least every 3-4 months.
There does not appear to be an association with breast or ovarian cancer and no additional surveillance 
is required.
It has been known for many years that severe oligo- and amenorrhoea in the presence of 
premenopausal levels of estrogen can lead to endometrial hyperplasia and carcinoma.43 In women 
with PCOS intervals between menstruation of more than 3 months may be associated with 
endometrial hyperplasia.44 Regular induction of a withdrawal bleed with cyclical gestogens, such as 
progestogens for at least 12 days,4546 oral contraceptive pills or the Mirena® intrauterine system 
would be advisable in oligomenorrhoeic women with PCOS. Women who are oligomenorrhoeic 
and do not have normal withdrawal bleeds should be investigated and managed according to local 
protocols.This may include ultrasound scan, endometrial sampling and/or hysteroscopy.47
Women with PCOS do not have any significant increase in risk of developing breast cancer compared with 
those without (RR 1.2; 95% CI 0.7-2.0).48 A small number of studies have addressed the possibility of an 
association between PCOS and epithelial ovarian cancer risk, the results are conflicting but generally 
reassuring.49 As there does not appear to be an association with breast or ovarian cancer, no additional 
surveillance is required beyond routine screening.
10. Strategies for reduction of risk
10.1 Exercise and weight control
How should women with PCOS be advised on lifestyle issues?
Women diagnosed with PCOS should be advised regarding weight loss through diet and exercise.
Evidence 
level Ha
Lifestyle changes through diet and exercise remain the first line for treatment of obesity in PCOS. PCOS is 
often associated with obesity and abnormal fat distribution, especially of abdominal fat, even where the BMI 
is normal. 50 Obesity worsens insulin resistance that may exacerbate this dysfunction. Loss of significant weight 
has been reported to result in spontaneous resumption of ovulation, 51 improvement in fertility,52 increased
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Evidence 
level Ib
SHBG and reduced basal level of insulin5354 accompanied by a normalisation in glucose metabolism.55 Lifestyle 
alteration will reduce the likelihood of developing type 2 diabetes later in life.There is no clear evidence of 
an effect of diet and exercise on the long-term health of women with PCOS who have normal body habitus, 
although it seems prudent to advise such patients to maintain their body weight within the normal range.
While there is little long-term data on the effect of lifestyle intervention in women with PCOS, 
the diabetes prevention trial examined subjects with similar metabolic profiles and risk factors. 
This study found that lifestyle intervention reduced the risk of diabetes by 58%.* In the absence 
of any robust long-term follow-up data for lifestyle interventions, it would seem prudent to advise 
regular exercise (aiming for a mean 30 minutes sweat-inducing exercise daily) as the most 
important lifestyle measure, and to have a healthy, balanced diet of regular, hypocalorific meals 
through the day.
10.2 Drug therapy
Is drug therapy appropriate for women with PCOS?
Insulin-sensitising agents have not been licensed in the UK for use in women who are not diabetic. 
Although a body of evidence has accumulated demonstrating the safety of these drugs, there is 
currently no evidence of a long-term benefit for the use of insulin-sensitising agents.
Use of weight-reduction drugs may be helpful in reducing insulin resistance through weight loss.
The demonstration of the potential long-term health consequences of PCOS have been 
accompanied by renewed interest in the use of insulin-sensitising agents such as metformin and the 
thiazolidinediones (troglitazone, rosiglitazone and pioglitazone) to reduce insulin resistance and 
thereby reduce risk of developing diabetes and other metabolic sequelae. Although a body of 
evidence as accumulated demonstrating the safety of these drugs, there is no evidence for a long- 
term benefit for use of sensitising agents. Both metformin57'64 and troglitazone65•* have been shown 
to have beneficial short-term effects on insulin resistance in women with PCOS who are not 
diabetic.There is evidence that metformin may modestly reduce androgen levels by around 11% in 
women with PCOS compared with placebo and modest reductions in body weight have been 
reported by some, but not all studies. Women with a body mass index of more than 37 may not 
respond well to metformin therapy. It must be emphasised that both metformin and the 
thiazolidinediones are unlicensed for use in PCOS and patients should be counselled before 
initiating therapy. There is no current robust evidence to support the use of these drugs for the 
prevention of cardiovascular disease in PCOS and further research in this area is required.This is of 
particular importance with respect to a recent meta-analysis suggesting an increase in myocardial 
infarction and death in women with diabetes treated with rosiglitazone.67 Inference from the 
diabetes prevention trial that examined a cohort of patients who had similar metabolic profiles to 
women with PCOS suggested that metformin is not superior to lifestyle intervention in improving 
cardiometabolic risk and progression to type 2 diabetes.68
Evidence 
level Ib
The use of metformin in induction of ovulation and fertility in women with PCOS will not be discussed here 
as it is beyond the remit of this guideline.
Orlistat69 and sibutramine70 have been shown to significantly reduce body weight and hyperandrogenism in 
women with PCOS. However, the use of sibutramine is not recommended in patients with systolic 
hypertension/There is currently no data on the use of rimonabant in women with PCOS but evidence suggests 
it may have benefit transferable to women with PCOS in weight reduction and improvement in the 
cardiometabolic profile.71 Bariatric surgery may be indicated in selected women with morbid obesity.72
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10.3 Surgery prognosis
What is the prognosis following surgery?
Ovarian electrocautery should be reserved for selected anovulatory women with a normal BMI.
Anovulation associated with PCOS has long been known to be amenable to surgical treatment. A recent long- 
term cohort study up to 20 years after laparoscopic ovarian electrocautery has shown persistence of ovulation 
and normalisation of serum androgens and SHBG in over 60% of subjects, particularly if they have a normal BMI.73
Insulin resistance and serum lipids were not assessed. The long-term benefits of ovarian drilling, including 
alterations in the endocrine profile are supported by a second study.74 However, no prospective studies have 
been powered to look at cardiovascular risk profiles and ovarian electrocautery should be reserved for 
selected anovulatory women with a normal body mass index or where a laparoscopy is required for other 
indications. It is also very important to highlight that ovarian surgery/drilling may affect the reproductive 
capacity of the ovaries in the future.
11. Image-related issues
How should women with hirsutism and acne be advised?
Women should be advised that there is insufficient evidence in favour of either metformin or the oral 
contraceptive pill in treating hirsutism or acne.
Effects of hyperandrogenisation are among the most deleterious long-term consequences of PCOS when 
taken into consideration of its impact on a woman's self-image perception and the subsequent psychological 
effects. Hirsutism in the setting of PCOS is difficult to treat and there are currently no large randomised 
control trials on its treatment in this patient group. A recent Cochrane review to compare the use of insulin 
sensitising drugs versus combined oral contraceptive pills concluded that the limited data available 
demonstrated no evidence of difference in effect between metformin and the pill on hirsutism and acne.75
Licensed treatments for hirsutism include oral contraceptive pills, dianette (oestrogen and cyproterone 
acetate), cosmetic measures (such as laser, electrolysis, bleaching, waxing and shaving) and topical facial 
eflornithine (Vaniqa®, SkinMedica Inc.). However, there is a paucity of good-quality robust placebo controlled 
trials for hirsutism treatment, particularly for combination therapy. In practice, a combination of methods is 
often required to achieve an acceptable cosmetic result for the woman. Non-licensed treatments are available 
and their use will depend on individual practice and expertise. These agents include spironolactone, 
antiandrogens, such as flutamide, finasteride and high-dose cyproterone acetate. Adequate contraceptive 
measures are essential with these medications. Metformin as an insulin sensitiser has been shown to have a 
modest effect on hirsutism associated with a 11% reduction in testosterone levels.76
12. Auditable standards
1. Accurate diagnosis of PCOS defined and based on two of the three criteria from the Rotterdam consensus.
2. Blood pressure measurement and a fasting blood glucose should be taken.
3. Women with a body mass index greater than 30 or a strong family history of type 2 diabetes should have 
a glucose tolerance test, particularly if fertility is an issue.
4. All overweight PCOS women should be provided with dietary and lifestyle advice.
'•>. Amenorrhoeic or severely oligomenorrhoeic women with PCOS should have induced withdrawal bleeds 
at regular intervals to reduce the risk of developing endometrial hyperplasia.
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APPENDIX
Clinical guidelines are: 'systematically developed statements which assist clinicians and patients in 
making decisions about appropriate treatment for specific conditions'. Each guideline is systematically 
developed using a standardised methodology. Exact details of this process can be found in Clinical 
Governance Advice No. 1: Guidance for the Development of RCOG Green-top Guidelines (available on 
the RCOG website at www.rcog.org.uk/clingnvT V Thp«p recommendations are not intended to dictate 
an exclusive course of management or treatment. They must be evaluated with reference to individual 
patient needs, resources and limitations unique to the institution and variations in local populations. It is 
hoped that this process of local ownership will help to incorporate these guidelines into routine 
practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.
The evidence used in this guideline was graded using the scheme below and the recommendations 
formulated in a similar fashion with a standardised grading scheme.
Classification of evidence levels
la Evidence obtained from meta-analysis of 
randomised controlled trials.
Ib Evidence obtained from at least one 
randomised controlled trial.
Ha Evidence obtained from at least one 
well-designed controlled study without 
randomisation.
nb Evidence obtained from at least one 
other type of well-designed quasi- 
experimental study.
HI Evidence obtained from well-designed 
non-experimental descriptive studies, 
such as comparative studies, correlation 
studies and case studies.
IV Evidence obtained from expert
committee reports or opinions and/or 
clinical experience of respected 
authorities.
Grades of recommendations
Requires at least one randomised 
controlled trial as part of a body of 
literature of overall good quality and 
consistency addressing the specific 
recommendation. (Evidence levels la, Ib)
Requires the availability of well controlled 
clinical studies but no randomised clinical 
trials on the topic of recommendations. 
(Evidence levels Ha, nb, Iff)
Requires evidence obtained from expert 
committee reports or opinions and/or 
clinical experiences of respected 
authorities. Indicates an absence of directly 
applicable clinical studies of good quality. 
(Evidence level IV)
Good practice point
Recommended best practice based on the 
clinical experience of the guideline 
development group.
DISCLAIMER
The Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical 
practice. They present recognised methods and techniques of clinical practice, based on published evidence, for 
consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement 
regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light 
of clinical data presented by the patient and the diagnostic and treatment options available.
This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to 
be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or 
guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken.
The Guidelines review process will commence in December 2010
unless otherwise indicated
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